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1. Introduction 
1.1. Bone Morphogenetic Proteins as members of Transforming Growth Factor β 
Superfamily 
 
Transforming growth factor β (TGFβ) and related molecules are members of the 
polypeptide growth factor superfamily. Based on sequence homology over 50 
evolutionary conserved members were identified and grouped into the following 
subfamilies: TGFβs, activins and inhibins, bone morphogenetic proteins (BMPs) and 
growth/differentiation factors (GDFs) (reviewed by Mehra et al., 2002). In addition 
proteins with a lower degree of similarity such as Mőllerian inhibitory substance (MIS) 
and glial cell line-derived neurotropic factor (GDNF) have been considered as members 
of the TGFβ family (Kingsley et al., 1994). Originally in the 1960s, only the activity of 
BMPs to induce bone formation, as their name suggests, was identified (Urist, 1965). 
More than two decades later this activity has been assigned to specific factors, when 
bovine osteogenin (BMP3) (Luyten et al., 1989), and human BMP2 and 4 (Wozney et 
al., 1988) were sequenced and purified. Later on, a number of GDFs has been also 
recognized as bone morphogenetic proteins, raising the number of BMPs to around 20 
(Yamashita et al., 1996). The BMPs/GDFs have been further grouped into six subsets 
based on amino acid sequence homology (Miyazono et al., 2005), as follows:  
1. BMP2 and BMP4 (BMP2b). 
2. BMP3 (Osteogenin) and BMP3b (GDF10). 
3. BMP5, BMP6 (Vg-1 related, Vgr-1), BMP7 (osteogenic protein-1, Op-1) and 
BMP8 (Op-2). 
4. BMP9 (GDF2) and BMP10. 
5. BMP12 (GDF7 or cartilage-derived morphogenetic protein-3, CDMP3), BMP13 
(GDF6 or CDMP2) and BMP14 (GDF5 or CDMP1). 
6. BMP11 (GDF11) and GDF8 (Myostatin). 
Since the TGFβ superfamily comprises so many protein families, it is obvious that 
sequence and percentage of homology among families, subsets and even between 
members of the same group varies significantly. However, there are common and 
consistent features that allow to classify them as TGFβ related proteins (i.e. synthesis as 
precursor, conserved tertiary structure etc.), as described below. 
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Members of the TGFβ superfamily, including BMPs, are synthesized as pre-pro-
protein precursors (of approximately 400-525 amino acids in case of BMPs), containing 
leader secretion sequence, pro-region and carboxy-terminal mature region (Gentry et al., 
1988). The pro-region facilitates proper dimerization of pro-proteins, and dimers are 
subsequently cleaved by endoproteases at conserved RXXR amino acid sequence 
(Mehra et al., 2002). Furin-like proteases are generally believed to convert the 
precursors into biologically active, mature forms (Matthews et al., 1994) prior to 
secretion. Mature peptides form a cystein knot which contains most ofen six cystein 
residues (Reddi, 1998), however, there may be additional one to three cysteines 
included in the sequence (Neuhaus et al., 1999). As for TGFβ1, the cleaved, disulfide-
linked pro-region has been shown to remain non-covalently associated with the mature 
peptide to form a “latent complex” (Lawrence, 1996) followed by secretion and further 
processing. The ability of other BMPs to create such a complex has not yet been shown. 
 A cystein knot, common for all mature TGFβ ligands, including BMPs, was also 
found in a number of other growth factors, as for example platelet-derived growth factor 
(PDGF) and glycol-protein hormone. These factors share no other sequence 
homology/similarity to TGFβ, but they are together defined by some authors as 
members of cystein-knot growth factor superfamily (Sun et al., 1995).  
 
 
1.2. BMPs receptors 
 
 The physiological effect of BMPs is achieved by binding of the secreted form to 
specific receptors. There are three known types of TGFβ receptors, type I, type II and 
type III, named according to the their mobility on SDS-PAGE gels (Cheifetz et al., 
1986). Type I of molecular mass of approximately 55 kDa, and a 70-85 kDa type II are 
transmembrane serine/threonine (Ser-Thr) receptor kinases, while 200-400 kDa type III 
receptors contain two distinct members, a proteoglycan (betaglycan) and a glycoprotein 
(endoglin) (Massague et al., 1994, Cheifetz et al., 1988). It is believed, that BMPs signal 
only through type I and II receptors (Liu et al., 1995). Type I receptors were firstly 
identified as activin receptor-like kinases 1-4 or ALK1-ALK4 (ten Dijke et al., 1993). 
At the same time, other groups cloned these and others type I receptors and named them 
according to their specificity of ligand binding. Because of this reason each receptor has 
at minimum of 2 names. ALK-2 is also known as ActR I or Acvr1 (activin receptor type 
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I), ALK-3 and ALK-6 as BMPR IA and IB (BMP receptor IA and IB), respectively, 
ALK-4 – ActR IB (activin receptor type IB) and finally ALK-5, based on its specificity 
to TGFβ, is also called TGFβ RI (reviewed by Mehra and Wrana, 2002). Four members 
of type II receptors have been identified and three of them preferentially bind activins 
(ActR II and ActR IIB) and TGFβ1 (TβR II) (Lin et al., 1992), while BMPs have a 
higher affinity to BMPRII, although they were shown to interact with ActR IIA as well 
(Mathews et al., 1991, Mathews et al., 1992). Known TGFβ/Activin/BMP receptors, are 
summarized in table 1. Receptors, which have been identified to bind BMP10, will be 
described separately in the chapter 1.4. 
 
Tab. 1. TGFβ/BMP receptors and their putative ligands (modified from Cytokine 
Mini-reviews, R&D Systems’, 2004) 
■ BMP2 
● BMP7 
 
● Act A 
● BMP7 
● GDF5 
 
● TGFβ-1 
● Act A 
● BMP2 
● BMP4 
● BMP7 
● GDF5 
● GDF6 
● BMP6 
 
● TGFβ-1 
 
 
ALK-6 
 ● Act A 
 
● TGFβ-1 
● Act A 
● BMP7 
● TGFβ-1 
 
 
ALK-5 
● Act A 
 
● BMP7 
● Act A 
■ GDF5 
● TGFβ-1 
● Act A 
● BMP7 
● TGFβ-1 
 
 
ALK-4 
● BMP2 
■ BMP7  
● GDF5 
● Act A 
 
● TGFβ-1 
● Act A 
● BMP2 
● BMP7 
● GDF5 
● GDF6 
● TGFβ-1 
 
 
 
ALK-3 
● Act A 
■ BMP7 
■ GDF5 
● GDF6 
● Act A 
● BMP7 
● GDF5 
● GDF6 
● BMP6 
 
● TGFβ-1 
● Act A 
● BMP2 
● BMP7 
● BMP6 
 
● TGFβ-1 
 
 
ALK-2 
● Act A ● Act A ● TGFβ-1 
● Act A 
● BMP7 
■ TGFβ-1  
ALK-1 
Type II Receptors 
    TGFβR II                   BMPR II                     ActR II                  ActR IIB  
 
Type I Receptors 
KEY 
● binding/signal transduction 
● no binding 
● binding/no signal transduction 
■ binding/signal transduction uncertain 
■ binding uncertain/no signal transduction 
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The serine/threonine kinase domain of type II receptors is constitutively active, and 
upon a ligand binding, phosphorylate glycine-serine domain (GS domain) of type I 
receptor, which results in induction of their kinase activity (Miyazono et al., 2005) and 
initiates downstream Smad-dependent or -independent signaling. Hence, specificity of 
induction is mainly achieved by type I receptor. BMPs bind to ALK-2, ALK-3 and 
ALK-6 type I receptors (ten Dijke et al., 1994, Chen et al., 1998, Macias-Silva et al., 
1998), although an interaction with ALK-1 cannot be excluded (Mazerbourg et al., 
2005). Some BMPs were also shown to bind to type II and I receptors in a cooperative, 
rather than in a stepwise manner (Knaus et al., 2001, Gilboa et al., 2000, Mehra et al., 
2002). It was also suggested that receptors of both types can constitutively form 
homodimers or can even heterotetramized, because the autophosphorylated type II 
naturally recruits type I receptor (Derynck et al., 1997, Cho et al., 1998). The precise 
mechanism of ligand-dependent receptor recruitment and action remains unknown. It is 
known that type I receptors are negatively regulated by various receptor-associated 
molecules, like FK506-binding protein 12 (FKBP12) (Wang et al., 1996), BMP and 
activin membrane bound inhibitor (BAMBI), and BMP receptor associated molecule 1 
(BRAM1). For instance, FKBP12 binds to type I receptor and possibly prevents its 
premature activation (reviewed by Massague et al., 2000).  
 In the signaling cascade, upon ligand binding, receptors are internalized and can 
be either recycled to the membrane or can be downregulated through endocytosis. 
Internalization of receptors is implicated as a mechanism of limitation or additional 
negative regulation of TGFβ/BMPs signaling (Mellman et al., 1996).   
 
 
1.3. Smad-dependent and Smad-independent signaling pathways 
 
As mentioned before, both type I and II receptors are necessary for BMPs signal 
transduction. After ligand binding they form a heterotetrameric-activated receptor 
complex, that transmits BMP signal through either Smad-dependent or Smad-
independent pathways. In addition to the canonical Smad-mediated pathway, BMPs 
activate also a number of mitogen activated protein kinases (MAPKs), like extra-
cellular signal-regulated kinases (ERKs), p38 MAP kinase (Iwasaki et al., 1999) or 
protein kinase C-dependent pathway (Hay et al., 2001). It was shown, that the mode of 
receptor oligomerization/recruitment prior to the ligand binding mainly determines 
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downstream signal transduction pathway (Hassel et al., 2003). A schematic 
representation of BMPs induced Smad-dependent signaling is shown in Fig. 1.1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.1. Schematic representation of the TGFβ/BMP induced Smad signaling 
pathway (modified from Massague et al., 2000).  
 
Smads are considered, however, as the major transducers for the serine/threonine 
kinase receptors. Eight Smad proteins have been identified so far in mammals and have 
been grouped into three classes, based on their function (Goumans et al., 2000): 
1. Receptor-regulated Smads (R-Smads). They can be further subdivided in 2 
groups: activated by TGFβ and activins (Smad2 and Smad3 – AR-Smads). The 
second group is activated by BMP receptors (Smad1,-5,-8 – BR-Smads) 
(Miyazono et al., 2005). Interaction of the R-Smads with a defined type I 
receptor determines the specificity of the TGFβ family members (ten Dijke et 
al., 2000). Unique c-terminal phosphorylation site is typical only for members of 
R-Smads.  
2. Common-partner Smads (co-Smads). This subgroup is represented only by 
Smad4 in mammals, but others might also exist, as two Smad4 homologues have 
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been found in Xenopus laevis. Smad4 is utilized in both BMP and TGFβ/activin 
signaling pathways (Masuyama et al., 1999).  
3. Inhibitory Smads (I-Smads). Smad6 and Smad7 have been recognized as 
inhibitors of BMP and TGFβ/activin signaling and their expression is induced by 
mature ligand binding (Christian et al., 1999). The inhibitory effect can be 
achieved by stable interaction with the activated type I receptor, thus preventing 
phosphorylation of R-Smads, or by competition for binding of co-Smad, thereby 
preventing the formation of R/co-Smads complex. The first mechanism applies 
to both I-Smads, while the later is unique for Smad6 and its inhibition of 
Smad1/Smad4 interaction (Hata et al., 1998). 
Upon ligand binding and activation by type II receptor, type I receptors phosphorylate 
R-Smads at their C-terminal SSXS sequence and oligomerize with a co-Smad (Heldin et 
al., 1997). This complex is translocated into the nucleus, where it regulates transcription 
of target genes by direct binding to specific DNA sequences, interacting with other 
DNA-binding proteins, and recruiting transcriptional co-activators or co-repressors (Fig. 
1.1) (Miyazono et al., 2000).  
 
 
1.4. Role of BMP signaling in heart development and angiogenesis 
 
At least six BMPs have been found to be expressed in the heart, i.e. BMP2, 
BMP4, BMP5, BMP6, BMP7 and BMP10, with distinct but partially overlapping 
distribution (reviewed by Schneider et al., 2003).   
Among the BMPs, the BMP2 expression patterns and function were the most 
intensively studied. BMP2 is widely expressed during mouse embryonic development 
as well as in the adult heart has dynamic expression pattern (Lyons et al., 1989, 1990). 
BMP2 was noted in cardiac crescent at E7.5 (Ma et al., 2005), and at E8.5 BMP2 
transcripts are detectable by in situ hybridization in the promyocardium and surrounding 
mesodermal cells, while the protein is localized in the atrioventricular (AV) 
myocardium and the dorsal wall of future atria as well (Sugi et al., 2004). One day later 
at E9.5, transcripts of BMP2 were observed in the region, where protein was found one 
day before (i.e. AV myocardium) and at a lower levels in the outflow tract. At E10.5 
BMP2 protein was diminished in myocardial cells, but was detectable in cushion AV 
mesenchyme and epicardium. This pattern of protein localization was preserved during 
                                                                                                               INTRODUCTION 
 7 
later stages of development- E13.5- E16.5, i.e. during valvulogenesis. By in situ 
hybridization, BMP2 expression in the AV canal was extinguished at E10.5 (Sugi et al., 
2004). On the other hand BMP2 transcripts were found in and ventricular myocardium 
by another group (Ma et al., 2005). In adult mouse heart, protein expression persisted in 
cardiac valve tissue (Sugi et al., 2004).   
BMP2 is implicated in multiple developmental and physiological processes. A 
homozygous null mutation of BMP2 causes, in addition to the amnion/chorion defects, 
abnormal development of the heart in the exocoelomic cavity, but the specification of 
the cardiac mesoderm occurs normally (Zhang et al., 1996). Conditional inactivation of 
BMP2 in the myocardium led to cardiac jelly loss and at later developmental stages 
resulted in failure in endocardial endothelial-mesenchymal transition (EMT) (Ma et al., 
2005). In vitro studies proved that BMP2 is required for myocardial segmental 
regulation of AV endocardial cushion mesenchymal cells formation (Sugi et al., 2004). 
Moreover BMP2 can direct regionalized myocardial patterning (Ma et al., 2005). In 
addition to cardiac development, BMP2 has been reported to exert both pro- and anti-
apoptotic effects, depending on cell type and circumstances (Yokouchi et al., 1996; 
Iwasaki et al., 1999; Bhatia et al., 1999). In neonatal cardiomyocytes in culture the 
inhibition of apoptosis by BMP2 was shown to occur through activation of Smad-1 and 
induction of anti-apoptotic gene Bclx expression (Izumi et al., 2001). Elevated levels of 
BMP2 expression in tumors, suggesting the possible role of this cytokine in promotion 
of tumor angiogenesis were recently reported. The authors found that BMP2 had no 
significant effect on proliferation, but promoted tube formation of human dermal 
microvascular endothelial cells in vitro (Raida et al., 2005).  
 BMP4 is the most widely expressed BMP gene throughout mouse 
developmental stages and in adult tissues. During embryonic heart development BMP4 
was found in the outflow tract at E8.5. In addition, BMP4 transcripts were found in 
muscular layer of the OFT and its derivatives (aorta and pulmonary trunk) and this 
expression is maintained until birth (Jiao et al., 2003). In the inflow region, BMP4 was 
first noticed in the sinus venosus at E8.5. At E9.0 expression was detected in the dorsal 
midline of common atrium and in the AV cushion, regions where the atrial septum 
primum is initiated (Jiao et al., 2003). Another report proved additionally the expression 
of BMP4 in parietal pericardium (Stottmann et al., 2004). In adult heart, in addition to 
expression in muscle layers of aorta and pulmonary trunk, BMP4 was found in valves 
and the annulus of mitral and tricuspid valves (Jiao et al., 2003).  
                                                                                                               INTRODUCTION 
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 Conditional inactivation of BMP4 in mouse hearts leads to atrioventricular canal 
defects (AVCD), and a single AV junction with a common valve.  In the outflow region 
of developing heart, BMP4 deficient embryos display a double-outlet right ventricle. 
Initiation of cushion formation and endothelial-mesenchymal transition was not 
affected, probably due to compensatory effects of other BMPs. However, after the 
cushion was formed BMP4 was required for the proper septation of the AVC (Jiao et 
al., 2003). Using the micro-bead delivery technique, BMP4 was shown to significantly 
induce programmed cell death in surrounding embryonic tissue explants in vitro. The 
highest induction of apoptosis by BMP4 was observed in the conotruncal cushion, while 
in myocardial and AV cushion explants the number of apoptotic cells was 
approximately two fold lower (Zhao et al., 2000).   
 BMP5, BMP6 and BMP7 belong to the same subgroup of BMPs, with an almost 
90% homology within the mature, active region (Solloway et al., 1999). BMP5 and 
BMP7 are strongly expressed in developing myocardium, whereas BMP6 is expressed 
in both the OFT myocardium and atrioventricular cushion (Dudley et al., 1997). 
Surprisingly, mice lacking BMP5 (Kingsley et al., 1992), BMP6 (Solloway et al., 1998), 
or BMP7 (Dudley et al., 1995) do not exhibit cardiac abnormalities. Double mutations, 
i.e. BMP5/BMP7 (Solloway et al., 1999) or BMP6/BMP7 (Kim et al., 2001) resulted in 
severe heart development retardation indicating that these closely related factors are 
interchangeable. In double BMP5/BMP7 knock-outs (Solloway et al., 1999) the general 
morphology of the heart was disorganized with reduced cell density and trabeculation. 
The authors explained the lack of endocardial cushion formation as a secondary effect 
of overall growth/development retardation.  
 BMP6 and BMP7 share 87% amino acid identity in the C-terminal mature 
domain (Kim et al., 2001). BMP6 expression in the heart was restricted to the AV 
cushion and OFT at E9.5 with its decrease on the right side of the OFT at E10.5 and 
was absent by E11.5. At later developmental stages BMP6 transcripts were also found 
in endothelium lining dorsal aorta and pulmonary trunk and valve leaflets. Asymmetric 
expression of BMP7 in myocardium of developing heart was also noted, with its down-
regulation in the left atrium and ventricles. Deletion of both BMP6 and BMP7 caused 
mouse embryonic lethality between E10.5- E12.5, a period when significant overlap in 
the BMP6 and BMP7 expression occur (Kim et al., 2001). Double BMP6/BMP7 knock-
outs had underdeveloped endocardial cushions of , reduced ventricular trabeculation and 
displaced venous valves within the heart. Additionally, both atrial chambers and cardiac 
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veins were dilated. However this edema might be secondary to heart failure and valvular 
malformation (Kim et al., 2001).  
 Since BMPs act through receptors, their localization and mutational analysis can 
provide valuable functional information. Activin receptor like kinase 1 (ALK-1) is able 
to bind TGFβ1 or activins in the presence of either TβR II or activin type II receptors, 
respectively. However preliminary data showed that it does not induce transcriptional 
activity (Kretzschmar et al., 1998, Bassing et al., 1994). Thus ALK-1 was considered as 
an orphan receptor. Expression of this receptor in arterial endothelium during 
embryogenesis (Roelen et al., 1997) and in adult tissues (Panchenko et al., 1996) 
suggested its potential role in the regulation of angiogenesis. Mice lacking ALK-1 
exhibit dilation of major vessels and fusion of capillaries (Oh et al., 2000). Similar 
phenotypes were observed in TGFβ1 (Dickson et al., 1995), TβR II (Oshima et al., 
1996), endoglin (Li et al., 1999) and Smad5 (Sankar et al., 1996) deficient mice. It is 
generally believed, that BMPs activate Smad 1/5/8 whereas TGFβs induce Smad 2/3 
pathway. Although ALK-1 has been identified to bind TGFβ1, the signal is most 
probably mediated through a BMPs Smad1/5 dependent pathway (Oh et al., 2000). 
Additionally, ALK-1 signaling was shown to be required for differentiation and proper 
localization of vascular smooth muscle cells to the perivascular region during 
embryogenesis (Oh et al., 2000). The most extensively studied cytokine in angiogenesis 
was TGFβ1 and its receptors, i.e. ALK-1 and ALK-5 (reviewed by Goumans et al., 
2003). It is proposed that two TGFβ signaling pathways (via ALK-1 and ALK-5) may 
play a balancing role in vascular development (Seki et al., 2006). As already mentioned, 
ALK-1 is expressed in the endothelial layer of arteries, while ALK-5 transcripts were 
found in vascular smooth muscle cells in medial and adventitial layers of blood vessels, 
but they were undetectable in the intimal layer in embryos. Some groups however, 
found ALK-5 expression in endothelial cell lines (reviewed by Goumans et al., 2003). 
ALK-5 was shown to exert its function via the Smad2/3, but not the Smad1/5/8 pathway 
(Lebrin et al., 2005). Moreover ALK-5 knock-outs exhibit defects in the formation of 
the smooth muscle layer, but no dilation of blood vessels, as in case of ALK-1, was 
observed. During embryonic heart development, ALK-5 was found to be expressed by 
trabecular muscle cells (Seki et al., 2006). Based on these data, the authors proposed 
that TGFβ signaling is involved in vascular morphogenesis utilizing two distinct type I 
receptors: ALK-1 in endothelial cells and ALK-5 in vascular smooth muscle cells. As 
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shown by the example of TGFβ1, one ligand might exhibit different functions 
depending on the binding to particular receptors in various cell types. 
Activin receptor like kinase 2 (ALK-2) has been shown to play a role in 
rightward looping of the primary heart tube in Xenopus leavis (Ramsdell et al., 1999). 
During mouse embryogenesis ALK-2 was found to be expressed at low levels in the 
myocardium, whereas an abundant expression was detected in endocardial cells and the 
underlying mesenchyma of AV canal (Wang et al., 2005). Interestingly, mice with a 
deficiency of ALK-2 in cardiomyocytes did not develop an obvious cardiac phenotype 
while severe septal and valvular defects were observed, when ALK-2 was ablated in 
endothelial cells, as a result of disturbed endothelial to mesenchyme transdifferentiation 
(Wang et al., 2005).       
It has been already mentioned, that BMPs act mainly through ALK-3 and ALK-
6 of type I receptor. ALK-3 is ubiquitously expressed throughout development, whereas 
ALK-6 is absent in the developing heart from midgestation (Dewulf et al., 1995). 
Cardiac specific ALK3 deletion results in many heart defects (Gaussin et al., 2002). 
Ablation of ALK-3 leads to increased apoptosis rate of cardiomyocytes, thus the ALK-3 
mediated pathway is required for myocyte survival. Additionally, ALK-3 expression in 
myocytes is necessary at mid-gestation for proper intraventricular septation, 
development of normal trabeculae, compact myocardium and endocardial cushion. 
Interestingly, in mutant embryos, BMP10 expression in trabeculae was unchanged, but 
precocious expression in atria was found (Gaussin et al., 2002). When ALK-3 
expression was abolished in the subset of cardiac myocytes of AVC, anomalies in mitral 
septal leaflets and tricuspid mural leaflets were found in adult animals. Downward 
displacement and disruption of the annulus fibrosus resulted in direct myocytic 
connection between atrium and ventricle that led to ventricular preexcitation (Gaussin et 
al., 2005). Surprising results were obtained when ALK-3 expression was ablated in 
neural crest cells (Stottmann et al., 2004). Most aspects of neural crest development 
occurred normally, but the mutant embryos died at midgestation due to acute heart 
failure. Mutants display a shortened with defective septation, lack of endocardial 
cushion and reduced rate of ventricular myocardial proliferation leading to little 
expansion of trabeculae and thinned compact myocardium. Ablation of ALK-3 in Isl1 
expressing cells (believed to be undifferentiated cardiac progenitors) leads to aberrant 
morphology of and right ventricle at E9.5. At E11.5 a thinner ventricular wall and 
reduced trabeculation was observed. At E13.5 severe defects in formation with 
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persistent truncus arteriosus and underdeveloped valves were noted. Thinner ventricular 
wall and septation defects appeared due to disturbed proliferation and apoptosis, 
respectively (Yang et al., 2006).  
Developmental events are also sensitive not only to complete absence but also to 
reduced BMP signaling (Délot et al., 2003). Mice lacking half of the ligand-binding 
domain in the BMP type II receptor die at midgestation as a result of severe 
cardiovascular defects. Mutants exhibit a very restricted phenotype, limited specifically 
to the outflow tract (OFT). The main defects of BMP signaling limitation are absence of 
septation in the developing heart with interruption of the aortic arch as well as lack of 
the semilunar valve, which prevents the backflow from aorta and pulmonary trunk into 
the ventricles (Délot et al., 2003).  
 
 
1.5. BMP10 as a heart specific member of the TGFβ superfamily 
 
BMP10 starts to be expressed during mouse embryogenesis exclusively in heart 
at E9.0. Its transcripts were found to be restricted to the trabeculated part of common 
ventricles and bulbus cordis, but to be absent in endocardial cells (Neuhaus et al., 1999). 
During later stages (E14.5), the signal also appears in the trabeculated inner atrial wall. 
The sequence of BMP10 displays all characteristic features of a bone morphogenetic 
protein family member, such as RRIR cleavage site, that divides 421 amino acid 
precursors into a pro-region with a hydrophobic leader sequence and the mature ligand 
with conserved cysteine residues. On the basis of sequence homology, BMP10 together 
with BMP9 and chicken dorsalin, constitute a new BMP subgroup (Neuhaus et al., 
1999). The closest relative to BMP10 is BMP9, which is not expressed in the heart. In 
adult tissues, northern blot analysis revealed that BMP10 transcripts are restricted to the 
right atrium of the healthy human heart (Neuhaus et al., 1999), and such kind of 
expression pattern was further confirmed in the mouse by another group (Chen et al., 
2004). Recently, studies concerning BMP10 ablation in the mouse have been published 
as well. Absence of BMP10 caused embryonic lethality, between E9.5 and E10.5. 
BMP10 deficient mice exhibit severe cardiac abnormalities with a profound hypoplastic 
ventricular wall, absence of ventricular trabeculation and halted at acellular stage the 
development of endocardial cushions in both  and the atrioventricular canal (AVC) 
(Chen et al., 2004). The authors found that lack of trabeculated myocardial layers in 
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mutants was caused by a defect in myocyte proliferation and ectopic expression of 
negative cell-cycle regulator p57kip2. Moreover, BMP10 expression was found to be 
upregulated in FKBP12- deficient mouse, which exhibit hypertrabeculation (Shou et al., 
1998). High ectopic levels of BMP10 expression were also found in adult hearts of 
ventricular cardiomyocyte restricted knock-out of Nkx2.5 (Pashmforoush et al., 2004). 
Hearts of Nkx2.5 deficient mice are hypertrabeculated due to persistent myocyte mitosis 
leading to complete heart block. Additionally, ventricular myocardium shows 
noncompaction and a disorganized conduction system with progressive fibrosis. 
Proliferative function of BMP10 was further confirmed by generation of transgenic 
mouse strains overexpressing the gene under the ANF promoter, which led to a similar 
phenotype of myocardial hypertrabeculation and noncompaction (Pashmforoush et al., 
2004). 
Receptor binding studies revealed that BMP10 can interact with type I receptors 
ALK-3 and ALK-6 and both type II receptors (BMPR II and ActR IIA) and activates 
Smad1/5/8 pathway. However the design of this study and results are questionable and 
more work is needed to clarify the details of BMP10 signal transduction (Mazerbourg et 
al., 2005). 
 
 
1.6. Aim of the project 
 
The general purpose of the present work was to investigate the role of BMP10 in 
the adult heart. A thorough knowledge of the expression and localization studies of 
BMP10 is a prerequisite for any further work. As BMP10 undergoes secretion from the 
cells where it is expressed, it was necessary to generate an antibody specific to the 
processed, mature secreted form of the protein to investigate the localization of BMP10. 
I was also interested to study the qualitative and quantitative changes of BMP10 
expression in genetic and drug induced models of dilated and hypertrophic 
cardiomyopathy. Additionally, in the work presented here I attempt to unveil the 
function of BMP10. Overexpression of active BMP10 in mammalian cells allowed to 
study the effects of this protein on cells of various origins in vitro. 
                                                                        Experimental procedures 
 13 
2. Experimental procedures 
 
2.1. Materials 
 
2.1.1. Basic materials 
 
MATERIALS COMPANY 
Biodyne® Nylon Membrane Pall (Dreieich, Germany) 
Bio-Traces® Nitrocelulose Pall (Dreieich, Germany) 
Blotting Paper 3MM Whatman International (Maidstone, 
England) 
Chamber slide w/cover permanox slide  Nunc (Roskilde, Denmark) 
Cell culture plates Nunc (Roskilde, Denmark) 
Filters Schleicher & Schüll (Hannover, Germany) 
Filters Minisart NML (0.2 und 0.45 µm) Sartorius (Göttingen, Germany) 
Glass slides and cover slides Roth (Karlsruhe, Germany) 
Glassware Schütt (Göttingen, Germany) 
Mini osmotic-pump 2002 Alzet (USA) 
NAP-5™ columns (Sephadex® G-25) Pharmacia  Biotech (Sweden) 
Nitrocellulose membrane Invitrogen (Karlsruhe) 
Plastic ware Nunc (Wiesbaden, Germany) 
Pro-Bond Ni-chelating Resins Invitrogen (Karlsruhe, Germany) 
Round cover slides Roth (Karlsruhe, Germany) 
X-ray developer Kodak (Frankfurt/Main, Germany) 
X-ray Film Kodak (Frankfurt/Main, Germany) 
Ni-NTA agarose Qiagen 
 
2.1.2. Chemicals 
 
Basic chemicals were purchased from the following companies: Boehringer 
Mannheim (Mannheim), Invitrogen (Karlsruhe, Germany), Merck (Darmstadt), 
Molecular Probes (Goettingen), New England Biolabs (Schwalbach), Pharmacia 
(Freiburg), Promega (Mannheim), Roth (Hamburg/Karlsruhe, Germany), Serva 
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Feinbiochemika (Heidelberg), Sigma-Aldrich (Deisenhofen), Stratagene (Heidelberg), 
Quiagen (Hilden). 
 
 
2.1.3. Radiochemicals 
 
Radioactive labelled nucleotides were purchased from Amerscham Buchler 
(Braunschweig) or PerkinElmer (Boston): 
• [α-32P] dCTP (6000 Ci/ml) 
 
 
2.1.4. Reagents 
 
• Avertin® 2,2,2-Tribromoethyl Alkohol    Boehringer (Mannheim) 
• Agar plaque plus agarose    BD Clontech (USA) 
• BaculoGold TNM-FH insect medium   BD Clontech (USA) 
• BCIP(5-Bromo-4-chloro-3-indolylphosphat)  Boehringer (Mannheim) 
• BMP-2      Sigma-Aldrich(Deisenhofen) 
• Chloroquine      Sigma-Aldrich(Deisenhofen) 
• DAB (3,3’-diaminobenzidine)    Sigma-Aldrich(Deisenhofen) 
• DAPI (4’,6-diamidino-2-phenylindole)  Invitrogen (Karlsruhe)  
• Dimethylsulfoxid      Sigma-Aldrich(Deisenhofen) 
• Dil-Ac-LDL      Cell Systems (Frankfurt) 
• Digoxigenin-UTP      Boehringer (Mannheim) 
• Dithyotreithol (DTT)     Promega (Mannheim) 
• Doxorubicine      Sigma-Aldrich(Deisenhofen) 
• Draq5™       (Alexis) 
• Dubelcco’s Modified Eagle Medium (D-MEM) 1.000 mg0/ml D-glucose, L-
glutamine and sodium pyruvate    Invitrogen (Karlsruhe) 
• Dubelcco’s Modified Eagle Medium (D-MEM) 4.500 mg0/ml D-glucose, L-
glutamine and sodium pyruvate    Invitrogen (Karlsruhe) 
• Eosin       Division Chroma 
• Fetal Bovine Serum      Invitrogen (Karlsruhe) 
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• Geneticin G-418      Invitrogen (Karlsruhe) 
• Grace’s insect medium    Invitrogen (Karlsruhe) 
• Gradient acrylamide 4-12% gels   Invitrogen (Karlsruhe) 
• Gradient acrylamide 8-20% gels   Anamed 
• Heparin       Sigma-Aldrich(Deisenhofen) 
• Haemalaun sauer     Division Chroma 
• IPTG (Isopropyl-β-D-tiogalactopyranosidase)  Roth (Karlsruhe) 
• Isoflurane      Forene (Germany) 
• Isoproterenol      Sigma-Aldrich(Deisenhofen) 
• Levamisole       Sigma-Aldrich(Deisenhofen) 
• Matrigel      BD Clontech (USA) 
• NBT (4-Nitro-Blue-Tetrazoliumchlorid)  Boehringer (Mannheim) 
• Neutral red      Sigma-Aldrich(Deisenhofen) 
• NP-40       Roth (Karlsruhe) 
• NuPAGE 4-12% Bis-Tris Gel   Invitrogen (Karlsruhe) 
• Mowiol      Merck (Darmstadt) 
• Opti-MEM® with GlutaMAXTM-I    Invitrogen (Karlsruhe) 
• PageRulerTM Prestained Protein Ladder  Fermentas (Lithuania)  
• Penicillin-Streptamycin-Glutamine    Invitrogen (Karlsruhe) 
• PFA (paraformaldehyde)    Merck (Darmstadt) 
• Phalloidin-TRITC conjugated   Sigma-Aldrich(Deisenhofen) 
• Phalloidin-FITC conjugated    Sigma-Aldrich(Deisenhofen) 
• PolyfreezeTM tissue freezing mediumTM  Polysciences Inc. (USA) 
• Prestained Protein Ladder 10-180 kDa   Fermentas 
• ProbondTM Resin      Invitrogen (Karlsruhe) 
• Protease inhibitor coctail EDTA-free   Roche (Karlsruhe) 
• RNasin®       Invitrogen (Karlsruhe) 
• Serum free insect medium     Sigma-Aldrich(Deisenhofen) 
• Sheep serum       Sigma-Aldrich(Deisenhofen) 
• Triton X-100      Roche (Karlsruhe) 
• Trizol®       Invitrogen (Karlsruhe) 
• Trypan blue      Sigma-Aldrich(Deisenhofen) 
                                                                        Experimental procedures 
 16 
• Trypsin 2,5%       Invitrogen (Karlsruhe) 
• Tween-20      Roche (Karlsruhe) 
• VectabondTM      Vector Laboratories 
• X-Gal        Roth (Karlsruhe) 
      (5-bromo-4-chloro-3-indolyl β-D-galactopyranoside)  
• Yeast tRNA      Boehringer (Mannheim) 
 
 
2.1.5. Enzymes 
 
Restriction endonucleases were obtained from Jena Bioscience, New England 
Biolabs and Fermentas. 
 
DNA Polymerase I Large Klenov Promega 
Expand High Fidelity Polymerase Roche 
RQ1 RNase Free DNase Promega 
RNA Polymerases (T7, T3, SP6) Promega 
SuperScriptTM II Reverse Transcriptase Invitrogen 
Taq DNA Polymerase Eppendorf 
T4 Polynucleotide Kinase Promega 
T4 DNA Ligase Promega 
 
 
2.1.6. Kits 
 
BaculoGold transfection kit  BD Clontech 
Baculovirus kit BD Clontech 
BrDu Immunohistochemistry system Oncogene 
Comassie PlusTM Protein Assay Kit Pierce 
ECL developing system  Amersham, Pierce 
FUGENE 6 transfection reagent Roche 
In situ cell death detection kit  Roche 
JetQuick PCR purification kit Genomed 
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JetQuick Gel extraction kit Genomed 
JetStar Maxi plasmid purification kit Genomed 
JetStar Mega plasmid/cosmid purification kit Genomed 
Micro-Fast Track 2.0TM mRNA isolation kit Invitrogen 
Ne-Per nuclear and cytoplasm extraction kit  Pierce 
Rapid Ligation Kit Fermentas 
TOPO®TA Cloning Kit Invitrogen 
Femto WB detection system Pierce 
 
 
2.1.7. Oligonucleotides 
 
All oligonucleotides were obtained from Roth, Invitrogen. 
 
Primer Sequence 5’→3’ 
T7 TAATACGACTCACTATAGGG 
T3 ATTAACCCTCACTAAAGGGA 
Sp6 ATTAGGTGACACTATAG 
M13 Forward GTAAAACGACGGCCAG 
M13 Reverse CAGGAAACAGCTATGAC 
5`-mouse-HPRT GCTGGTGAAAAGGACCTCT 
3`-mouse-HPRT CACAGGACTAGAACACCTGC 
5’-mouse-GAPDH GTGGCAAAGTGGAGATTGTTGCC 
3’-mouse-GAPDH GATGATGACCCGTTTGGCCC 
5’-mouse-BMPRII ATGACTTCCTCGCTGCATCGGCCA 
3’-mouse-BMPRII CAGCTAACACAGAAACTGATGCCAAAG 
5’-pRSET-BMP10 CGGATCAGCTCGAGCGCCAAGGGGAACTAC 
3’-pRSET-BMP10 GCCTCTGGTACCCTATCTACAGCCACACTC 
5’-3’arm-BMP10-
ApaI-ko 
GGAGAGGAGAGGGGGCCCATGGC 
3’-3’arm-BMP10-
ApaI-ko 
CAAGGCTGATTTCAGGGCCCAAGCTC 
5’-5’ex2-BMP10- CATACTGCAAGTCTGGTACCTCATAAGTATC 
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KpnI-ko 
3’-5’ex2-BMP10-
KpnI-ko 
GCCACACTCAGACGGTACCATCCCTTC 
5’-PVL-BMP10-NotI GCGGCCGCATGGGGTCTCTGGTTCTGC 
3’-PVL-BMP10-
XbaI 
TCTAGACTATCTACAGCCACACTCAGACAC 
5’-IRES-GFP-
BMP10-PstI 
CTCGCTGCAGGCCATGGGCTCTCTGGTCCTG 
3’-IRES-GFP-
BMP10-XmaI 
GGGCCCGGGCTTTGTGGGCACACAGCAG 
5’-5’arm-BMP10-ko GGAAGGATCCATGGCCGCGGAGCTGAGC 
3’-5’arm-BMP10-ko CCAGACTTGCCGCGGGCTTCATAATATAGC 
5’-mouse-BNP GTTACAGGAGCAGCGCAACC 
3’-mouse-BNP AGGCCACTGGAGGAGCTGAT 
5’-mouse-ANF CTCCTTCTCCATCACCAAGG 
5’-mouse-ANF CTCTGGGCTCCAATCCTGTC 
5’-mouse-pDGFRß GGCAGGTCATACCATGAT 
5’-mouse-pDGFRß TCGAGGTGGTCTTGAGCT 
5’-mouse-SM-actin GAGAAGCCCAGCCAGTCG 
3’-mouse-SM-actin CTCTTGCTCTGGGCTTCA 
5’mouse-calponin GAAATACGACCATCAGCGGG 
3’mouse-calponin CCAGTTTGGGATCATAGAGG 
5’ mouse-BMP10 GGA AAC TAC TGT AAG AGG ACC CC 
3’ mouse-BMP10 CTA TCT ACA GCC ACA TTC GGA GAC 
5’ mouse-PECAM AGGGGACCAGCTGCACATTAGG 
3’ mouse-PECAM AGGCCGCTTCTCTTGACCACTT 
5’mouse-POD1 GGCAAGCAGGTCCAGCGCAAC 
3’mouse-POD1 CAAGCGGTTGGCGGTCACCAC 
5’mouse-ALK1 CCTTGGGGAGCTTCAGAAGGGGC 
3’mouse-ALK1 GGGCCACCAGGACCGGCAAG 
5’mouse-ALK2 GCCGCCCGGGCCACCCGCCCGCGG 
3’mouse-ALK2 CTGCTGGCCTTCACAGTGGTCCTCGTTCC 
5’mouse-ALK3 GCTATACACTTACATCAGATTACTGGG 
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3’mouse-ALK3 CCATGGAAATGAGCACAACCAG 
5’mouse-ALK5 CTGCTCCCGGGGGCGAAGGCATTACAG 
3’mouse-ALK5 GGTGGTGCCCTCTGAAATGAAAGGGCG 
5’mouse-ALK6 GGAGGATGGAGAGAGTACAGCCCC 
3’mouse-ALK6 CAGCCCAATGCTGTACCGAGGTCG 
5’mouse-ALK7 GGTAAGCCTGCTATTGCTCACCGA 
3’mouse-ALK7 GCCACTGGTTTGGGAGATTTGGTC 
5’mouse-Mef2C GCGTGCTGTGCGACTGTGAGATTGC 
3’mouse-Mef2C CCGCCCATCAGACCGCCTGTGTTACC 
5’mouse-p57 AGTCTGTGCCCGCCTTCTAC 
3’mouse-p57 CTCAGTTCCCAGCTCATCACCC 
5’mouse-CHISEL GGGAGCCTTTCGTCCGGGAGCTGG 
3’mouse-CHISEL CATCTCCTGATTCTAAGCATCCAATG 
5’mouse-dHAND CCCGTGCACCATGAGGGCTACCC 
3’mouse-dHAND CTTCACTGCTTGAGCTCCAGGGCCCAG 
5’mouse-Nkx-2.5 TTCAAGCCCGAGGCCTACTCTG 
5’mouse-Nkx-2.5 TGAATCCCCTCCTTCCGCATT 
 
 
2.1.8. Vectors and Plasmids 
 
 
pGEM  
T-Vector 
Promega Contains TA cloning ends for PCR products.  
pCR TOPO 2.1 Invitrogen Contains TA cloning ends for PCR products. 
pCR TOPO II Invitrogen Contains TA cloning ends for PCR products. 
pEGFP-C2 Clontech Contains CMV the promoter and GFP coding 
sequence at C-terminal end; constructed for 
production of fused protein.  
pRSET A Invitrogen Contains 6 copies of Histidine tag which is 
recognized by the monoclonal antibody; 
constructed for production of the epitope-
tagged protein which can be overexpressed in 
E.coli. 
pVL1392 Clontech For protein over-expression in baculovirus 
pIRES2-GFP Clontech Contains CMV promoter and  GFP coding 
sequence at C-terminal end; constructed for 
production of fused protein 
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pHTOP-
BMP10 
Generous gift 
from Dr. 
Neuhaus 
Contains the full length cDNA of human 
BMP10  
BMP10-gen2-
BamHI/HindIII 
Generous gift 
from Dr. 
Neuhaus 
Conteins flanking region of the genomic 
BMP10 locus. Used as probe for ES screening 
BMP10pro Generous gift 
from Dr. 
Neuhaus 
Contains exon 1 and 2 of the human BMP10.  
BMP10-gen10 Generous gift 
from Dr. 
Neuhaus 
Contains part of the BMP10 genomic locus. 
pBlusescript-
BMP10-gen-
locus 
Generous gift 
from Dr. 
Neuhaus 
Contains fragment of the BMP-10 genomic 
locus. 
 
 
2.1.8.1. Plasmids for riboprobes synthesis 
 
 
Antisense 
probe GENE INSERT SIZE (kb) VECTOR 
Enzyme Pol. 
BMP10 BMP10 pro region 1,8kb pBluscript BamH1 T7 
ANF ANF  0,8 kb 
pGEM-T-
Vector 
HindIII T7 
FHL2 FHL2  0,5 kb pBluscript EcoRI T7 
 
 
2.1.9. Bacterial strains 
 
Bacterial strain Company Brief destription 
TOP10F` E.coli (Invitrogen) 
[F`[lacIq,Tn10(TetR)]], mercA, ∆(mrr-hsdRMS-
mcrBC), 
φ80lacZ∆M15, ∆lacX74, deoR, recA1, araD139 
∆(ara-leu)7697, galK, rpsL(StrR), endA1, nupG, 
XL1-Blue E. coli (Stratagene) 
recA1, endA1, gyrA96, thi-1, hsdR17(rK-,mK+), 
supE44, relA1, l-, lac-, [F' proAB, lacIqZD M15, 
Tn10(Tetr)] 
Stbl2 E. coli (Invitrogen) F
-
 mcrA ∆(mrr-hsdRMS-mcrBC) recA1 endA1 
lon gyrA96 thi-1 supE44 relA1 λ- ∆(lac-proAB) 
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BL21(DE3)pLysE 
E. Coli (Stratagene) 
B,F, dcm, ompT, hsdSB(rB-mB-)gal(DE3) [pLysS 
Camr, T7 lysozyme, T7 RNA polymerase inhibitor 
 
 
2.1.10. Cell lines 
 
BM-MASC Belema Bedada et al., 2005 
COS-1 ATCC No: CRL-1650 
C3H10T1/2 ATCC No: CCL-226; murine mesenchymal fibroblasts 
C2C12 ATCC No: CRL-1722; murine myoblastoma cell line 
SF9 ATCC No: CRL-1711 
293T ATCC No: CRL-11268; human kidney cell line, contains Adeno 
and SV-40 viral DNA sequence 
 
 
2.1.11. Antibodies 
 
• Alexa Fluor 488 labelled chicken anti-rabbit IgG, (Molecular Probes) 
• Alexa Fluor 488 labelled goat anti-mouse IgG, (Molecular Probes) 
• Alexa Fluor 594 labelled chicken anti-mouse IgG, (Molecular Probes) 
• Alexa Fluor 594 labelled chicken anti-rabbit IgG, (Molecular Probes) 
• Digoxygenin FAB Fragment (Roche) 
• Donkey Anti- rabbit IgG horse radish peroxidase linked (Amersham) 
• Donkey anti-goat IgG Cy2 (Jackson Immnunoresearch) 
• Donkey anti-goat IgG Cy3 (Chemicon) 
• Donkey anti-mouse IgG Cy2 (Jackson Immnunoresearch) 
• Donkey anti-rabbit IgG Cy3 (Chemicon) 
• Goat anti-mouse FAB fragment (Chemicon) 
• Goat anti-mouse whole antibody (Chemicon) 
• Goat anti-rabbit IgG (H+L) Biotin SP-conjugated (Jackson Immnunoresearch) 
• Goat polyclonal anti- Nkx-2.5 antibody (Santa Cruz)  
• Goat polyclonal anti- PDGFRß antibody (Santa Cruz)  
• Goat polyclonal anti- PECAM antibody (Santa Cruz)  
• Goat polyclonal anti- POD1 antibody (Santa Cruz) 
• MF-20:  Mouse monoclonal antibody anti myosin heavy chain, (Schafer et al. 
1999) 
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• Mouse monoclonal Anti HisG antibody (Invitrogen) 
• Mouse monoclonal anti- NCL-CCC9 antibody (Novocastra) 
• Mouse monoclonal anti SM-actin clone 1A4 Cy3 conjugated antibody (Sigma) 
• Mouse monoclonal anti SM-actin clone 1A4 FITC conjugated antibody (Sigma) 
• Mouse monoclonal anti-calponin antibody (Sigma) 
• Mouse monoclonal anti-desmoplakin antibody (Labgen) 
• Mouse monoclonal anti-plakoglobin antibody clone 15F11 (Sigma)  
• Mouse monoclonal anti-vimentin antibody clone V9 Cy3 conjugated (Sigma) 
• Mouse monoclonal anti-vinculin antibody clone VIN 11-5  (Sigma) 
• Peroxidase conjugated streptavidin antibody (Rockland) 
• Polyclonal rabbit anti-GFP (Invitrogen) 
• Rabbit affinity purified anti-collagen VI antibody (Rockland) 
• Rabbit polyclonal anti phospho-histone 3 antibody (Upstate)  
• Rabbit polyclonal anti-Aurora B antibody (Abcam) 
• Rabbit polyclonal anti-BMP10 antibody (Abgent) 
• Rabbit polyclonal anti-BMP10 antibody (Acris) 
• Rabbit polyclonal anti-dystrophin antibody (H300) (Santa Cruz) 
• Rat monoclonal anti-ScaI (D7) antibody (BD Clontech) 
• Sheep Anti- mouse IgG horse radish peroxidase linked (Amersham) 
• Streptavidin-Cy2 conjugated (Chemicon) 
• Streptavidin-Cy3 conjugated (Chemicon) 
• Texas Red dye conjugated streptavidin antibody (Jackson Immnunoresearch) 
 
 
2.1.12. Mouse strains 
 
• ICR (CD31) – albino inbred strain used as wild type in the present study. 
• BL6C/57 –inbred strain commonly used for the generation of transgenic mice. 
• MnSOD knock-out (kind gift from Dr. T. Loch) 
• Desmin-LacZ (generous gift from Prof. Braun) 
• Sca1-GFP (generous gift from Prof. Braun) 
 
 
                                                                        Experimental procedures 
 23 
2.1.13. Buffers and solutions 
 
All buffers and solutions were prepared in accordance with standard protocols 
included in “Molecular Cloning” (Sambrook et al., 1989) or “Current Protocols in 
Molecular Biology” (Ausubel et al., 1992). All solutions were made in double-distilled 
water or demineralized MilliQ water. Solutions were either autoclaved or filter-
sterilized. 
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2.2. Methods 
 
2.2.1. Standard molecular biology methods 
 
All molecular biology procedures were used according to the standard protocols 
of “Molecular Cloning” (Sambrook at al. 1989) and “Current Protocols in Molecular 
Biology” (Ausubel et al. 1992). Procedures used during current study are described 
below only if they differ from the manufacture’s instructions. 
 
 
2.2.2. Cloning methods 
 
All plasmids, during the current studies, were prepared as follows. Inserts of 
interests were amplified using Taq Polymerase (Eppendorf) or Expand High Fidelity 
Polymerase (Roche) with specific primers (2.1.7). PCR amplified fragments were 
cloned into the pGEM-T-vector (Promega) or pCR TOPO II (Invitrogen). Plasmid DNA 
was isolated according to the protocol (Sambrook at al. 1989). Clones were verified by 
digesting with restriction endonuclease enzymes, followed by sequencing of positive 
clones. Typically, a standard sequencing reaction contained around 50-100 ng of 
plasmid DNA, 3.2 pmol of the indicated sequencing primer (2.1.7) supplemented with 
buffers from DNA Cycle Sequencing Kit (Abi, Weiterstadt). Sequencing reactions were 
prepared using the ABI 310 Genetic Analyzer sequencer (Perkin Elmer). Sequences and 
their alignments were validated using the following data bases: www.ncbi.nih.gov. 
BLAST, www.ensembl.org and DNA-Star, Lasergene 99 software. Clones with proper 
sequences were used for further studies. Fragments were cut out with restriction 
enzymes and subcloned into the target vectors (2.1.8). 
 
 
2.2.3. Plasmids generated during the studies 
 
 Plasmids generated during the presented work were prepared as described in the 
chapter 2.2.2 and summarized in the table. The table contains: primers’ pairs used for 
PCR amplification (2.1.7) as well as their applications for further studies. 
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Plasmid 
name 
Primers names Cloning 
sites Applications 
pCRII-TOPO-
GAPDH 
5’-m-GAPDH 
3’-m-GAPDH - 
320 bp GAPDH fragment 
obtained using RT-PCR for 
qRT-PCR. 
pRSET-B- 
mature-
BMP10 
5’-pRSET-BMP10 
3’-pRSET-BMP10 
KpnI 
XhoI 
Over-expression of the fused 
mature region of the BMP10 
protein to the N-terminal 
6×His- tag. in E.coli.  
pVL1392-
BMP10 
5’pvl-BMP10 
3’pvl-BMP10 
NotI 
XbaI 
Over-expression of the full 
length BMP10 in insect cells. 
Transfer plasmid. 
pCRII-TOPO-
ANF 
5’-m-ANF 
3’-m-ANF - 
The ANF fragment obtained 
using RT-PCR for qRT-PCR. 
pIRES2-GFP- 
BMP10 
5’pIRES-BMP10 
3’pIRES-BMP10 
PstI 
XmaI 
Expression of the full length 
of the human BMP10 protein 
in eukaryotic cell lines. 
pCRII-TOPO-
3’flanking-
arm-BMP10 
5’-3’arm-BMP10 
3’-3’arm-BMP10 ApaI 
Construct for the conditional 
inactivation of BMP10. 
pCRII-TOPO-
5’flanking-
arm-BMP10 
5’-5’arm-BMP10 
3’-5’arm-BMP10 SacII 
Construct for the conditional 
inactivation of BMP10. 
pCRII-TOPO-
Exon2-
BMP10 
5’-ex2-BMP10 
3’-ex2-BMP10 KpnI 
Construct for the conditional 
inactivation of BMP10. 
pK11-loxP-
BMP10-loxP - - 
Construct for the conditional 
inactivation of BMP10. 
pCRII-TOPO-
BNP 
5’-m-BNP 
3’-m-BNP - 
The BNP fragment obtained 
using RT-PCR. 
pCRII-TOPO-
FHL2 
5’-m-FHL2 
3’-m-FHL2 - 
The FHL2 fragment obtained 
using RT-PCR. 
pCRII-TOPO-
BMPRII 
5’-m-BMPRII 
3’-m-BMPRII - 
The BMPRII fragment 
obtained using RT-PCR. 
pCRII-TOPO-
PDGFRß 
5’-m-PDGFRß 
3’-m-PDGFRß - 
The PDGFRß fragment 
obtained using RT-PCR. 
pCRII-TOPO-
PECAM 
5’-m-PECAM 
3’-m-PECAM - 
The PECAM fragment 
obtained using RT-PCR. 
pCRII-TOPO-
calponin 
5’-m-calponin 
3’-m-calponin - 
The calponin fragment 
obtained using RT-PCR. 
pCRII-TOPO-
POD1 
5’-m-POD1 
3’-m-POD1 - 
The POD1 fragment 
obtained using RT-PCR. 
 
Plasmids used for riboprobes synthesis were generated by cloning of RT-PCR 
amplified fragments into the pCR TOPO II (Invitrogen) and are listed in the chapter 
2.1.8.1. 
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2.2.4. Conditional inactivation of BMP10 gene 
 
The plasmid containing the genomic locus of the BMP10 gene was kindly 
provided by Dr. Herbert Neuhaus (2.1.8). Flanking arms (5’ and 3’) as well as exon 2 of 
the BMP10 gene were amplified by PCR using Expand High Fidelity polymerase 
(Roche) and specific primers (2.1.7). All fragments were cloned into the pCRII-TOPO 
vector (Invitrogen) and verified by sequencing including also internal set of primers. 
Next, 3’ flanking region (1.6 kb) was inserted into the pK11 vector with the ApaI site 
followed by cloning exon2 of BMP10 using the KpnI site. Finally, the 5’ flanking arm 
(4.8 kb) was subcloned into the pK11-3’-arm-exon2 plasmid with the SacII site. A 
schematic overview of the construct for the conditional BMP-10 ablation in mice is 
shown in Fig. 2.1. 
 
 
 
  
 
Fig. 2.1. The organization of the BMP-10 modified locus including major 
restriction sites is shown.  
 
The targeting vector contains also a neomycin resistance gene (neo) under the control of 
the phosphoglycerol kinase (PGK) promoter flanked by two FRT sites. The pK11-
BMP-10-ko plasmid was linearized with the PvuI restriction enzyme for ES cells 
transfection. Culture plates used for embryonic stem (ES) cells growth were covered 
with 0.2% gelatine. ES cells were cultivated on a monolayer of feeder cells treated with 
mitomycin C (kind gift from Dr. T. Loch). Usually, feeder cells were plated one day 
prior to ES cells seeding. The culture of ES cells was propagated in ES-medium in a 
humidified atmosphere containing 10% CO2 at 37OC. The medium was changed daily. 
ES cells before trypsinization were washed with HEPES/EDTA buffer and detached 
using 0.25% trypsin in HEPES/EDTA buffer. The target construct was introduced into 
ES cells by electroporation methods. Briefly, cells were harvested and around 14×106 
cells were suspended in 600µl of OPTI-MEM medium and 25µg of the linearized 
plasmid DNA was added. Electroporation was done using 4 mm gap electroporation 
cuvettes (Peqlab) at the following conditions: low voltage mode, 250 V and 1 
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millisecond pulse. Then cells (2×4×106 and 2×7×105) were plated in 10-cm dishes. One 
day later, the medium was replaced by selection medium (ES-medium supplemented 
with G418 at 400 µg/ml). Transfected ES cells were grown in selection medium for 14 
days and the medium was replaced daily. After 10 days single colonies were picked and 
propagated in 96 well plates followed by their growth in 24 well plates. Only around 
80-100 clones were obtained after a single electroporation. A part of the ES culture was 
prepared for DNA isolation. These clones were grown in 24 well plates for 7-8 days 
until they reached confluence. Genomic DNA was isolated from around 100 clones 
using the proteinase K extraction method, and southern blot analysis was done using 
specific probe. None of the screened clones were positive for a mutated allele (data not 
shown). 
 
 
2.2.5. In situ hybridization 
 
2.2.5.1. Embryos preparation 
 
Isolated embryos at the different stages were immediately washed with ice-cold 
1×PBS and fixed in 4%PFA over night. Next, samples were dehydrated in 25%, 50%, 
and 75% methanol  in PBT and 2 times in 100% methanol -10 minutes each at room 
temperature. Dehydrated embryos were stored in -20OC in 100% methanol. 
 
 
2.2.5.2. Tissue preparation for paraffin embedding 
  
Dissected tissues samples were immediately washed in ice-cold 1×PBS, 
followed by fixation in 4% PFA over night. Next, tissues were dehydrated in ethanol 
(25%, 50%, 75%, 96% for 60 minutes each step and twice in 99.8% ethanol for 10 
minutes followed by 99,8% EtOH at -20oC over night). Next day, tissues samples were 
treated twice with 99.8% ethanol/xylol (1:1) for 1 hour, twice per 1 hour with xylol at 
room temperature and incubated for 2 hours at 60oC with a mixture of Xylol/ Paraffin 
(1:1), followed by two changes of pure paraffin at 60oC. Finally, tissues were embedded 
in paraffin. Sections 7-13 µm thick were prepared using a microtome (Leica). Samples 
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were attached to glass slides coated prior to use with VectabondTM solution according to 
the manufacture’s instruction. 
 
 
2.2.5.3. In vitro transcription 
 
An antisense and sense riboprobes were synthesized using linearized plasmid 
DNA with RNA polymerases (T7, T3, SP6), depending on the plasmid (2.1.8.1). The 
typical reaction mixture contains: 
 
 Linearized plasmid  1 µg 
 5 transcription buffer  4 µl 
 0.1M DTT   2 µl 
 Dig-Mix   2 µl 
 RNA polymerase  1 µl 
 RNasin   2.5 µl 
 H2O     ad 20 µl 
 
The reaction was done for 2 hours at 37oC. A plasmid DNA was enzymatically digested 
using DNase I for 30 minutes at 37oC followed by DNase heat inactivation at 65oC for 
15 minutes. Synthesized riboprobes were purified by precipitation with ethanol 
supplemented with lithium chloride. Next, probes were redissolved in water 
supplemented with RNase inhibitor. The quality of RNA was checked by 
electrophoresis on 1% agarose gel. 
 
 
2.2.5.4. Whole mount in situ hybridization 
 
Embryos at E10.5 were prepared as described in 2.2.5.1. Digoxigenin labeled 
anti-sense and sense probes were synthesized as described in 5.2.5.3. Whole amount in 
situ hybridization was done according to Wilkinson. The following steps were applied: 
 
I. Pre-hybrydization washes: 
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 100% Methanol   5 min.   RT 
 75% Methanol/PBT   5 min.   RT 
 50% Methanol/PBT   5 min.   RT 
 25% Methanol/PBT   5 min.   RT 
 2×PBT    5 min.   RT 
 6% H2O 2    45 min.  RT 
 3×PBT    5 min.   RT 
 Proteinase K (10µg/ml)/PBT  11 min.  RT 
 Glycine (2mg/ml)/PBT  5 min.   RT 
 2×PBT    5 min.   RT 
 0.2% glutaraldehyde/4% PFA 20 min.   RT 
 3×PBT    5 min.   RT 
 Prehybridization Buffer  120 min.  65OC  
 Hybridization Buffer   o.n.   65OC 
 
II. Post-hybridization washes: 
 
 2 x Solution 1    30 min.  70OC 
 Solution 1:Solution 2 (1:1)  10 min.  70OC 
 3x Solution 2    5 min.   RT 
 RNase A (1 mg/ml)/ Solution 2 30 min.  37OC 
 Solution 2    5 min.   RT 
 Solution 3    5 min.   RT 
 2 x Solution 3    30 min.   65OC 
 3 x TBST    5 min.    RT 
 10% Sheep serum/TBST  70 min.   RT 
 Anti-digoxigenin antibody  o.n.   +4OC  
1:2000 in 1% sheep serum/TBST 
 
III. Alkaline Phosphatase staining 
 
 6 x TBST    60 min.   RT 
 3 x NTMT    10 min.   RT 
 NBT/BCIP in NTMT      RT   
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The alkaline phosphate staining of the samples was stopped with PBT at room 
temperature followed by overnight fixation in 4% PFA at 4oC. Embryos were 
documented. 
 
 
2.2.5.5. In situ hybridization in paraffin embedded tissue slides 
 
Tissues samples were prepared as described in 2.2.5.2. Digoxigenin labeled anti-
sense and sense probes were synthesized as described in 2.2.5.3. In situ hybridization 
was done in the following steps: 
 
I. Pre-hybrydization washes: 
 
 2 x 99.8% Ethanol   2 min.   RT 
 96% Ethanol    1 min.    RT 
 70% Ethanol    1 min.    RT 
 50% Ethanol    1 min.    RT 
 30% Ethanol    1 min.    RT 
 PBS     5 min.    RT 
 4% PFA    15 min.   RT 
 PBS     5 min.    RT 
 Proteinase K (10µg/ml)/PBS  5 min.   RT 
 Glycine (2mg/ml)/PBS  5 min.   RT 
 PBS     5 min.    RT 
 4% PFA    15 min.   RT 
 Acetic Anhydrate/0.25% TEA/H2O  10 min.   RT 
 2 x PBS     5 min.    RT 
 Pre-hybridization buffer  15 min.   65OC 
 Hybridization buffer   o.n.   65OC 
 
II. Posthybridization wash. 
 
 3 x Solution I    15 min.   65OC 
 3 x Solution III   15 min.   65OC 
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 3 x TBST    10 min.  RT 
 10% Sheep serum/TBST  30 min.   RT 
 Anti-digoxigenin antibody  o.n.   +4OC  
1:2000 in 1% sheep serum/TBST 
 
III. Alkaline Phosphatase Staining. 
 
 3 x TBST    15 min.   RT 
 3 x NTMT    10 min.   RT 
 NBT/BCIP in NTMT      RT  
 
The alkaline phosphate staining of the samples was stopped with PBS at room 
temperature followed by fixation in 4% PFA for 60 minutes. Next, sections were stained 
with eosin (2.2.5.6) followed by dehydratation. Finally tissues samples were embedded 
in Entelan and documented. 
 
 
2.2.5.5.1. In situ hybridization solutions and buffers 
 
 Solution 1    50% Formamide 
5 x SSC pH 4.5 
1% SDS 
 Solution 2    0.5 M NaCl 
10 mM Tris-HCl pH 7.5 
0.1% Tween-20 
 Solution 3    50 % Formamide 
2 x SSC pH 4.5 
 NTMT    100 mM Tris-HCl pH 9.5 
100 mM NaCl 
0.05 M MgCl2 
0.1% Tween-20/levamisole 
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2.2.5.6. Hematoxylin/eosin staining 
 
After completing the in situ hybridization procedure, sections were stained with 
2% eosin solution (Division Chroma) for 5 minutes and washed several times with 
water.  
Cryosections were fixed in 4% PFA for 10 minutes, washed with PBS followed 
by nuclear staining with hematoxylin (Division Chroma) for 10 minutes and washed 
with water. The cytoplasm was visualized by eosin staining. Next, sections were 
dehydrated in increasing concentrations of ethanol and finally in xylol followed by 
embedding in Entelan. 
 
 
2.2.6. Basic cell culture methods 
 
2.2.6.1. Maintenance of cell lines 
 
C3H10T1/2, 293T, C2C12 and COS-1 cell lines were grown in D-MEM 
medium containing 1.000 mg/ml and 4.500 mg/ml glucose respectively, supplemented 
with 10% FBS, 100 U/ml of penicillin, 100 µg/ml of streptomycin and 0.292 mg/ml L-
glutamine. Cells were grown for 2 days to reach around 80% confluence in a humidified 
atmosphere containing 10% CO2 at 37°C. Cells were harvested with trypsin solution 
(PAA Laboratories) and split in different ratios, depending on the cell line. Stocks of 
cells were made in DMEM medium containing: 20% FBS and 10% DMSO. 
 
 
2.2.6.2. Transient transfections 
 
2.2.6.2.1. Calcium phosphate method 
 
The calcium phosphate method was used to transiently transfect 293T and COS-1 
cell lines. Cells were seeded 24 hours prior to transfection on 6 cm plates (if applicable, 
containing sterile glass cover slides (Roth)). Cells were plated with a density of 
approximately 5×104 cells per 6cm plate. Approximately 10 minutes before 
transfection, the medium was replaced with fresh growth medium supplemented with 50 
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µM chloroquine (Sigma). Next, 1-30 µg of total plasmid DNA was mixed with 500 µl 
of 2xHBS buffer (100 mM NaCl; 6.5 mM KCl; 0.8 M Na2HPO4 ⋅ 2H2O; 210 mM 
HEPES pH 7.05) followed by addition of 62 µl of 2 M CaCl2. The transfection cocktail 
was immediately mixed by pipeting and added to a plate in dropwise fashion. Usually, 
3-4 hours later medium was replaced and fresh medium was applied. 
 
 
2.2.6.2.2. Fugene 6 transfection reagent 
 
The Fugene 6 transfection reagent was used to transiently transfect the 10T1/2 
cell line according to the published protocol (Roche). 
 
 
2.2.6.3. Overexpression of BMP10 in the 293T cell line, preparation of conditioned 
medium  
 
 The 293T cell line was transiently transfected using the calcium method 
(2.2.6.2.1) or the Fugene 6 reagent (2.2.6.2.2) with pBMP10-IRES2-GFP plasmid or 
pEGFP-C2 vector. Twenty-four hours after transfection, the medium was replaced by 
serum free medium D-MEM containing 1.000 mg/ml glucose supplemented with 100 
U/ml of penicillin, 100 µg/ml of streptomycin and 0.292 mg/ml L-glutamine. Seventy-
two hours after transfection, its efficiency was proved by fluorescence microscopy and 
the medium enriched in BMP10 protein as well as control medium were collected, 
filtrated and used in further experiments. In addition, cells were homogenized in 
TRIZOL and total RNA was isolated followed by RT-PCR examination. BMP10 
conditioned medium and control medium were examined by western blot and the 
activity of the BMP10 protein to induce alkaline phosphatase (2.6.7) in C2C12 cells was 
tested. 
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2.6.7. Alkaline Phosphatase detection 
 
The activity of the BMP10 protein in conditioned medium was analysed by its 
ability to induce alkaline phosphatase activity in C2C12 cells. Briefly, 1x104 C2C12 
cells were seeded per 1 well using 96 well plates. The next day, conditioned medium 
containing secreted BMP10 protein and BMP-2 (Sigma) as positive control were 
applied. As negative control serum free medium collected from 293T cells transfected 
with the pEGFP-C2 vector as well as standard GM were applied. Different 
concentrations of BMP-2 in the range 200 ng, 150 ng, 100 ng, 75 ng, 50 ng, 25 ng per 
ml were used. In the case of BMP10 conditioned medium and control serum free 
medium 100%, 75%, 50%, 10%, 5% were used. All tested conditions were done in 
triplicate. After 48 hours cells were washed a few times in PBS, followed by fixation in 
4% PFA for 10 min. Next, cells were washed three times with buffer containing 100 
mM Tris-HCl pH 9.5, 0.1% Triton X-100, 0.5 mM MgCl2. Finally, cells were incubated 
with the NBT/BCIP staining solution at 37OC for 10-15 minutes followed by washing 4-
5 times with PBS and fixation in 4% PFA for 10 minutes. Cells were documented by 
photographing using a digital camera (Canon). 
 
 
2.2.8. Mouse adult heart non-cardiomyocyte isolation 
 
 Non-cardiomyocyte populations were isolated from BL6C/57 or Sca-1-GFP 
mice strains. Animals were anesthetized with pentobarbital sodium. The murine hearts 
were quickly removed and perfused by the aorta with Ca2+ free buffer containing: 113 
mM NaCl, 4.7 mM KCl, 0.6 mM KH2PO4, 1.2 mM MgSO4×7H2O, 12 mM NaHCO3, 
10 mM HEPES, 30 mM Taurin, 10 mM 2,3-butanedione monoxime, 5.5 mM glucose. 
The enzymatic digestion was initiated by applying Liberase Blendzyme and Trypsin. 
Next, hearts were gently minced and enzymatic digestion was stopped by supplying 
bovine calf serum. The suspension was filtered via a 100µM cells strainer. Cells were 
adjusted with CaCl2 solution to the final 1 mM concentration of Ca2+ in four steps and 
counted for viability. The cell suspension was centrifuged at 300 rpm for 1 minute. The 
supernatant contained the fraction of non-cardiomyocytes cell, which were seeded on 
standard cell culture plates. Non-cardiomyocytes were grown in D-MEM medium 
containing 1.000 mg/ml glucose, supplemented with, 100 U/ml of penicillin, 100 µg/ml 
                                                                        Experimental procedures 
 35 
of streptomycin and 0.292 mg/ml L-glutamine and 10% FBS in a humidified 
atmosphere containing 10% CO2 at 37°C. Isolation of murine adult non-cardiomyocytes 
were done together with Marion Winslet. The culture purity was checked by 
immucytochemistry (Fig. 2.2). 
 
 
 
 
 
 
 
 
 
 
Fig. 2.2. Immunocytochemistry of non-cardiomyocytes isolated from the murine 
adult heart. Cells were stained with SM-actin conjugated FITC antibody (green) 
and vimentin conjugated TRITC antibody (red) to quantify the number of 
fibroblasts (vimentin positive), smooth muscle cells (SMA positive) and 
myofibroblasts (SMA and vimentin positive). Nuclei were visualized by DAPI 
staining (blue). 
 
 
2.2.9. Terminal dUTP deoxynucleotidyl transferase nick end-labeling (TUNEL) 
assay 
 
 The TUNEL assay was performed on mouse heart cryosections. Cryosections 
were prepared from at least three animals from each of the tested model of CMP and 
compared to age and strain matched control animals. As a positive control ischemic dog 
heart was used (Kindly provided by Dr. Sawa Kostin). The In situ Cell Death detection 
kit (Roche) was used according to supplier’s manual. 
 
 
2.2.10. Immunocytochemistry 
 
Cells after culture were washed several times with PBS, fixed in 4% PFA for 10-
20 minutes followed by incubation with PBS/0.1% Triton-X100 solution and blocked 
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with 5% horse serum in PBS/0.1% Triton-X100 solution. Cells were incubated with the 
primary antibody at 4oC over night or for 1 hour at room temperature, washed with PBS 
and incubated with secondary, fluorochrom-conjugated antibody for 45 minutes. After 
three washes with PBS, the cells were embedded in Mowiol (6g of glycerol was mixed 
with 2,4 g of Mowiol and 6 ml H2O, followed by incubation for 4 hours at room 
temperature, mixed with 12 ml of 0.2 M Tris-HCl pH 8.5, heated for 10 minutes at 
50OC and aliquoted). 
 
 
2.2.11. Immunohistochemistry 
 
Depending on the aim of the study and/or primary antibody, different staining 
protocols and detection systems were used. 
Cryosections were washed with PBS, fixed in 4% PFA for 10-20 minutes 
followed by incubation with PBS solution and blocked with 0.1% BSA in PBS. 
Cryosections were incubated with the primary antibody at 4oC, washed with PBS and 
incubated with secondary, fluorochrom-conjugated antibody for 45-60 minutes. After 
three washes with PBS, sections were embedded in Mowiol. When the signal had to be 
amplified the two step detection of the primary antibody with the biotin-streptavidin 
system was used. 
 
 
2.2.12. β-galactosidase staining 
 
Tissues samples were fixed in PFA solution followed by preparation of the 
cryosections. Sections were washed with PBS and treated with the staining solution ( 5 
mM potassium ferricyjanide, 5 mM potassium ferrocyjanide, 1 mM magnesium 
chloride, 0.002% NP-40, 0.05% Na-deoxycholate) containing 0.1% X-Gal for 5-30 
minutes. Reaction was stopped by washing with PBS. Cryosections were embedded in 
Mowiol. 
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2.2.13. Total RNA isolation from tissues and cells 
 
Total RNA was isolated using the TrizolTM reagent according to the 
manufacture’s instructions (Invitrogene). All equipments for RNA isolation were 
sterilized by treating with 0.5 M NaOH for 30 minutes at room temperature followed by 
washing with DEPC water. Tissue samples were homogenized using the Ultra Turrax 
homogenizer (IKA Works, Wilmington, USA). Solutions used during the RNA isolation 
procedure were prepared on the base of RNAse free water. Typically 1 ml of TrizolTM 
reagent was applied to 100 mg of tissue or per 106 cells.  
 
 
2.2.14. Reverse transcription reaction 
 
The reverse transcription reaction was performed on the template total RNA 
extracted with the TRIzolTM reagent (2.2.13). Total RNA concentration was estimated 
with the Eppendorf BioPhotometer by measuring absorbance at 260 nm in triplicate. 
Firstly, due to the possibility of DNA contamination, RNA was treated with RQ1 
RNase-free DNase (1 U of DNase per 1 µg of RNA) followed by DNase heat 
inactivation (65OC, 10 minutes). DNA free samples were used for first stranded cDNA 
synthesis. Reverse transcription reactions were carried out using SuperscriptII reverse 
transcriptase (Invitrogen) and oligodT(15) (Promega) according to the manufacture’s 
protocol. Reaction was done at 42OC for 60 minutes followed by heat inactivation of 
Superscript II at 70OC for 10 minutes. cDNAs obtained were freshly used for PCR 
reaction or stored in -20OC for further experiments. 
 
 
2.2.15. PCR reaction 
 
PCR conditions were optimized experimentally for each primer pair according to 
the manufacturer’s instructions (Eppendorf). Usually, the template DNA was used in the 
range 1-10 ng in the case of plasmid DNA or 2-4 µl of cDNA after the RT reaction. The 
amount of cDNA used for the PCR reaction depended on the level of gene expression in 
the samples. The typical reaction mixture contained: 10 x buffer, 5 x Enhancer buffer, 
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0.2 pmol of each primer, 5U of Taq polymerase (Eppendorf) and when necessary 
supplemented with MgCl2. Thermal cycling conditions were optimized empirically. 
 
 
2.2.16. Semi-quantitative and quantitative Real Time PCR reactions 
 
The semi-quantitative PCR analysis was performed using 2-4 µl of cDNA as a 
template for the PCR reaction. Expression of each of the examined genes was tested 
individually with a decreasing number of cycles, and repeated in triple. As a reference, 
the level of the housekeeping genes GAPDH or HPRT was used. 
The quantitative Real Time analysis was done using the iCycler iQ Multi Colour 
Real Time PCR thermocycler (Biorad Laboratories). The typical reaction mixture is 
described in 2.2.15. It was supplemented by SYBR green and fluorescein according to 
the published protocol. A standard curve was determined by the expression level of the 
housekeeping gene GAPDH. 
 
 
2.2.17. P32 labeling probe preparation 
 
Plasmid DNA was digested with specific restriction endonucleases, followed by 
electrophoresis on the agarose gel. Inserts were cut out and purified with the JetQuick 
Gel extraction kit (Genomed). Typically, 25-50 ng of purified DNA was mixed together 
with random hexanucleotides as primers and denatured at 95OC for 5 minutes followed 
by cooling down on ice. These components were mixed with: dNTPs, BSA, Klenow 
enzyme, 5 µl of [α-32P] dCTP (6000 Ci/ml) and incubated at 37OC for 2 hours. A 
random primed labeled probe was purified from not nucleotides incorporated using 
NAP-5TM columns (Sephadex® G-25) (Pharmacia Biotech). 
 
 
2.2.18. Southern blot analysis 
 
Southern blot analysis was performed according to Sambrook et al. 1989. The 
genomic DNA was obtained from the ES cells clones (2.2.4). To screen the ES clones, 
genomic DNA was digested with KpnI and separated on 1% agarose gel followed by 
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DNA depurination (incubation in 0.25% HCl for 15-20 minutes at room temperature). 
The transfer was done in alkaline conditions (0.4 M NaOH), over night. More than 12 
hours later, the membrane was washed in 2xSSC pH 7.5 for 10 minutes and air-dried. 
The membrane with bound DNA was hybridized with radioactively labeled DNA probe. 
In the first step, the membrane was pre-hybridized at 65OC for 2-3 hours in Church and 
Gilbert hybridization buffer (0.5M Na2HPO4, 1 mM EDTA, 7% SDS) containing 0.2 
mg/ml denaturated herring sperm DNA. Hybridization was carried out in Church and 
Gilbert hybridization buffer containing a reduced amount of denaturated herring sperm 
DNA to 0.1 mg/ml and 3 x 106 cpm/ml of labeled probe. The reaction was done at 65OC 
with rolling over night. Typically, the next day the membrane was washed three times 
with solution containing 1xSSC pH 7.0, 1% SDS at 65OC. The results were visualized 
using X-ray films (Kodak). 
 
 
2.2.19. Western blot analysis 
 
Typically, proteins were separated on standard denaturing SDS-PAGE gels. 
However, depending on the aim of the experiment, different types of gels were used. 
The first type of gels was performed according to Sambrook et al. 1989, and was 
composed of 5% stacking gel and separating gel in the range of 6% to 15%. This type of 
gels was used for detection of higher amount of proteins. Gradient gels were bought 
from Invitrogen and Anamed. Upon completion of electrophoresis, proteins were 
transferred onto nitrocellulose membranes using two systems: semi-dry electroblotting 
method (Fastblot B 43, Biometra) or the so called wet system according to the manual 
(Invitrogen). In the case of semi-dry blotting, 4 pieces of Whatman 3MM paper and 1 
piece of BioTrace® Nitrocellulose Membrane were cut to the size of the gel and together 
with the gel soaked for a few minutes in electroblotting buffer. Two layers of 3MM 
paper were placed on an anode. On the top of that, the nylon membrane was placed. 
Gels were laid on the membrane and covered with 2 additional layers of 3MM paper. 
The whole stack was covered with the cathode. Electroblotting was run at a current of 5 
mA per cm2 of the blot for 45-60 minutes. The membrane was stained with Ponceau S 
for a few minutes to visualize the transferred protein bands followed by blocking in 5% 
non-fat dry milk powder (Roth) in TBST solution for 60 minutes at room temperature. 
The membrane was incubated at 4°C over night with the primary antibody in blocking 
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buffer containing 3% non-fat dry milk powder in TBST buffer. Next, three 5 min. 
washings in TBST buffer preceded 45 min. incubation (room temperature) with the 
secondary antibody in TBST with 1% non-fat dry milk. All incubations were done on 
the rotating platform. 
Depending on the type of experiment and the level of proteins, different 
detection systems were used. When highly expressed proteins were monitored, the 
system based on DAB staining was used. After 3 washings (5 min. each) in TBST, the 
membrane was incubated with ABC solution (2 drops of ‘label A’ and 2 drops of ‘label 
B’ in 5 ml TBST prepared 30 min. in advance, Vector Laboratories) for 30 min. After 
that the membrane was washed three times with TBST buffer. Detection was done with 
DAB (2.5 mg/ml) in 10 ml of 0.1 M Tris⋅HCl pH 7.2 with 5 µl 30% H2O2. Staining was 
stopped by rinsing in water. When the proteins were not abundant or isolated from 
different cell lines and tissues, the ECL detection (Amersham) or Femto WB detection 
system (Pierce) were used according to published manuals. 
 
 
2.2.20. Protein isolation 
 
Tissues samples after isolation were sonicated in the extraction buffer (0.1 M 
Tris-HCl pH 8.0, 0.01 M EDTA, 0.04 M DTT, 10% SDS supplemented with proteases 
inhibitor). After sonication, protein crude was incubated for 2 min. at 99OC followed by 
centrifugation at room temperature with maximum speed. Specific fractions of protein 
were isolated using NE-PER extraction kit (Pierce) according to the manual. Protein 
concentration was determined using BioRad Dc assay according to the protocol. 
 
 
2.2.21. Overexpression and purification of the His-tagged mature region of BMP10 
 
In order to overexpress BMP10 in bacteria, the pRSET vector (Invitrogen) was 
used which contains N-terminal 6HisG tag. The his tag not only facilitates affinity 
chromatography purification on a Ni 2+-NTA column but also the detection of the 
overexpressed protein, since a specific anti-HisG antibody (Invitrogen) is available. 
Additionally, as the main aim of the study was the generation of a BMP10 antibody, the 
His tag is believed to be the least immunogenic. The mature region of BMP10 was PCR 
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amplified with specific primers, containing in-frame XhoI and KpnI restriction sites and 
the product was cloned into the pCR2.1-Topo vector (Invitrogen) followed by 
sequencing. After sequence verification, the XhoI/KpnI fragment was subcloned into 
the pRSET-B vector. The Bl21DE3 bacterial strain (Invitrogen) was used for protein 
overexpression. The conditions for BMP10 overexpression were estimated empirically. 
After transformation of Bl21DE3, colonies were picked from plates and then grown in 
the suspension culture at 37 OC, with shaking of 250 rpm in 50 ml culture volume. After 
over night culture, bacterial cells were placed into the fresh culture medium with 
dilution 1:50 and grown at 37OC or 30OC or RT in various culture volumes (25-150ml). 
Overexpression was induced by applying 1 mM IPTG. 1ml samples were collected 
every hour. The level of protein overexpression was monitored by SDS-PAGE gel 
electrophoresis followed by staining with Coomassie blue solution. The mature region 
of the BMP10 fused to His tag was efficiently overexpressed at all tested conditions, but 
unfortunately the test of solubility revealed that it is insoluble independent on 
culture/overexpression conditions in phosphate buffer, in the pH range compatible for 
protein binding to Ni2+ resins (Fig. 2.3). Hence Mat-BMP10 was overexpressed at 37OC 
and bacteria were collected 4 hours after induction with IPTG (Figs. 2.3, 2.4). In 
addition Western blot was done to verify the identity of the protein band. Overexpressed 
protein was purified under denaturing conditions on a Ni2+ chelating column (Figs. 2.4, 
2.5) as described in the manufacture’s instructions (Qiagen). Fractions (approximately 3 
mg) with the highest degree of purity were subjected to separation on SDS-PAGE on 
standard 15% preparative gels. Proteins were visualized with the ethanol Coomasie 
solution, appropriate bands were cut out and in this form sent for immunization of 
rabbits, that was carried out by Dabio (Regensburg, Germany).  
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Fig. 2.3. Overexpression of the 6His-tagged BMP10 in E.coli (A). Lane 1- 
negative control; 2 and 5- 4 hours after IPTG induction in 30oC and 37 oC, 
respectively; 3 and 6- 2 hours after IPTG induction in 30oC and 37 oC; 4and 7 
before induction with IPTG. Overexpression of the expected 17 kDa mature 
region of BMP10 fused to His-tag was apparent (A). The test of solubility in 
phosphate buffer (B,C) shows that in all tested conditions majority of the 
overexpressed protein remains insoluble. Overexpression in 30oC (B), with 
various oxygen accessibility, i.e. culture volume (1 and 2- 50 ml culture, 3 and 
4- 20 ml culture) did not improve solubility compared with overexpression in 
37oC (C). Lanes 2, 4, 5 show the protein detected with specific anti HisG 
antibody His-BMP10 in insoluble fractions (arrow), lanes 1,3,6- protein detected 
in soluble fractions (arrowhead).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.4. Purification of His-tagged mature region of BMP10. Panel A shows 
SDS-PAGE of collected fractions eluted with 8M urea at pH 4.5 with the highest 
protein content as judged on the basis of the elution profile (B) followed by dot 
blot analysis with anti-HisG antibody of enriched in BMP10 fractions (C). 
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Fig. 2.5. Purification of the His-tagged mature region of BMP10. Panels A and B 
show different tested conditions to obtain the native mature region of BMP10. 
Panel A: lanes -1-3: buffer containing 10 mM HEPES, 10µM Zn(CH3COO)2, 50 
mM NaCl supplemented with 5 mM ß-mercaptoethanol (line 1), 20 mM ß-
mercaptoethanol (line 2), 1mM DTT (line 3), lane 4 – 50 mM Tris-HCl pH 7.5, 
lane 5 – 50 mM Tris-HCl pH 8.0, lane 6 – PBS.  Panel B, phosphate buffer 
supplemented with: 0.1%, 0.2% and 0.5% Tween-20 (lines 1-3 respectively), 
0.1%, 0.2% and 0.5% Triton X-100 (lines 4-6 respectively), 0.1%, 0.2% and 
0.5% NP-40 (lines 7-9 respectively). 
 
 
2.2.22. Osmotic mini-pump implantation 
 
 To induce heart hypertrophy/CMP doxorubicin (15µg/g) and isoproterenol 
(225µg/g) were administrated in the ICR mouse strain by surgical implantation of the 
mini-osmotic pump model 2002 according to supply instructions (Alzet). In all 
experiments both male and female mice were used. Mice were anesthetized with 
Avertin injection or by Isoflurane together with oxygen inhalation followed by 
subcutaneous pump implantation. The skin incision was closed with wound clips. Using 
this pump model, drugs were administrated at 0.5µl per hour for 14 days. 
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2.2.23. Magnetic Resonance Imaging 
 
MRI measurements and data evaluation were done by Dr. Astrid Wietelmann 
and Ursula Hoffmann. The study was carried out on 11 C57bl/6 and 7 ICR animals 
(both genders) of varying ages and weight (22 - 30 g). Animals were anaesthesed by 
using 2.5% isoflurane (Forene, Abbott, Germany) in air and oxygen and then 
maintained during the whole MR experiment with 1.5 to 2.5% (v/v ) isoflurane at 0.5 
l/min air and 0.5 l/min oxygen flow, delivered via a nose-cone (surgivit/Anesco, Hugo 
Sachs Elektronik-Harvard, Germany). The gaseous mixture was bubbled through water 
to prevent damage of the mucous membrane of the mouse from the dry gaseous 
mixture. For electrocardiogram (ECG) triggering ECG leads (Neonatel Monitoring 
Electrode, Red Dot, 3M Health Care, Germany) were attached to both front paws and 
the tail. The leads were attached to a preamplifier (ESS ECG Transducer Box, Bruker 
BioSpin MRI, Germany) to amplify the ECG signal for detection on the magnetic 
resonance system. The mice were positioned supine on a cradle and then placed into the 
MRI receiving coil. The temperature of the probe assembly was maintained at 37°C by 
running heated water through the water channels of the probe assembly to maintain the 
body temperature of the mouse. 
MR acquisitions were performed on a 7.05 T horizontal-bore (16 cm) MR 
scanner (Bruker, Germany) equipped with a 300mT/m gradient system and with 300.51 
MHz for isotope 1H. A 2.6 cm usable diameter quadrature low-pass birdcage coil 
constructed as described previously (Wagener et al. 2004) was used in all experiments. 
MRI experiments were conducted by applying an ECG-triggered gradient-echo 
sequence with the following imaging parameters: echo time (TE) = 2.2ms; repetition 
time (TR) = 12.11ms; field of view (FOV) = 3.00cm2; acquisition matrix = 129 x 129; 
maximal in-plane resolution =  233µm2; slice thickness = 1.0mm. 
At a heart rate of 450 beats/min, the corresponding cardiac cycle length was ms, 
allowing for acquisition of  frames within each cardiac cycle with the given temporal 
resolution of  ms. A sufficient number of dummy scans (5 scans within 2 s) were run to 
bring the magnetization to steady state prior to imaging data readout. Four 
accumulations were made to obtain a sufficient signal to noise ratio. 
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2.2.24. Confocal microscopy and three-dimensional (3D) reconstructions 
 
Sections and cells were examined by laser scanning confocal microscopy (Leica 
TCS SP2, AOBS). After data acquisition, the images were transferred to Silicon 
Graphics Indy workstation (Silicon Graphics) for three-dimensional (3D) reconstruction 
using Imaris, the 3D multichanel image processing software (Bitplane, Zürich, 
Switzerland) as desribed by Kostin (Kostin et al., 1999). All confocal images and 3D 
images were done by or in cooperation with Dr. Sawa Kostin. 
 
 
2.2.25. Embryonic heart cultures 
 
Embryonic hearts were isolated from mouse ICR embryos at stage E9.5 – E11.5. 
Hearts were grown in D-MEM medium containing 1.000 mg/ml glucose, supplemented 
with 100 U/ml of penicillin, 100 µg/ml of streptomycin and 0.292 mg/ml L-glutamine 
as well as with 2.5%, 5% and 10% FBS or in serum free medium. Hearts were 
maintained in a humidified atmosphere containing 10% CO2 at 37°C for 48 – 96 hours 
after isolation (Fig. 2.6). 
Due to the fact that embryonic hearts are able to survive in serum free medium 
the next obvious question was whether they still express typical markers during in vitro 
culture. mRNA was isolated from collected embryonic hearts from in vitro cultures and 
compared to hearts isolated from E9.5 – E11.5. Markers like Nkx-2.5, MEF2C, 
CHISEL, dHAND, ANF were unchanged. The only p57 transcripts have shown 
differences in expression level (Fig. 2.7). 
In addition to RT-PCR analysis the proliferation test was performed. Embryonic 
hearts were grown in the presence of Bromo-deoxy-Uridine (BrdU) for 6 – 8 hours. 
Next, hearts were embedded in OCT medium and 7µM sections were prepared. 
Cryosections of embryonic hearts were fixed with Methanol/Acetone for 10 minutes in -
20OC followed by immuno-detection using the BrdU kit (Oncogene) accordingly to the 
manufacture’s instructions. 
As shown in Fig. 2.8, there were no drastic differences between in vitro 
cultivated hearts in cells proliferation. Taken together, established methods can be 
useful tools in further studies. 
 
                                                                        Experimental procedures 
 46 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.6. Embryonic hearts isolated from mouse embryos at E 9.5 immediately 
after isolation, 24 and 48 hours in culture in medium containing different 
amounts of serum as well as in serum free medium. 
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Fig. 2.7. RT-PCR analysis of E11.5 heart cultured in vitro in comparison to 
freshly isolated embryonic hearts at different stages. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.8. Comparison of BrdU incorporation between in vitro cultured embryonic 
hearts and in vivo injected BrdU followed by embryonic heart isolation, 
sectioning and signal detection. Similar rate of proliferation was observed. 
 
In addition, embryonic hearts were infected with adenovirus carrying the GFP 
cassette to label the epicardial layer (kindly provided by Dr. H. Ebelt). Twenty-four 
hours after infection expression of GFP was monitored by fluorescence microscopy 
(Fig. 2.9A). Next, infected embryonic hearts were embedded in the agarose type IX-A 
(Sigma) followed by cutting into 30-40µm thick sections using a Vibratom (Leica). 
Sections of embryonic hearts were placed onto cell culture plates coated with growth 
factors reduced MatrigelTM (BD Clontech) and grown in the same conditions like whole 
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embryonic hearts. Embryonic heart slices were documented daily as shown in Fig.2.9B-
D and the culture was carried up to 10 days.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.9. Panel A- in vitro labeling of E11.5 embryonic heart epicardium with 
GFP expressing adenovirus (green). Panel B illustrates the infected epicardial 
layer directly after sectioning, panels C and D spreading of infected cells after 
48 and 72 hours pi (24 and 48 hours after sectioning), respectively. Note 
discontinuous green layer and increased in the number of GFP positive cells.  
 
 
2.2.26. Overexpression of BMP10 using the baculovirus/insect cell system 
 
 All methods used and described below are a combination of published 
baculovirus/insect cells protocols (O´Reilly et al, 1992; King et al., 1992; BD 
Pharmingen Baculovirus Procedures and Methods Manual). 
 
 
2.2.26.1. Generation of the expression construct 
  
 Full length human BMP10 cDNA was PCR amplified with specific primers 
including Pst I/XmaI restriction sites and cloned into the pCR2.1-Topo vector 
(Invitrogen) followed by sequencing. After sequence verification, BMP10 cDNA was 
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subcloned into the pVL1392 transfer vector. The pVL1392 vector contains the 
polyhedrin gene locus of the Autographa californica nuclear polyhedrosis virus 
(AcNPV), but lacks part of the polyhedron gene coding sequence. Although the 
polyhedron is not essential for virus replication in cell culture, it is responsible for a 
visible plaque characteristic-the presence of polyhedral occlusion bodies in the nucleus 
of infected cells (O’Reilly et al, 1992). 
 
 
2.2.26.2. Routine sub-culturing of the Sf9 cell line in monolayer culture 
  
 The Sf9 cell line derived from Spodoptera frugiperda (Fall army worm) was 
cultured in monolayer in 10% FCS supplemented TNF-FH medium (BD Pharmingen) 
with gentamycine (50µg/ml) in a humidified incubator at 27oC until cells reached 
confluence, without CO2 supplementation. For sub-culturing, cells were dislodged by 
rapidly pipetting medium over the cells. Cells were counted and dependent on the assay 
Sf9 cells were plated at particular densities as indicated below. 
 
Assay Plate size Number of cells  
per assay 
%  
Confluent 
Transfection 60 mm 2.0 x 106 ~60% 
End-point Dilution 
Assay 
96 well plate 1.0 x 104 
 
~30% 
Plaque Assay 100 mm 
35 mm 
6.2 x 106 
1.0 x 106 
~70% 
~70% 
Viral Amplification 100 mm 5.0 x 106 ~70% 
Protein 
Overexpression 
100 mm 5.0 x 106 ~70% 
 
 
2.2.26.3. Co-Transfection of Sf9 cells 
 
Insertion of the BMP10 gene into a baculovirus genome was achieved by 
homologous recombination between BMP10-pVL1392 transfer plasmid and viral DNA 
in Sf9 cells. The liposome mediated co-transfection method of BMP10-pVL1392 and 
linearized BaculoGold AcNPV viral DNA was carried according to the manufacture’s 
instructions. Linearized viral DNA contains lethal deletion in the polyhedrine gene that 
can be complemented by recombination with the transfer plasmid, thus only 
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recombinant viruses form plaques (O’Reilly et al, 1992). Simultaneously, co-
transfection of control transfer plasmid XylE-pVL1392 (positive control) with 
BaculoGold DNA and infection with wild-type AcNPV virus was performed. Medium 
containing virus was harvested 4 days post transfection.  
 
 
 
 
 
 
 
 
 
Fig. 2.10. Representative images of Sf9 cells co-transfected with BMP10-
pVL1392 (A) or control XylE-pVL1392 (B).. 
 
 
2.2.26.4. Plaque assay 
 
The plaque assay was performed to titer, separate and purifies individual 
recombinant viruses. Usually, 1.0 x 106 cells were seeded on a 35 mm dish and grown 
overnight at 28oC. The log (1 in 10) dilution series in the range 103 to 108 of co-
transfection supernatant (medium containing virus) were prepared. TNM-FH growth 
medium was removed from the cells and cells were overlaid with 100µl at the 
appropriate dilution. Plates were rocked gently for 1 hour at room temperature. Next, 
the inoculum was removed and cells were covered with agarose overlay (5% low 
melting agarose in 2x Grace’s medium). Cells were incubated at 28oC for 4-5 days until 
plaques developed. Plaques were more easily visualized by staining the monolayer with 
neutral red (Sigma) solution (0.025% w/v in PBS). The staining solution was applied on 
the agarose overlay followed by incubation at 28oC for 1 hour. Then, the staining 
solution was removed and dishes were inverted upside-down and stored at room 
temperature for 2 hours in the dark. Plaques appeared as clear patches in a background 
of red, living cells. Individual plaques were picked for the further the virus 
amplification. Usually 10-50 plaques were picked. Plaque of agarose was taken up with 
Pasteur pipette and placed in 0.5ml TNM-FH growth medium. Virus particles were 
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released from the plaque by vortexing followed by overnight incubation at 4oC with 
gentle shaking.  
 
 
2.2.26.5. Amplification of virus and preparation of high-titer working stock 
 
Sf9 cells were seeded on 150mm plates at 5x106 and incubated 2 hours to attach. 
Next 250µl of virus inoculum from purified agarose plaque was applied to growth 
medium. Infected cells were grown for four days. Then supernatant was harvested 
followed by centrifugation to remove cellular debris and the next round of amplification 
was performed until a high titer stock, i.e. 1x108 pfu/ml was obtained. After each step of 
amplification the virus titer was determined by plaque assay and end-point dilution 
method.  
 
 
2.2.26.6. End-point dilution assay 
 
Sf9 cells were diluted to a final concentration of 1x104 and 100µl aliquots of the 
cells were seeded into a 96 well plate. Tenfold serial dilution of the amplified virus 
stock was prepared (10-3 to 10-8) and 10µl of each dilution was added per well. The end-
point dilution assay was always performed in triplicates, and each dilution was applied 
to ten wells. Additionally, uninfected controls were included in the experiment. Cells 
were incubated at 28oC in humidified environment. After 5-7 days each well was 
examined for virus infection. The total number of positive and negative wells for each 
virus dilution was counted and the virus titer was calculated using the method of Reed 
and Muench, as described by King and Possee (King and Possee, 1992). 
 
 
2.2.26.7. Detection of recombinant virus and overexpressed BMP10 protein 
 
To prove that recombination between BMP10-pVL1392 transfer plasmid and 
linearized baculovirus DNA had occurred and BMP10 was transcribed in infected Sf9 
cells. The RT-PCR reaction on RNA isolated from 10 clones separated by plaque assay 
was performed. RNA was isolated from transfected Sf9 cells using the TRizol reagent 
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and RT-PCR was done as already described with specific primers. The same clones 
were used for protein isolation to check protein expression by Western Blot. 
Additionally, as the secretion sequence was included in BMP10 cDNA cloned into the 
transfer vector, the supernatant of cells infected with high titer virus for BMP10 
overexpression was collected and the presence of the secreted protein was monitored by 
Western Blot. Fig. 2.11 illustrates the results of RT-PCR analysis of BMP10 
transcription on example of the 7 clones selected plaques/clones as well negative and 
positive controls. The lower panels in Fig. 2.11 show that BMP10 protein is efficiently 
expressed in Sf9 cells, however, it is not secreted to the medium (supernatant). This 
phenomenon of ignoring the secretion leader sequence is well known and described 
(reviewed by O’Reilly et al., 1992). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.11. Representative results of BMP10 transcription/expression and 
secretion in infected insect Sf9 cells of 7 clones/plaques. Upper panel- RT-PCR 
analysis with BMP10 specific primers proved transcription of the foreign gene. 
C+ positive control, i.e. PCR on the BMP10-pVL1392 plasmid. C- negative 
control, RNA and proteins isolated from SSf9 cells infected with wild-type 
AcNPV virus. Lower panels- Western Blot analysis of BMP10 expression and 
secretion in BMP10-baculovirus infected Sf9 cells. Proteins and supernatant 
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were prepared from the same clones as for RT-PCR analysis. The marginal 
signal in the supernatant in case of 4 clones is most probably a result of BMP10 
protein release from dead cells and not due to recognition of the secretion 
sequence. 
 
 
2.2.27. Microscopy 
 
Stained sections and cells were documented using Leica system: DFC300Fx camera 
connected to DMRB microscope.  
 
 
2.2.28. Statistics 
 
Unless otherwise stated all data are means ± SD. Statistical analysis was 
performed using Exel software (Microsoft). Student’s t tests were used. Data were 
considered significant when p<0.05. 
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3. Results 
 
3.1. BMP10 expression during mouse embryonic development and in the adult 
heart 
 
 Detailed and careful analysis of BMP10 expression was a prerequisite for further 
experiments, hence in situ hybridization was performed. Antisense and sense riboprobes 
were synthetised on the plasmid containing pro-region of BMP10 (generous gift from 
Dr. H. Neuhaus) linearized with BamHI and EcoRI, respectively and specificity was 
confirmed by whole mount in situ hybridization on mouse embryos at E10.5.  
 
  
 
 
 
 
 
 
 
 
Fig. 3.1. Whole-mount in situ hybridization with antisense (A) and sense probe 
for BMP10 (B). Expression is detectable only with the antisense riboprobe  in the 
developing heart (arrow, blue label).  
 
As shown in Fig.3.1, the antisense probe detects BMP10 transcripts only in the 
developing heart, while the sense probe gives no signal. In adult tissues, RT-PCRs 
results (Fig. 3.2A) revealed the BMP10 transcript only in the heart. To further 
investigate the localization of BMP10 transcripts within the adult murine heart, in situ 
hybridization analysis on paraffin embedded tissue slides was used.  Twelve µm thick 
sections were hybridized with the antisense digoxygenin labeled BMP10 probe. A 
strong and obvious expression of BMP10 was identified in the right atrium. The 
majority of the cells in the trabeculated wall of entire right atrial appendage were 
positive for BMP10. Both atrial cardiomyocytes and interstitial cells in this part of the 
heart expressed BMP10. Transcripts were also detectable in the region neighboring the 
interatrial septum. The detailed analysis revealed lack of BMP10 expression in the 
ventricular part of the heart, left atrium and left atrial appendage.  
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Fig. 3.2. (A) Expression of BMP10 in adult mouse tissues is confined to the heart 
as revealed by the RT-PCR analysis. Within the heart the PCR product is 
exclusively localized in the right atrium. (B-G) In situ hybridization of the BMP10 
riboprobe on paraffin embedded heart tissue sections (blue label) confirms the RT-
PCR results. Transcripts are detectable in the right atrium (RA), right atrial 
appendage (RAA) and interatrial septum (IAS). LA, left atrium; LAA, left atrial 
appendage; LV, left ventricle; RV, right ventricle; EPI, epicardial leyer; Ao, aorta.  
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Experiments that will be presented in next chapters of this work required BMP10 
expression analysis in different knock-out mice at various age and with different 
backgrounds. In order to verify possible age and strain dependent changes of BMP10 
expression, the level of transcripts was analyzed by semi-quantitative RT-PCR. RNA 
was isolated from 6 weeks and 6 months old ICR and C57Bl6 mice hearts and a RT-
PCR analysis with BMP10 specific primers was performed. BMP10 expression was 
normalized to control GAPDH PCR product (22 cycles), as shown in Fig. 3.3. The 
obtained results indicate a higher level of BMP10 expression in ICR than the C57Bl6 
strain and additionally, an age dependent decrease was noted. However, the localization 
of BMP10 transcripts remains unchanged and restricted to the right atrium and seems to 
be not age and strain dependent as judged by the in situ hybridization results (data not 
shown).  
 
 
 
 
 
 
 
 
 
Fig. 3.3. Semi-quantitative RT-PCR analysis of BMP10 expression in 6 weeks 
(lanes 1 and 3) and 6 months (lanes 2 and 4) old ICR (1,3) and C57Bl6 (2,4). An 
equal amount of RNA was controlled by the level of the GAPDH PCR product.  
 
 
3.2. A polyclonal anti-matBMP10 antibody specifically recognizes the processed 
mature region of BMP10  
 
 As was already mentioned, BMP10 has a leader secretion sequence. BMP10 is 
synthesized as pre-pro-protein followed by its secretion to the extracellular matrix and 
processing. In this case, cells expressing BMP10, identified by in situ hybridization 
might, but do not have to overlap with the localization of the active, mature protein and 
its target cells. As there are no commercially available antibodies against BMP10 it was 
necessary to generate such an antibody. Overexpression of the mature region of BMP10 
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fused to His tag in E.coli and purification of the protein were prerequisites for further 
experiments.  
 
 
3.2.1. Test of antibody specificity 
 
Detailed and careful verification of the specificity of the generated antibody was 
necessary to avoid artifacts in further experiments. The next chapters describe 
experimental approaches that were used to verify specificity and applications of the 
generated antibody.  
 
 
3.2.1.1. Western Blot analysis  
 
The first step of analysis required to test whether the antibody specifically 
recognizes BMP10, but not the His-tag fused to protein. For this reason, unrelated to 
BMP10 protein - 6HisG-∆VITO1 (kindly provided by Dr. M. Mielcarek), cloned to 
pRSET-A vector and overexpressed under the same conditions as His-tagged BMP10 
was selected. Fig. 3.4 shows the detection of 6HisG-BMP10, but not the tagged 
∆VITO1 by obtained antibody.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.4. Western Blot analysis of His-tagged VITO1 and BMP10. Polyclonal anti-
BMP10 antibody specifically recognized 17kDa 6HisG-BMP10 (lane 2, arrow), 
but not 30kDa 6HisG-∆VITO1 (lane 1, arrowhead).  
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Next, the ability of the antibody to recognize the mature region of mouse BMP10 was 
investigated. Proteins were extracted from the left and right atrium and nuclear, 
cytosolic and membrane fractions were separated. BMP10 was immunodetected with a 
commercially available (Abgent, Orbigen) and the newly generated antibody. The 
preimmune serum was used as a negative control. Western blotting of protein extracts 
revealed 2 bands. The approximately 40kDa band corresponds to the full length BMP10 
precursor while the second band corresponds to the mature monomer with the predicted 
molecular mass of 12 kDa. As shown in Fig. 3.5, the generated anti-mat-BMP10 
antibody was specific for the processed form of BMP10 and did not recognize the full 
length propeptide.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.5. Western Blot analysis of membrane, cytosolic and nuclear protein 
fraction isolated from mouse atria. The generated anti-matBMP10, control 
preimmune serum and two commercially available antibodies were used to 
detect BMP10. The mature form of the protein of predicted 12kDa was detected 
by the newly generated antibody (but not by preimmune serum). The Abgent 
antibody gave a signal of 40kDa in right and left atrium, whereas The Orbigen 
antibody showed the highest specificity to BMP10 precursor of approximately 
40 kDa in the cytosolic fraction isolated from right atrium.  
 
Commercially available antibodies detected only the propeptide form of BMP10. All 
antibodies detected the strongest signal in protein extracts isolated from right atrium. 
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The Orbigen antibody showed the highest specificity as indicated by the cytoplasmic 
detection of the BMP10 precursor in the fraction isolated from right atrium. 
 
 
3.2.1.2. Immunocytochemistry 
 
The unspecific bands, which were observed by Western Blot analysis suggested 
cross-reactivity of the newly generated anti-BMP10 antibody with other proteins. To 
test the ability of the newly generated antibody to detect BMP10 by 
immunohistochemistry, an in situ staining of cells overexpressing BMP10 was 
performed. COS1 and 293T cells were transiently transfected with the BMP10-IRES-
GFP expression plasmid or empty pEGFP vector. Forty-eight hours later, cells were 
fixed and immunostained with anti-BMP10 antibodies and preimmune serum. Both 
commercially available antibodies did not detect BMP10 (data not shown) and seem to 
be not useful for immunohistochemistry. Preimmune serum gave also only marginal, 
background signal while the new anti-BMP10 antibody showed a strong staining in 
cells transfected with BMP10-IRES-GFP (Fig. 3.6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.6. COS1 cells transfected with BMP10-IRES-GFP (green) and 
immunostained (red) with control preimmune serum (A, merged C) or anti-
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BMP10 antibody (B, merged D). Only the generated anti-BMP10 antibody gave a 
strong staining in cells transfected with BMP10-IRES-GFP (B,D). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.7. The Anti-BMP10 antibody specifically recognizes the BMP10 protein. 
293T cells transfected with the expression construct BMP10-IRES-GFP (green) 
and immunostained with the anti-BMP10 antibody (red) (A,B).  
 
Interesingly, immunodetection of BMP10 in 293T cells showed a strong signal not only 
in transfected cells, as judged on the basis of GFP expression, but also in neighboring 
cells (Fig. 3.7). This might be explained by the efficient release from trensfected cell 
and subsequent binding to adjacent cells.  
 
 
3.2.1.3. Immunohistochemistry 
 
Since the tested antibody gave satisfactory results in transfected cells, the 
determination of the ability to detect the native BMP10 in tissue sections was the last 
and most important test to prove its specificity. Fig. 3.8 shows representative confocal 
images of BMP10 detection in mouse heart. A membrane localization of BMP10 in the 
right atrium and the right atrial appendage (Fig. 3.8 A and B, respectively) is apparent. 
Using the same laser set up, the left atrium and ventricles (Fig. 3.8 C and D) were 
examined for a signal. The relative differences in signal intensity between the examined 
parts were clearly visible. Since the antibody staining of BMP10 matched the in situ 
hybridization data it seems likely that the antibody generated against the mature region 
of BMP10 works reliably and specifically.  
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Fig. 3.8. Confocal images of mouse heart immunolabeled with anti BMP10 
antibody (A-D) or preimmune serum (E) followed by detection and signal 
amplification using the biotin-streptavidin system (green). Staining was confined 
to the right atrium and the right atrial appendage and membrane localization of 
BMP10 is apparent (A and B). Only a marginal signal was noted in the left atrium 
(C) and no BMP10 positive cells were found in the ventricular part of the heart 
(D). Preimmune serum gives no signal (E). Panel F represents the same section 
like in E counterstained with phalloidin-TRITC (red). Nuclei were visualized with 
Draq5 (A-D red; E and F blue).  
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3.3. Localization versus expression of BMP10 
 
 Since the newly generated anti-BMP10 antibody allowed specific detection of 
the BMP10 protein, the comparison of BMP10 expression with its targeted localization 
became possible.  
 In situ hybridization with the BMP10 specific probe had already revealed that 
during mouse embryogenesis BMP10 expression is restricted to the trabeculated part of 
the developing heart. The immunohistochemical analysis of BMP10 location in mouse 
embryos is presented in Figs. 3.9 and 3.10.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.9. Low magnification images showing BMP10 localization (green 
fluorescence, panel A) in the developing mouse embryonic heart at E11.5; (B) 
nuclear staining (blue); (C) merge. The signal was apparent in the trabeculated 
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part, but also in the non-compacted myocardium and outflow tract. Panel D- 
higher magnification of in situ hybridization with the BMP10 specific probe at 
E11.5. BMP10 transcripts (dark blue label) are detectable exclusively in 
trabeculae but not in other structures of the developing heart. H, heart; OFT, 
outflow tract; TR, trabeculae.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.10. Higher magnification of BMP10 localization (green) in embryonic heart 
at E11.5 (A, B). BMP10 was detected in a subpopulation of trabeculae a with 
gradual decrease of staining intensity in non-compacted myocardium. Note, that 
epicardial cells are positive for BMP10 (arrow). Nuclei were visualized by Dapi 
(blue) and sections were counterstained with phalloidin-TRITC (red in C and D). 
TR, trabeculae; Epi, epicardium. 
 
In contrast to in situ hybridization, accumulation of BMP10 positive cells was 
also found in the outflow tract (Fig. 3.9). BMP10 in embryonic heart was found in 
trabeculated myocardium and showed the highest staining intensity compared with 
other cardiac structures (Fig. 3.10). At higher magnification, a gradual decrease of the 
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staining intensity in non-compacted myocardium was clearly visible. At E11.5 of mouse 
embryonic development, the epicardium is apparent and also cells that constitute the 
fine epicardial layer were positive for BMP10. 
In the neonatal mouse heart, BMP10 transcripts were no longer detectable in the 
ventricular part and the expression was restricted to the right atrium (Fig. 3.11 C). A 
fibrous layer separating atria from ventricles limits BMP10 expression within the right 
atrium. However, by immunostaining of BMP10, a vestigial amount of protein was 
detectable in ventricles (Fig. 3.11 A). The signal was also partially observed in the 
epicardial layer. In the right atrium, in addition to the expected membrane location, a 
cytoplasmic accumulation of BMP10 was found.  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.11. Detection of BMP10 protein (A- green) and transcripts (C- blue) in the 
neonatal mouse heart. BMP10 was predominantly localized in cells of the right 
atrium. Asterisks indicate two types of pattern: cytoplasmic accumulation and 
membrane location (A). Arrows point to vestigial amount of BMP10 in the right 
ventricle. Nuclei were stained with Dapi (A and B- blue). Panel B represents the 
same section counterstained with phalloidin (red). C- In situ hybridization of 
paraffin embedded neonatal heart sections showed the restriction of BMP10 
expression to the right atrium (blue label).  The arrow indicates the fibrous ring 
separating atrium from ventricle. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.12. Immunostaining of BMP10 (A-green) and localization of BMP10 
transcripts (C- blue) in the adult mouse heart. Expression and localization were 
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restricted to the right atrium. Panel B represents the same section as A, 
counterstained with phalloidin-TRITC (red), nuclei were stained with Dapi (A and 
B- blue). 
 
In adult mice, BMP10 protein was detectable neither in ventricles nor in the 
epicardium (Fig. 3.12). Additional signals were found in the tricuspid valve and in 
single cells around big vessels in the atrial area, which initially were not detected by in 
situ hybridization (Fig. 3.13). 
 
 
 
 
 
 
 
 
 
Fig. 3.13. Specific BMP10 expression and localization was found around big 
vessels in the atrial area (A- blue, arrows) and in the tricuspid valve (arrows in B- 
blue; C- green). A,B- in situ hybridization, C- immunodetection of BMP10 
(green). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.14. RT-PCR analysis of selected BMPs receptors in different parts of the 
adult murine heart. Equal amounts of RNA used for reverse transcription were 
monitored by the HPRT PCR product.  
 
 
BMP10, as other members of the TGFβ family, acts via receptors and for this 
reason the expression of bone morphogenetic proteins receptors (type I and II) in adult 
and embryonic heart was analyzed. RT-PCR analysis revealed comparable expression 
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levels of Alk1 and BMPRII in the adult and embryonic heart. The ALK4 PCR product 
was weaker in the adult than in the embryonic heart and the opposite situation was 
observed in the case of ALK3. Expression of ALK6 was restricted to embryonic heart, 
but this receptor is not expressed in adult myocardium (data not shown). Next, the 
expression of selected receptors was examined in atria and ventricles of the adult heart 
(Fig. 3.14). RT-PCR analysis revealed higher expression levels of ALK3 and BMPRII 
in the right atrium, while the ALK1 PCR product was barely visible in this heart 
chamber.  
 
 
3.4. Murine models of cardiomyopathies 
 
 The primary aim of this work was the characterization of changes of BMP10 
expression in pathological hearts. Two genetic models of cardiomyopathy, i.e. Desmin 
knock-out (Desmin LacZ strain; generous gift from Prof. T. Braun) and 10 months old 
MnSOD (SOD2) heterozygous mice (generous gift from Dr. T. Loch; laboratory 
collection) as well two drug-induced (doxorubicin and isoproterenol) models of 
cardiomyopathy were investigated. The degree of pathological changes was estimated 
on the basis of Magnetic Resonance Imaging (MRI) analysis as well as detailed 
histological examination.  
 
 
3.4.1. Magnetic Resonance Imaging (MRI) 
  
Cardiovascular MRI allows the accurate evaluation of ventricular function and 
determination of myocardial volumes and ejection fraction (EF). In this study, Desmin 
knock-outs, doxorubicin and isoproterenol treated mice as well as PBS treated age and 
strain matched controls were measured. Fig. 3.15 shows an example of Desmin knock-
out and control in coronal plane for anatomical imaging of apparent heart hypertrophy 
in the knock-out mouse. End-systolic and end-diastolic frames at the papillary muscle 
level are presented to demonstrate chamber dilation with increase of myocardial 
thickness. 
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Fig. 3.15. Representative transversal and coronal MRI images of Desmin knock-
out (left panel) and control (age and strain matched) mouse. Heart hypertrophy 
and chambers dilatation are evident in the knock-out. 
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Fig. 3.16. Examples of MRI analysis of doxorubicin (left panel) and 
isoproterenol (right panel) treated mice. In the centre a representative control for 
both drugs is presented. See text for the details.  
 
Similar sets of images of doxorubicin and isoproterenol treated and control mice are 
shown in Fig. 3.16. Heart hypertrophy, chamber dilation and impaired systolic function 
in isoproterenol induced cardiomyopathy are clearly visible. 
Administration of doxorubicin did not cause a degree of heart failure as severe 
as treatment with isoproterenol (Fig. 3.16, left panel). However, as seen in humans, 
chronic cardiotoxic effects might develop even after several weeks or months after 
doxorubicin administration (Singal et al., 1987). To obtain a more severe 
cardiomyopathy, higher concentrations of adriamycin were applied. Since the higher 
dose was lethal for the animals, only the modest cardiomyopathy, caused by the low 
doxorubicin concentration was analyzed further. 
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A characteristic feature of dilated cardiomyopathy is the enlargement of the 
ventricles with impaired systolic function. In the present study, changes in ejection 
fraction (EF) and myocardial volumes were used as main parameters to determine heart 
failure. All examined models showed a decrease of ejection fraction. Desmin knock-
outs (n=5) exhibited 11% reduction compared with controls (47.8%±3.34 and 
53.6%±3.75, respectively). The most pronounced decrease was noted in isoproterenol 
treated mice. The average value of ejection fraction from five measurements was 
calculated as 17.3%±1.21, whereas it was 61.6%±4.15 in ICR control mice. 
Doxorubicin administration caused a reduction of ejection fraction by 13% in 
comparison to controls. A graphic illustration of changes in ejection fraction and 
myocardial volumes is depicted in Fig. 3.17. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.17. Graphic presentation of average values of ejection fractions (EF) – 
panel A and myocardial volumes (B) in representative groups of all examined 
models.  
 
The myocardial volumes were estimated in both systole and diastole as 
illustrated in Fig. 3.17 B. An increase of the myocardial volume was apparent in 
Desmin LacZ strain and was calculated in systole (0.110ml) and in diastole (0.103ml). 
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The same parameters were also determined in control C57Bl6 mice ( systole: 0.075ml, 
diastole: 0.069ml). A comparison between both strains revealed an increase of 46% in 
systole and 49% in diastole in Desmin knock-out mice. In isoproterenol treated mice the 
changes in myocardial volume were less pronounced (increase of 11% in systole and 
28% in diastole compared with ICR controls). Induction of cardiomyopathy with 
doxorubicin resulted in reduction of myocardial volume of 17% and 10% (0.053ml and 
0.045ml, controls- 0.064ml and 0.050ml) in systole and diastole, respectively. An 
additional parameter, which indicates heart failure, was the heart weight (mg) to body 
weight (g) ratio. As shown in Fig. 3.18 this ratio was elevated in all models compared to 
control mice.  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.18. Heart weight to body weight ratio.  
 
 
3.4.2. Pathomorphological analysis of murine models of cardiomyopathy  
 
 The histopathological analysis of murine models of cardiomyopathies included 
the following features: 
• Myofiber disarray 
• Replacement fibrosis 
• Cardiomyocyte hypertrophy 
• Cell death 
Originally, a disarray of hypertrophied and disorganized myocytes was described 
in humans as a unique feature of hypertrophic cardiomyopathy. However, identical 
histological abnormalities have been reported in the absence of myocardial thickening 
(Shapiro et al., 1996). A striking and consistent feature of cardiomyopathy in Desmin 
knock-out was myofiber disarray, which is characterized by severe disarrangement of 
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the myocardial architecture resulting in bizzarely shaped myocytes (Fig. 3.19). A milder 
degree of disarray developed after doxorubicin administration. Neither SOD2 
heterozygous nor isoproterenol treated mice exhibited this feature (data not shown). 
Another typical pathological feature in cardiomyopathic hearts is the formation of 
focal fibrosis. The extracellular matrix to which cardiomyocytes are attached plays a 
vital role in cardiac contraction (McKenna et al., 1996). In the healthy heart collagen VI 
is localized around myocytes as a fine, thin sheet (Fig. 3.20). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.19. Representative images of myocyte disarray in Desmin knock-out and 
doxorubicin treated mice. The left panel shows detection of LacZ in Desmin 
knock out. Disarray in Doxorubicin treated mice is visualized by phalloidin-
FITC staining, nuclei are shown in red. 
 
In pathological hearts an increased collagen deposition was clearly visible (as 
shown in Desmin knock-out and doxorubicin treated mice). Especially, the Desmin 
knock-out hearts showed an abundant accumulation of collagen VI in areas of 
replacement fibrosis. In MnSOD heterozygous and isoproterenol treated mice collagen 
deposits were not as pronounced as in Desmin LacZ, and resembled a modest fibrosis as 
seen after adriamycin administration (data not shown). 
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Fig. 3.20. Different degrees of increased collagen VI (green) deposition in 
Desmin knock-out and doxorubicin treated mice and adequate controls. Sections 
were counterstained with phalloidin-TRITC (red) and nuclei were visualized by 
DAPI staining (blue).  
 
Basically, hypertrophy is defined as an increase in the size of the cardiac 
myocytes in response to pathological stimuli. As shown in Fig. 3.21, mice treated with 
isoproterenol showed an increase in myocyte size. Immunostaining for intercalated disk 
and/or membrane associated proteins is exceptionally helpful to clearly illustrate 
hypertrophic cardiomyocytes. Detection of plakoglobin in MnSOD heterozygous (left 
panel) and desmoplakin in isoproterenol treated mice (right panel- higher magnification) 
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demonstrates moderate and severe increase in myocytes size, respectively. Induction of 
cardiomyopathy by doxorubicin treatmentdid not result in cellular hypertrophy, as 
shown in Fig. 3.22 by vinculin staining. Desmin knock-out mice exhibited the highest 
degree of hypertrophy among all models tested. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.21. Immunodetection of plakoglobin (green) in SOD2 heterozygous (left 
panel) and vinculin in isoproterenol treated mice (right panel -green) illustrates 
different degrees of myocyte hypertrophy in both models in comparison to 
adequate controls. Sections were counterstained with phalloidin-TRITC (red). 
Nuclei are visualized in blue by DAPI.  
 
Numerous experimental and clinical studies have demonstrated that myocyte 
death is a critical determinant of cardiac remodeling and heart failure in different 
pathological settings, including cardiomyopathies. Two distinct types of cell death are 
known and recognized, namely necrosis and apoptosis (reviewed by Kostin, 2005). 
Necrosis is defined as an accidental type of cell death caused by ischemia, inflammatory 
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reaction or toxic agents. In contrast, apoptosis is a pre-programmed cell suicide. To 
distinguish between both types of cell death tissue sections were stained for 
Complement9 - a part of membrane-attack complex (Homeister et al., 1992), which is a 
marker of necrosis and TUNEL protocol was used to detect apoptotic DNA 
fragmentation.  
Examples of necrotic and apoptotic cells are shown in Fig. 3.23.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.22. Doxorubicin treated mice did not exhibit cardiomyocyte hypertrophy 
(left panel) as demonstrated by vinculin detection (green), while in Desmin 
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knock-out mice an increase in myocytes size is apparent. Nuclei are visualized in 
red by Draq5.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.23. Example of a Complement9 positive myocyte (A-green). Panel B 
represents the same section as in A counterstained with phalloidin-TRITC (red). 
Nuclei were visualized with Draq5 (blue). Apoptotic cells (C and D- red) in 
isoproterenol (A-C) and doxorubicin (D) treated mice.  Sections C and D were 
counterstained with phalloidin-FITC (green).  
 
Desmin knock-out displays the most severe cardiac phenotype among the 
models examined, albeit neither necrotic nor apoptotic cells were detectable (data not 
shown). In MnSOD heterozygous only necrosis was noted (data not shown) while 
isoproterenol and doxorubicin administration was inducing both types of cell death.  
Many studies showed that dystrophin cleavage is associated with advanced heart 
failure (Kawada et al., 2005). In the healthy heart, a continuous dystrophin distribution 
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covers the cytoplasmic face of the peripheral plasma membrane, as described by 
Kaprielian (Kaprielian et al., 2000) and illustrated in examples of control mouse heart in 
Fig. 3.24. Cells lacking this membrane-associated protein were found in doxorubicin 
induced DCM, but not in the other tested models. Results of the histopathological 
analysis are summarized in table 3.1.  
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.24. Immunolabelling of dystrophin (A-green) in doxorubicin treated mouse 
heart. Arrows indicate cardiomyocytes lacking dystrophin. Panel B represents the 
same section counterstained with phalloidin-TRITC (red), panel C- merged 
images. Nuclei were visualized with Draq5 (blue).  
 
 
Summary of histopathological analysis. 
Tab. 3.1. Results of pathomorphological analysis.   
Cell Death  
Disarray Fibrosis 
Myocyte 
Hypertrophy 
Dystrophin 
lost Necrosis Apoptosis 
Desmin -/- + + + - - - 
MnSOD+/- - + + - + - 
Isoproterenol - + + - + + 
Doxorubicin + + - + + + 
                                                                                               RESULTS 
 77 
3.5. BMP10 expression in Cardiomyopathies 
 
 The main aim of the study was the determination of BMP10 expression under 
pathological conditions. Changes in the expression level were assessed by in situ 
hybridization and immunohistochemistry. To estimate the deregulation of BMP10 on 
the RNA level semi-quantitative RT-PCR analysis was performed and followed by 
Western Blot analysis for protein quantification.  
 
 
3.5.1. BMP10 is ectopically expressed in ventricles of Desmin knock-out mice  
 
As described in the previous chapter, mice lacking desmin exhibit the most 
severe cardiac phenotype among the tested murine models of cardiomyopathy. 
Detection of BMP10 transcripts by in situ hybridization revealed an ectopic expression 
in the ventricular myocardium of Desmin knock-out mice (Fig. 3.25). Based on the in 
situ hybridization result it is difficult to decide, whether this BMP10 expression occurs 
in cardiomyocytes or in other types of cells  
 
 
 
 
 
 
 
 
Fig. 3.25. In situ hybridization (blue label) on paraffin embedded Desmin knock-
out heart slides.  Panel A- low magnification; B- concentration of BMP10 
expressing cells in the left ventricle; C- high magnification of BMP10 positive 
cells in the myocardium indicate expression in interstitial cells. Sections were 
counterstained with eosin.  
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Fig. 3.26. Immunostaining of BMP10 in cryosections of Desmin knock-out heart. 
Panel A- BMP10 positive cells were found in or in the vicinity of vessels. B- 
Higher magnification of (A) showing small cell nearby an artery. Note, that the 
appearance of the nucleus might indicate cell division, or there are two cells close 
to each other. Panel C- cluster of BMP10 positive cells localized between 
cardiomyocytes. 
 
To increase the level of resolution and to determine the identity of BMP10 
expressing cells in the ventricular myocardium immunofluorescent stainings were 
employed. In addition to the right atrium, some labeling was also noted in ventricular 
cells (Fig. 3.26). BMP10 positive cells were found often, but not exclusively, in the 
proximity of vessels or even as incorporated cells in walls of coronary arteries. In 
Desmin knock-out mice, ventricular cells positive for BMP10 often appeared as clusters 
of interstitial cells. In some cases it was difficult to identify individual cells since the 
nuclei seemed not to be separated completely. Qualitative and quantitative changes of 
BMP10 protein were also found in right atrium (Fig. 3.27). An increase in the amount 
of BMP10 and its cellular redistribution from membrane to cytosolic accumulation was 
apparent. This pattern resembled the protein distribution in the neonatal atrium. The 
upregulation of BMP10 expression in Desmin knock-out, as judged by 
immunohistochemistry was also confirmed by semi-quantitative RT-PCR (Fig. 3.28) 
and Western Blot analysis (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.27. BMP10 localization in the right atrium of WT (A) and Desmin knock-
out mice (B). Note increased amount of BMP10 protein accumulated in the 
cytoplasm (green) in the knock-outs right atrium. Cryosections were 
counterstained with F-actin (red) and nuclei were visualized by Draq5 (blue).  
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Fig. 3.28. Semi-quantitative RT-PCR analysis of BMP10 (left panel) and ANF 
expression (right panel) in Desmin knock-out and control WT mice. Up-regulation 
of BMP10 expression is apparent.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.29. In situ hybridization with an ANF specific antisense probe (blue label) 
in control (A,B) and Desmin knock-out (C,D) mouse heart. Upregulation of ANF 
expression in septum (A,C) and apex (B,D) of knock-out, but not in WT.   
 
An upregulation of BMP10 expression on both, RNA and protein levels were found in 
Desmin knock-outs in comparison to wild type controls. Changes in ANF transcript 
levels, a well known marker of cardiomyopathy were also checked. As expected, higher 
expression of this gene was also found. This observation was confirmed by in situ 
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hybridization with an ANF specific riboprobe (Fig. 3.29). Strong signals in the septum 
and apex as well as small foci in the ventricular free wall were apparent. 
 
 
3.5.2. Qualitative and quantitative changes of BMP10 expression in the 
heterozygous MnSOD knock-out mice 
 
 The second genetic model examined for BMP10 expression was MnSOD 
heterozygous.  Six months old mice exhibit impaired systolic function and reduced 
ejection fraction (data kindly provided by Dr. T. Loch, personal communication). In situ 
hybridization with the BMP10 antisense probe revealed a significant reduction of 
BMP10 expression in right atrium (Fig. 3.30) yielding a population of cells that was 
negative for BMP10. Furthermore, an ectopic expression of BMP10 was scored in some 
ventricular cells of MnSOD heterozygous mice (data not shown), but not in age and 
strain matched controls.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.30. Representative images of in situ hybridization with a BMP10 specific 
antisense probe in MnSOD heterozygous mice heart (A,B) and matched controls 
(C,D). B and D show higher magnification of right atrium of images A and C, 
respectively and illustrate decreased expression of BMP10 in MnSOD+/-. The 
signal is present in blue.  
 
The deregulation of BMP10 transcription in the right atrium was confirmed by 
immunodetection of the protein. In transgenic mice, a heterogeneous pattern of BMP10 
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distribution was observed, as shown in Fig. 3.31. Three different types of BMP10 
cellular localization were found: 
1. Preserved membrane location, typical for wild type mice 
2.  Cytosolic accumulation of BMP10 granules 
3.  Absence of the signal 
 
In ventricles, cells expressing BMP10 were detected in MnSOD heterozygous, but not 
WT mice. Clusters of BMP10 positive interstitial cells were found in the subepicardial 
layer and the myocardium (Fig. 3.31C and D).  
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Fig. 3.31. Confocal images of BMP10 localization (green) in heterozygous 
MnSOD (B-D) and control (A) mice. Panels A and B- BMP10 distribution in the 
right atrium. Panels C,D- BMP10 positive cells were found in ventricles of the 
transgenic mouse. Sections were counterstained with phalloidin-TRITC (red). 
Panels E and F- higher magnification of (D) illustrating a BMP10 positive cell on 
an myocyte (E), F- counterstained with phalloidin-TRITC (red). Panels E and F 
represent different layers of confocal image to illustrate localization of BMP10 in 
the interstitial cell. Nuclei were visualized with Draq5 (blue).  
 
The stained cell presented in Fig. 3.31D seems to resemble a small 
cardiomyocyte, but confocal analysis revealed that it is an interstitial cell situated on a 
myocyte. 
The relative level of BMP10 transcription in transgenic mice was reduced in 
comparison to wild type control (Fig. 3.32A), as revealed by semi-quantitative RT-PCR. 
Analysis of BMP10 expression on the protein level also indicated a decreased amount 
of BMP10 (Fig. 3.32B) whereas ANF expression was upregulated in SOD2 
heterozygous (Fig. 3.32C). In situ hybridization with an ANF probe revealed specific 
localization in the proximity of vessels of ANF transcripts in knock-outs (Fig. 3.33).  
 
 
 
 
 
 
 
 
 
 
Fig. 3.32. Panel A- semi-quantitative RT-PCR analysis of BMP10 expression in 
MnSOD heterozygous and control mice. Panel B- Western Blot shows relative 
difference in BMP10 protein level in transgenic and control mice. Panel C- semi-
quantitative analysis of ANF expression in WT and SOD2 heterozygous. An equal 
amount of RNA was monitored by the level of the GAPDH PCR product (22 
cycles). 
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Fig. 3.33. In situ hybridization in paraffin embedded heart slices with an antisense 
ANF probe. ANF expression in ventricles in WT (A) is restricted to single cells, 
whereas in MnSOD heterozygous foci of interstitial cells surrounding vessels (B) 
and myocytes (C) ANF positive cells were detectable. 
 
 
3.5.3. Redistribution and upregulation of BMP10 in doxorubicin induced CMP 
 
Clear changes of the BMP10 expression pattern were found in Desmin knock-
out and SOD2 heterozygous mice, which might be considered as models of chronic 
heart failure. On the other hand, drug induced cardiomyopathies might serve as models 
of acute cardiac disorder.  
Mice treated with doxorubicin exhibited apparent changes in the BMP10 
expression as revealed by in situ hybridization. BMP10 transcripts were detectable not 
only in the right atrium (Fig. 3.34A), but also in single, ventricular interstitial cells (Fig. 
3.34B). The number of positive cells was not abundant, and definitely lower than in 
Desmin knock-out and MnSOD heterozygous. It should also be noted that the chamber 
dilation did not only affected ventricles but also the atria. 
 
 
 
 
 
 
 
 
 
 
Fig. 3.34. In situ hybridization with an antisense BMP10 specific probe in 
doxorubicin treated mouse heart. Panel A- BMP10 expression in the right atrium 
(blue label), dilation of the left ventricle and the right atrium is also visible. Panel 
B- higher magnification of (A), the arrow indicates the BMP10 signal in the 
septum. 
 
Using immunohistochemistry, an ectopic expression of BMP10 in the 
ventricular myocardium was confirmed (Fig. 3.35). Clusters of BMP10 positive cells, 
however, were not found in this model. Only single cells stained with BMP10 antibody 
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were detected and, as was already mentioned, their number was lower than in genetic 
models.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.35. Representative confocal images illustrating BMP10 (green) expression 
in the right atrium (A) and ventricles (B) in heart of doxorubicin treated mouse. 
Sections were counterstained with phalloidin-TRITC (red) and nuclei were 
visualized with Draq5 (blue).  
 
Administration of doxorubicin resulted in redistribution of BMP10 protein in the 
atrium, as shown in Fig. 3.35A. BMP10 was accumulated in the cytoplasm and only a 
minor amount was localized at the membrane. Quantitative determination of BMP10 
expression revealed an upregulation of BMP10 in adriamycin treated mice. Results of 
semi-quantitative RT-PCR and Western Blot analysis are presented in Fig. 3.36. 
Additionally, ANF expression was only slightly upregulated (Fig. 3.36C) and ANF 
transcripts were detectable in single, ventricular cells, as shown in Fig. 3.37. 
 
 
 
 
 
 
 
 
 
Fig. 3.36. Semi-quantitative RT-PCR of BMP10 (A) and ANF (C) in doxorubicin 
(right) and PBS (left-WT) treated mouse heart. B- Western Blot presenting up-
regulation of BMP10 on the protein level. 
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Fig. 3.37. In situ hybridization in paraffin embedded heart slides with an antisense 
ANF probe. ANF expression was not detectable in ventricles in PBS treated 
control (A,B). In doxorubicin induced cardiomyopathy (C,D) transcripts were 
detectable in single, ventricular cells (blue label) and indicated a slight 
upregulation of ANF expression in the pathological heart. 
 
 
3.5.4. Downregulation of BMP10 in isoproterenol induced hypertrophic CMP 
 
 The previously described models represent the dilated type of cardiomyopathy 
(DCM). It was unclear, whether changes in BMP10 expression and localization were 
typical only for DCM or whether it is a common marker of heart failure. Hence, 
isoproterenol induction of hypertrophy was included in the study as a model of acute 
hypertrophic CMP.  
 In situ hybridization (Fig. 3.38) as well as immunolabeling (Fig. 3.39) revealed 
qualitative changes in BMP10 expression. In the right atrium, some cells did not express 
BMP10 anymore (Fig. 3.38B and C), while other strongly expressed BMP10.  
 
 
 
 
 
 
 
                                                                                               RESULTS 
 86 
Fig. 3.38. In situ detection of BMP10 transcripts (blue label) in isoproterenol 
treated mouse heart. Panel A- shows an overview. Panel B- illustrates 
downregulation of BMP10 in the right atrium. Note lack of BMP10 expression in 
some areas of the right atrial appendage. Panel C- higher magnification of the 
BMP10 signal in cardiomyocytes and interstitial cells in the right atrium. Arrows 
indicate lack of BMP10 expression. 
 
 
 
 
 
 
 
 
 
 
Fig. 3.39. Representative confocal images of BMP10 (green) localization in 
isoproterenol treated mouse heart.  Panel A- homogeneous pattern of BMP10 
downregulation. Panel B- heterogeneity of BMP10 distribution. Panel C- example 
of ectopic BMP10 expression in ventricles. Sections were counterstained with 
phalloidin-TRITC (red), nuclei with Draq5 (blue). 
 
Similar results were obtained on the protein level. In the isoproterenol treated mice two 
distinct patterns were observed in the atrium: 
1. Homogeneous downregulation (Fig. 3.39A) 
2. Heterogeneous pattern (Fig. 3.39B), as already described for MnSOD 
heterozygous mice. 
 
A number of cells expressing BMP10 were found in the ventricles, as shown 
above. Only single, separated BMP10 positive cells were detected. These cells did not 
form clusters as in genetic models, however pairs were sometimes found. It was 
difficult to determine the overall BMP10 expression level due to the heterogeneity of 
the expression and localization pattern. Hence, quantification by PCR and Western Blot 
analysis had to be performed (Fig. 3.40). Preliminary determination on RNA level 
revealed a decrease of BMP10 expression (Fig. 3.40A), while ANF (Fig. 3.40C,D), 
FHL2 and BNP (data not shown) were upregulated. To verify differences in BMP10 
levels real-time quantitative RT-PCR was used (Fig. 3.40D). In hypertrophied hearts, 
the ANF level increased 4.5 fold, while BMP10 was down-regulated by a factor of 7.3. 
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Western Blot confirmed results obtained from RT-PCR analysis. FHL2 has been 
described as specific and reliable marker of hypertrophy (Kong et al., 2001), hence in 
situ hybridization with FHL2 specific riboprobe was performed. Transcript detection 
revealed expression of this gene in most of the ventricular cells of the treated heart (Fig. 
3.41), while in control only a weak signal was detected.  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.40. Semi-quantitative RT-PCR of BMP10 (A) and ANF (C) in isoproterenol 
(right) and PBS (left-WT) treated mouse heart. B- Western Blot showing 
downregulation of BMP10 on protein level. Preliminary semi-quantitative RT-
PCR was confirmed by real time PCR analysis (D). Results were normalized to 
GAPDH expression and are presented as copy number of gene of interest per 100 
GAPDH copies.  
 
 
 
 
 
 
Fig. 3.41. FHL2 transcript detection (blue label) by in situ hybridization in control 
(A) and isoproterenol treated (B,C) hearts. Only a weak signal was detectable in 
control hearts (A). Strong induction of FHL2 expression in isoproterenol treated 
hearts was observed (B,C). 
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3.5.5. Deregulation of BMP10 expression in neonatal SOD2 knock-outs  
 
 Homozygous SOD2 knock-outs die shortly after the birth due to severe dilated 
cardiomyopathy (Li et al., 1996; Lebovitz et al., 1996). It was interesting therefore to 
check changes in BMP10 expression in this genetic model. Three days old MnSOD 
homozygous, heterozygous and WT mice from the same litter, on mixed C57Bl6/ICR 
background (generous gift from Dr. T. Loch) were used for the analysis. In situ 
hybridization in paraffin embedded hearts slides revealed striking differences in BMP10 
transcription (Fig. 3.42). In knock-out mice, ectopic expression was detected in 
ventricles, while in the right atrium the signal intensity was apparently diminished. 
Neonatal heterozygous MnSOD mutant mice, which do not show impairment of cardiac 
function and which have a virtually normal lifespan, did not exhibit any apparent 
changes in BMP10 expression (data not shown).  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.42. Recapitulation of BMP10 expression in ventricles and downregulation 
of its atrial transcription in three day old MnSOD knock-out. In situ hybridization 
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with the BMP10 specific antisense riboprobe (blue label). Panels A and B- 
illustrate the BMP10 expression in three day old wild type control. Panels C,D- 
show decrease of BMP10 expression in the right atrium of SOD2 homozygotes. 
Panels B,D- represent higher magnification of the atria in wild type and knock-
out, respectively. E,F- higher magnification of (C) illustrating the signal detected 
in the ventricles of neonatal SOD2 homozygous. 
  
Immunostaining of BMP10 showed a striking decrease of protein expression in 
the right atria of knock-outs (Fig. 3.43), but not in heterozygous (data not shown) and 
wild type controls. Representative confocal images of BMP10 localization in two 
different SOD2 homozygous and in control mouse are shown in Fig. 3.43. As already 
mentioned, membrane location and cytoplasmic accumulation of BMP10 in the cells of 
right atrium is typical for wild type neonatal mouse. However, in neonatal MnSOD 
knock-outs the BMP10 signal in the cytoplasm was not detectable and only membrane 
bound BMP10 was found in the subset of atrial cells. 
 
 
 
 
 
 
 
 
 
 
Fig. 3.43. The representative images of the BMP10 in situ immunodetection 
results. Downregulation of atrial BMP10 (green) expression in neonatal MnSOD 
homozygous (C,D) mice as compared to the control wild type (A). Sections were 
counterstained with phalloidin-TRITC (red) and nuclei were visualized with DAPI 
(blue).  
 
The relative comparison of BMP10 expression level in MnSOD homozygous 
with heterozygous and wild type controls by semi-quantitative RT-PCR confirmed the 
overall downregulation of the gene in knock-out animals. Simultaneously, expression of 
known markers of cardiomyopathy, i.e. BNP and ANF was monitored and a strong 
increase was detected. As shown in Fig. 3.44, a decreased expression of BMP10 was 
detected only in MnSOD-/-, but not in heterozygous mice. An increase of ANF was 
observed exclusively in knock-outs.  
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Fig. 3.44. Semi-quantitative RT-PCR analysis of BMP10 (left panel) and ANF 
expression (right panel) in three day old wild type, heterozygous and homozygous 
MnSOD knock-outs. Downregulation of BMP10 expression in SOD2-/- is 
correlated with an increase of ANF.  
 
 
3.6. Characterization of ventricular BMP10 positive cells in pathological adult 
hearts 
 
 The induction of BMP10 expression in different regions of the failing ventricles 
suggested its role in an adaptive or pathological response. To determine its positive or 
negative action, it was necessary to characterize the ventricular BMP10 positive cells. 
Based on preliminary observations, i.e. localization in the close proximity to vessels and 
the presence of cell clusters- endothelial, smooth muscle and proliferation markers were 
chosen to unequivocally identify BMP10 expressing cells.  
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Fig. 3.45. A subpopulation of BMP10 positive cells express the endothelial marker 
PECAM. Double immunodetection of endothelial marker CD31/PECAM (A, red) 
and BMP10 (B, green) in the ventricles of Desmin knock-out mouse heart. Nuclei 
were visualized with DAPI (C, blue). Panel D shows merged images. For exact 
description see text. 
 
As shown above, a subpopulation of BMP10 positive cells was positive for the 
endothelial marker- platelet endothelial cell adhesion molecule PECAM/CD31 (Fig. 
3.45). It should be noted, that BMP10 was not found in all endothelial cells (data not 
shown). Similar results were obtained when smooth muscle actin was used as a marker 
(Fig. 3.46). Again, BMP10 was detected in a subpopulation of smooth muscles cells. 
Most of the BMP10 positive cells exhibited moderate expression of the smooth muscle 
marker, but only a minority of smooth muscles cells in the heart stained positive for 
BMP10.  
 
 
 
 
 
 
 
Fig. 3.46. A minority of SMA positive cells in ventricles of MnSOD heterozygous 
expressed BMP10. Merged images of double immunostaining (A-B) of smooth 
muscle actin- SMA (red) and BMP10 (green)- yellowish when co-localize. The 
arrow indicates the cell expressing both BMP10 and SMA, arrowhead- 
BMP10pos./SMAneg. cell. Nuclei were visualized with DAPI (blue).  
 
Double immunolabeling of BMP10 and the proliferation markers phospo-histone 
H3 (Fig. 3.47) and Aurora B (Fig. 3.48), revealed that a major subpopulation of BMP10 
positive cells underwent mitosis. Phospo-histone H3 marks cells in both G2 and mitosis 
(Fig. 3.47), while Aurora B marks those in anaphase, telophase and cytokinesis. On the 
basis of the Aurora B pattern, BMP10 positive cells in cytokinesis were found in the 
different genetic models of cardiomyopathy (Fig. 3.48) and isoprotererol induced (data 
not shown) models. Surprisingly, in doxorubicin treated mouse heart, an accumulation 
of Aurora B was detected in nuclei of BMP10 positive cells although these cells did not 
exhibit features of cytokinesis (Fig. 3.48). 
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Fig. 3.47. In a subpopulation of BMP10 positive cells (green) phosphorylated 
histone H3 is detectable (pink, nuclear location).  Nuclei were visualized with 
DAPI (blue) and sections were counterstained with phalloidin 633 (dark red).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                               RESULTS 
 93 
Fig. 3.48. BMP10 is detectable in proliferating cells. Proliferation marker- Aurora 
B (red) co-localizes with BMP10 (green) in ventricles of MnSOD heterozygous 
(SOD+/-) and doxorubicin (DOX) treated mice. Nuclei were stained with DAPI 
(blue). Note the accumulation of Aurora B in nuclei of BMP10 positive cells in 
doxorubicin treated heart, however, these cells did not exhibit features of 
cytokinesis. 
 
During the analysis of BMP10 expression in different models of 
cardiomyopathies, the question arose whether BMP10 is present in ventricular 
cardiomyocytes. As already mentioned in the case of MnSOD heterozygous, due to the 
small size of BMP10 positive cells it was easy to confuse BMP10 positive cells as heart 
muscle cells. Sometimes even a careful confocal analysis did not give clear answer. 
Hence, two distinct cardiomyocyte specific markers, Nkx2.5 and MHC were selected 
and used in double labeling experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.49. Immunolabeling of Myosin Heavy Chain (red) with MF20 antibody 
(A) and BMP10 (B, green) in isoproterenol induced hypertrophy showed that 
BMP10 is expressed in interstitial cells but not in cardiomyocytes in ventricles 
of the failing heart. Nuclei are shown in blue by DAPI staining (C). Panel D- 
merged images.  
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Fig. 3.50. Immunostaining of MF20 (A,E- red) and BMP10 (B,F- green) in the 
developing mouse heart at E11.5. BMP10 is detected not only in cardiomyocytes, 
but also in surrounding cells. Nuclei were visualized with DAPI (C,G- blue). D 
and H show merged images.  
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Representative results of MF20 and BMP10 double staining are shown in Fig. 
3.49. Hypertrophied ventricular cardiomyocytes in isoproterenol treated mouse are 
negative for BMP10 and BMP10 positive cell do not express myosin. It should be 
emphasized however, that in the right atrium BMP10 staining was detected in myocytes 
(illustrated in Fig. 3.51 on the example of Nkx2.5). 
In the developing mouse heart, BMP10 was detected by in situ hybridization 
(Neuhaus et al., 1999) and immunostaining (own results) in the trabeculated 
myocardium. Additionally, embryonic BMP10 deficiency (Chen et al., 2004) leads to 
defective outgrowth of these structures, hence it was interesting to analyze, whether 
BMP10 localization is restricted to cardiomyocytes in embryonic ventricles.  
In trabeculae, centrally located MF20 and BMP10 positive cells were 
surrounded by non-cardiomyocytes which did also express BMP10. Hence both 
myocytes and non-cardiomyocytes express BMP10 in embryonic hearts (Fig. 3.50.)  
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.51. A and B- ventricular BMP10 positive cells (green) do not express 
Nkx2.5 (purple in merge with blue DAPI). Section B was counterstained with 
phalloidin 633. C- High magnification of atrial cardiomyocytes with membrane 
location of BMP10 (green) and Nkx2.5 staining (red) in nucleus. 
 
Since structural proteins label only relatively mature cardiomyocytes, the 
transcription factor Nkx2.5 was used as an additional marker for cardiomyocytes. The 
double immunostaining with BMP10 and Nkx2.5 specific antibody (Fig. 3.51) resolved 
my prior observations concerning a possible BMP10 expression in cardiomyocytes. 
Under pathological conditions BMP10 expression was not detected in ventricular 
myocytes, but only in interstitial cells.  
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Fig. 3.52. Immunostaining of Nkx2.5 (A- red) and BMP10 (B- green) in 
developing mouse heart at E11.5. BMP10 is detected not only in cardiomyocytes, 
but also in other cells. Nuclei were visualized with DAPI (C- blue). D shows 
merged images.  
 
Since BMP10 was detected only in pathologically altered ventricles, but not in 
healthy hearts I wanted to identify the origin of these BMP10 expressing cells. It is 
believed that pluripotent progenitor cells reside in the heart and can be characterized by 
stem cell antigen 1 (Sca1)/Ly6A expression (Oh, H., 2003). Additionally, resident Sca1 
positive cells in the heart were further subdivided into two: CD31- and 31+ cardiac side 
populations (Pfister et al., 2005). For this reason I used transgenic mice overexpressing 
GFP under the control of a Sca1 promoter (generous gift from Prof. T. Braun). An 
additional advantage of using a transgenic strain is the amount and stability of the 
expressed GFP and the possibility to monitor Sca1 promoter induction changes on the 
basis of GFP intensity differences.  
First, the number of progenitor cells in the heart was verified on the basis of 
green fluorescence. As shown in Fig. 3.53, an enormous number of cells expressing 
GFP were found in the heart, even without signal amplification with an anti-GFP 
antibody.  
In addition it was analyzed whether PECAM/CD31 and Sca1-GFP were 
expressed in the same cells. CD31 positive cells incorporated in vessels did not express 
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Sca1 (data not shown), only a minority of Sca1-GFP positive cells outside of the vessel 
wall expressed platelet endothelial cell adhesion molecule (Fig. 3.54).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.53. A high number of stem cell antigen 1 positive cells reside in the heart as 
shown by visualization of GFP expression driven by Sca1 promoter (A). Panel B- 
the same section as in A counterstained with phalloidin-TRITC (red), C- nuclei 
were visualized with DAPI (blue) D-merged images.  
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Fig. 3.54. Colocalization of CD31 (A-red) and Sca1-GFP (B-green) cells in Ly6A 
transgenic mouse heart. The arrow indicates colocalization of PECAM and Sca1 
antigen, arrowheads PECAMneg./Sca1pos. cells. Nuclei were visualized in blue with 
DAPI (C). Panel D presents merged images. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.55. BMP10 co-localizes with Sca1 antigen in the ventricles of isoproterenol 
treated Sca1-GFP transgenic mice. Membrane bound BMP10 (red) was found in 
Sca1 positive cells which underwent cytokinesis (arrow). BMP10 accumulated in 
cytoplasm correlated with the marginal GFP signal (arrowhead). GFP was not 
amplified by antibody staining. For nuclei visualization DAPI was used (blue).  
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To study BMP10 expression in Sca1-GFP mice, cardiac dilation or/and 
hypertrophy had to be induced by doxorubicin and isoproterenol administration, 
respectively, prior to immunohistochemical analysis.  In mice treated with both drugs, 
BMP10 was found in Sca1pos., but also in cells negative or weakly expressing Sca1 (Fig. 
3.55). As shown below, in a model of hypertrophic cardiomyopathy, BMP10 was 
detected in separating GFP positive cells (Fig. 3.55, left panel, arrow). Note the 
difference between BMP10 locations: in the left panel BMP10 is membrane bound in 
cells probably undergoing cytokinesis, , whereas in clustered cells on the left side of the 
image, a clear cytosolic accumulation is visible (Fig. 3.55, left panel, arrowhead). It 
should be mentioned that the presence of cytosolic BMP10 accumulation was most 
often but not always correlated with weak Sca1 expression, as shown in Fig. 3.55. The 
right panel shows a rare example of cell strongly positive for BMP10 with a preserved 
Sca1 signal. From two BMP10pos. cells, one exhibits strong GFP fluorescence, while the 
second has diminished, marginal GFP expression (limited to the disappearing signal in 
nucleus). On this image a Sca1pos. cell with membrane location of BMP10 is also 
shown.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.56. BMP10 (A- red) was detected in single ventricular Sca1 positive cells 
(B-green) in doxorubicin treated Sca1-GFP transgenic mice. For nuclei 
visualization DAPI was used (C- blue). Panel D shows merged images.  
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Induction of BMP10 with doxorubicin yielded similar results. BMP10 was 
localized in both Sca1pos. and Sca1neg. cells and a correlation of GFP intensity and 
BMP10 accumulation was noticed. As already mentioned, ventricular cells, which 
ectopically expressed BMP10 due to doxorubicin administration, did not show the 
tendency to cluster and only single BMP10 positive cells were found.  When Sca1pos. 
cells were marked with GFP, very often pairs or even clusters of Sca1pos. cells were 
present, but in contrast to isoproterenol there was only single BMP10pos. cell among 
them (Fig. 3.56).  
 
 
3.7. Growth and differentiation function of BMP10- in vitro studies 
 
3.7.1. The BMP10-IRES-GFP construct produces functional BMP10 protein 
 
 To test the function of BMP10 in vitro, a BMP10 expression construct was 
generated. 293T cells were transiently transfected with the BMP10-IRES2-GFP 
construct or pEGFP empty vector (control). Twenty-four hours after transfection, when 
the GFP reporter molecule expression was apparent and transfection efficiency was 
estimated to comprise a minimum level of 80% (based on GFP fluorescence), the 
growth medium containing 10% FCS was replaced with serum free DMEM medium. 
Forty-eight hours later, medium and cells were collected to test whether BMP10 and 
GFP proteins overexpressed in mammalian cells show the following properities: 
1. Detection of BMP10 by Western Blot in cells as well in medium due to the 
leader secretion sequence included in BMP10 cDNA. GFP should be detectable 
only in transfected cell lysates. 
2. Induction of alkaline phosphatase (ALP) in C2C12 cells by BMP10 containig 
supernatant from transfected cells.  
As shown in Fig. 3.57 293T cells were efficiently transfected with the BMP10-
IRES-GFP plasmid (Fig. 3.57A) and the pEGFP control vector (data not shown). Using 
Western Blot analysis GFP was detected with the anti-GFP antibody in the lysate of 
cells transfected with either the BMP10-IRES2-GFP expression construct or the control 
vector. 
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A weak signal was also visible in both control and conditioned serum free media; which 
is probably derived from dying transfected cells. In case of BMP10, Western Blot 
revealed the expression of the full length protein in 293T cells transfected with the 
plasmid, but not with the empty vector. A stronger band of appropriate size was also 
detectable in BMP10 conditioned medium, which indicates efficient secretion and 
accumulation of full length protein in this medium. The band was not present in control 
serum free medium after pEGFP transfection (Fig. 3.57B). 
 
 
 
 
 
 
 
 
  
 
Fig. 3.57. Panel A- Typical transfection efficiency of 293T cells necessary for 
enrichment of the medium with BMP10. Panel B- Western Blot analysis of cell 
lysates (lanes 1 and 3) and serum free medium (lanes 2 and 4) 72 hours after 
transfection with BMP10-IRES-GFP (lanes 1 and 2) or control pEGFP (lanes 3 
and 4).  
 
Since the protein of the expected size was efficiently synthesized, secreted and 
accumulated in the medium, the most important was to verify the biological activity of 
the overexpressed BMP10. All members of the Bone Morphogenetic Proteins family are 
known to induce osteoblast differentiation of myoblastic cells, such as C2C12 cells 
(Katagiri et al., 1994; Aoki et al., 2001).  
 
 
 
 
 
 
 
Fig. 3.58. BMP10 induces differentiation of C2C12 cells into osteoblasts. Alkaline 
phosphatase activity detection (blue) in C2C12 cells treated with SF control (A), 
BMP10 enriched medium (B-D) and BMP2 (E- positive control). Panel A- 100% 
of control serum free medium medium; B and C (high magnification)- 100% of 
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BMP10 conditioned medium, D-5% of BMP10 conditioned medium; E- positive 
control 200ng/ml BMP2. 
 
Osteoblasts exhibit high levels of alkaline phosphatase (ALP) activity (Katagiri 
et al., 1994). Thus, induction of ALP by BMP10 would prove the biological activity of 
BMP10. Hence, C2C12 cells were plated in 96-well dishes in regular growth medium 
and 24 hours later the medium was replaced with serum free medium enriched in 
BMP10 or with control medium of different concentrations. Medium collected from 
pEGFP transfected 293T cells was prepared in parallel and used as a negative control. 
Commercially available BMP2 (Sigma) was used as a positive control. Cells were 
cultured for further 48 hours followed by detection of alkaline phosphatase (ALP) 
activity as described in Experimental Procedures. 
The BMP10-IRES-GFP expression construct produced a functional BMP10 
protein which is capable of activating ALP at a level comparable to BMP2. BMP10 is 
efficiently overexpressed and secreted since only 5% of BMP10 conditioned medium 
was sufficient to induce alkaline phosphatase activity in C2C12 cells (Fig. 3.58). ALP 
was neither induced in control conditioned medium (Fig. 3.58A) nor in DMEM serum 
free medium (data not shown).  
A similar set of experiments was also carried using 10T1/2 and 293T cells. In 
both cell lines alkaline phosphatase expression/activity was not induced by BMP10 
conditioned medium.  
 
 
3.7.2. Cell line selection for in vitro studies 
 
On the basis of immunohistochemistry BMP10 positive cells in pathological murine 
hearts exhibited the following features: 
1. They reside in the vicinity or are incorporated in vessels 
2. They express proliferation markers 
3. A subpopulation coexpresses the smooth muscle marker- SM actin 
4. A subpopulation coexpresses the endothelial marker -PECAM 
5. They can originate from Sca1 positive cells 
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Based on these observations, which suggest that BMP10 might exert effects on vessel-
associated cells 3 different cell lines were chosen to test the function of BMP10: 
1. mBM-MASC1- mouse bone marrow derived mesenchymal stem cells- because 
of their pluripotency and high expression of the Sca1 antigene (Belema Bedada 
et al., 2005).  
2. The multipotent mouse embryonic fibroblastic 10T1/2 cell line because of its 
ability to differentiate into pericytes/vascular smooth muscle cells (vSMCs) 
(Hirschi et al., 1998), a process stimulated by TGFβ1. 
3. Mouse adult non-cardiomyocytes (mANCM) isolated from adult wild type 
murine hearts. For this particular experiment cells were also isolated from the 
transgenic strain with GFP expression under control of the stem cell antigen 1 
promoter- Sca1 (Ly6A)-GFP. The heterogeneity of the mANCM culture was 
checked by immunocytochemistry on the basis of the expression of various 
markers: fibroblasts (vimentin), myofibroblasts (vimentin and SMA), smooth 
muscle cells (SMA) and endothelial cells (PECAM and AcLDL uptake).   
Serum free medium collected from 293T cells transfected with empty vector and 
prepared identical to BMP10 conditioned medium served as a negative control in each 
cell culture experiment.  
As BMP10 exerts its function via receptor binding, the expression profile of 
BMPs/TGFβ type I receptors in all cell lines used in the project was analyzed by RT-
PCRs (Tab. 3.2). 10T1/2, C2C12 and bm-MASCs express all type I receptors. In 293T 
cells ALK1 is not present, while COS1 cells lack ALK1, ALK5 and ALK6, described 
already as the least responsive cell line to BMP10 (Mazerbourg et al., 2005).    
 
Expression profile of BMPs/TGFβ receptors in cell lines used in this study 
 ALK1 ALK3 ALK5 ALK6 
Cos1 - + - - 
10T1/2 + + + + 
C2C12 + + + + 
293T - + + + 
BM-MASC1 + + + + 
Tab. 3.2. Collective representation of TGFβ type I receptor expression profile in 
cell lines used in this study (RT-PCRs results).  
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3.7.3. BMP10 induces proliferation 
 
As mentioned before, the only consistent feature of all ventricular BMP10 positive 
cells in pathological murine hearts was the co-expression of proliferation markers. Since 
BMP10 knock-out embryos display a complete loss of ventricular cell proliferation 
(Chen et al., 2004), and overexpression of BMP10 in the embryonic myocardium results 
in increased cellular mitosis (Pashmforoush et al., 2004) the effects of BMP10 on 
growth of non-cardiomyocytes as well of various cell lines of embryonic and adult was 
investigated. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.59. BMP10 induced proliferation of 10T1/2 cells and mANCM isolated 
from the heart. Panels A-C- 10T1/2 cell line. Panels D-F- mANCM. Mitosis and 
cytokinesis marker- Aurora-B immunostaining (red) of  cultured in standard 
growth medium containing 10% FCS (A and D), control serum free medium (B 
and E) and BMP10 conditioned medium (C and F) indicated the higher number of 
proliferating cells in BMP10 enriched medium compared to control SF medium, 
but lower than in growth medium. Nuclei are visualized in blue by DAPI.  
 
Non-cardiomyocytes isolated from adult mouse heart (Fig. 3.59), 10T1/2 (Fig. 
3.59) and mBM-MASC1 (Fig. 3.61) were plated at equal density. Cells were grown in 
standard growth medium containing 10% FCS or serum free control or BMP10 
conditioned medium for 48 hours. Aurora-B staining was used to visualize cells 
undergoing mitosis and cytokinesis. Proliferating cells in late stages of mitosis and 
cytokinesis were counted and the relative ratio of proliferation was calculated with the 
number of dividing cells in control serum free medium was taken as 1. The summarized 
                                                                                               RESULTS 
 105 
results are shown in Fig. 3.60. BMP10 induced proliferation in all tested cell lines 
compared to serum free control medium. In mBM-MASCs the number of mitotic cells 
increased 3.3 fold while in 10T1/2 and mANCM 2.4 and 2.2 fold more proliferating 
cells were noted, respectively in BMP10 conditioned than control medium.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.60. BMP10 induces proliferation of cells in serum free medium. Relative 
proliferation ratio of mBM-MASCs, 10T1/2 and mANCM cells grown in standard 
growth medium supplemented with 10% FCS (bars 1) serum free control medium 
(bars 2)- reference value calculated as1 and serum free BMP10 enriched medium 
(bars 3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.61. BMP10 induces proliferation of mBM-MASCs. Note, that proliferating 
BMP10 treated mBM-MASCs cells (B-D) are morphologically distinct from 
control (A). Aurora-B immunostaining (red) of mBM-MASCs cultured in control 
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serum free medium (A) and BMP10 conditioned medium (B-D). Nuclei are 
visualized in blue by DAPI. F-actin was stained with phalloidin-FITC (green).  
 
 
3.7.4. BMP10 induces morphological changes of various cell types 
 
 During the studies that addressed the effects of BMP10 on proliferation, not only 
the induction of mitosis, but also changes in the morphology of treated cells were noted. 
Forty-eight hours after replacing the growth medium to conditioned or control medium, 
BMP10 addition caused an intensive proliferation of smaller cells than in control 
medium as illustrated in mBM-MASCs (Fig. 3.61) and this morphology was preserved 
after cell division (Fig. 3.62).  
 
 
 
 
 
 
 
 
 
 
Fig. 3.62. mBM-MASCs grown in control serum free (A) and BMP10 enriched 
(B) medium were counterstained with phalloidin-TRITC (red). Nuclei are 
visualized in blue by DAPI. Note that the BMP10 treated cells formed far-
reaching cell-cell contacts (arrow). 
 
These cells created long processes enabling far-reaching cell-cell contacts (Figs. 3.62B, 
3.63B,C). Most of them exhibited a spindle-like shape with centrally located nuclei and 
elongated cytoplasm. The nuclei of the newly appeared subpopulation of cells upon 
BMP10 addition in mBM-MASCs as well as in 10T1/2 were much smaller than in 
control cultures (Fig. 3.59C and 3.61B-D, respectively for both cell lines). It should be 
mentioned that in control medium serum deprivation also caused induction of a sub-
population of smaller cells; however, to a much lower degree and they failed to form 
long distance cell-cell contacts.  
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Fig. 3.63. 10T1/2 grown in control serum free (A) and BMP10 enriched (B,C) 
medium show distinct morphology. Arrows indicate created cell-cell contacts in 
BMP10 treated culture. Cells were counterstained with phalloidin-TRITC (red) 
and nuclei are visualized in blue by DAPI. 
 
It is a well known phenomenon that serum deprivation induces SM-actin expression of 
10T1/2 cells and differentiation to pericytes is strongly amplified by TGFβ-1 addition as 
judged by the expression of others pericyte markers (Hirshi et al., 1998).  Kale et al., 
noted maximal SM-actin expression after 48 hours of 10T1/2 induction with TGFβ-1 
(Kale et al., 2004). On the basis of this observation smooth muscle actin was firstly 
analyzed in the cell lines after 2 days of BMP10 addition. In 10T1/2 cells a robust 
expression of SM-actin was detected in BMP10 treated cultures, while only single cells 
in the control culture expressed this marker. No signal was detectable in cells grown in 
medium supplemented with 10% FCS. BMP10 induced SM-actin expression also in 
mesenchymal stem cells but in this case the expression was limited to a morphologically 
distinct subpopulation (Fig. 3.64).  
 
 
 
 
 
 
 
 
 
Fig. 3.64. SM-actin immunodetection in mBM-MASCs. Panel A- SMA 
expression (green) was induced by serum deprivation in control SF medium in 
cells with fibroblast-like morphology. Note the highly organized pattern of actin 
filaments. Panel B- SM-actin positive mBM-MASCs cells (green) grown in 
BMP10 enriched serum free medium for 48h showed a different morphology and 
accumulation of disorganized actin filaments. Nuclei were visualized by DAPI 
staining (blue). 
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In mBM-MASCs cells growing in control SF medium an expression of SM-actin was 
found in some larger cells with fibroblast-like morphology and the actin filaments 
showed a high degree of organization (Fig. 3.64A) opposite to the BMP10 treated cells 
where disorganized SMA was accumulated in the cytoplasm (Fig. 3.64).  
 
 
3.7.5. BMP10 induces a distinct subset of mBM-MASC-derived cells and tube-like 
formation  
 
Since 48 hours treatment of mesenchymal cells with BMP10 caused induction of 
a morphologically distinguishable cell population, the effect of this factor during later 
time-points was further studied.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.65. Phase-contrast micrographs of mBM-MASCs after 96 hours of culture 
in serum free control (A,B) and BMP10 conditioned medium (C,D).  
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Fig. 3.65 illustrates the difference between mBM-MASCs cultured in control and 
BMP10 enriched serum free medium for 4 days. Cells stimulated with BMP10 failed to 
form a monolayer and recruited neighboring cells to create characteristic line or ring-
shaped patterns. This observation indicated stem cell differentiation into endothelial 
(EC) or pericytes/vSM cells. Hence the expression of EC markers (PECAM and 
Capsulin/POD/Epicardin as well Ac-LDL uptake), pericyte specific markers (PDGFRβ, 
SMA) and smooth muscle specific molecule (Calponin) were tested.  
As mentioned in the previous chapter, SM-actin expression was first noted 48h 
after BMP10 stimulation. Forty-eight hours later (96 hours in conditioned or control 
medium) SMA expression was analyzed again and was found mostly in “line-like” 
structures composed of a population of small cells with disorganized actin filaments.  
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Fig. 3.66. BMP10 induced PECAM (red) and SM-actin (green) expression in 
mBM-MASCs (left panel). Note the co-localization of endothelial and smooth 
muscle cell markers upon BMP10 treatment. In mBM-MASCs grown in control 
SF medium (middle panel) and standard growth medium (right panel) expression 
of CD31 and SMA was also noted, but co-localization of signals was never 
observed. Nuclei were stained with DAPI (blue). 
 
Surprisingly, PECAM was also detectable in some SMA positive cells (Fig. 3.66), 
although some cells were found that expressed only a single marker. mBM-MASCs 
cultured in control serum free generatedmedium single cells positive for one marker 
were also found. However, co-localization of signals was never observed. SMA 
expression was detected in some of the cells with highly organized actin filaments when 
mBM-MASCs reached confluence in standard growth medium supplemented with 10% 
FCS.  
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Fig. 3.67. The endothelial marker– epicardin (red) co-localizes with calponin 
expression (green) in a subpopulation of BMP10 treated cells (left panel). Both 
markers were only occasionally found in control SF medium (middle panel) or 
growth medium (right panel). Nuclei were stained with DAPI (blue).  
 
This might be explained by spontaneous differentiation of stem cells in all types of cells 
due to their pluripotency when they are confluent (data kindly provided by Dr. F. 
Belema Bedada, personal communication). Similar results were observed in the case of 
serum deprivation. 
Unexpectedly PECAM and SMA co-localized in some BMP10 treated cells. To 
further investigate the identity of these cells another set of smooth muscle and 
endothelial cell markers - calponin and epicardin, was studied.   
A specific nuclear localization of epicardin was found in “line-like structures”, 
but not in other cells, and the majority of capsulin positive cells expressed also calponin 
(Fig. 3.67). On the other hand, in approximately of 70% cells positive for calponin the 
endothelial marker was not detectable. Only a minor amount of cells grown in control 
serum free or standard growth medium (GM) was calponin positive, as it is a more 
specific marker and expressed later than SM-actin.  
The most specific method to identify an endothelial cells subpopulation is their 
ability to take up Ac-LDL (Acetylated Low Density Lipoprotein). Some mBM-MASCs 
induced with BMP10 were positive for Ac-LDL uptake as presented above (Fig. 3.68). 
Red fluorescence, specifically indicating the endothelial character of labeled cells 
partially overlapped with diminished SM-actin staining, but most of the ECs were not 
expressing smooth muscle actin. Neither cells from the control culture nor stem cells 
grown in standard GM were positive for Ac-LDL uptake.     
As mentioned previously, TGFβ is known to induce differentiation of 10T1/2 
cells to pericytes/vSMCs. Several markers are commonly used to identify pericytes, e.g. 
SM-actin and platelet-derived growth factor receptor β (PDGFRβ). There is evidence 
that pericytes may also give rise to other types of cells, including fibroblasts, 
osteoblasts, chondrocytes and adipocytes (Collet et al., 2005, Armulik et al., 2005). To 
address the question whether BMP10 induced expression of other pericyte markers in 
MASC mesenchymal stem cells I also investigated the presence of PDGFRβ (Fig. 3.69). 
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Fig. 3.68. Representative images of Dil- labeled Ac-LDL (red) uptake by mBM-
MASCs grown in the presence of BMP10 (left panel). The drug was not 
detectable in mBM-MASCs grown in control SF medium (right panel). Cells 
were stained with anti-SM actin (green) and nuclei were visualized with DAPI. 
                                                                                               RESULTS 
 113 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.69. Immunostaining of PDGFRβ receptor (red) and SMA (green) in mBM-
MASCs. PDGFRβ is specifically detected in BMP10 treated cells (left panel), but 
not in control cells (middle panel- control SF medium; right panel- standard GM). 
DAPI stains nuclei in blue.  
 
PDGFRβ expression was specifically induced by BMP10 addition, but not by 
serum deprivation in a control culture of bone marrow derived mesenchymal stem cells. 
Approximately 50% of PDGFRβ positive cells express SM-actin as well. In addition I 
also detected cells with only one of the two tested markers. As before, SMA was 
detected in both serum free control medium and 10%FCS supplemented growth 
medium. Moreover, SMA co-localized in some BMP10 treated cells with vimentin 
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expression (Fig. 3.70). Vimentin was not found in control untreated cells and BM-
MASCs grown in growth medium. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.70. Immunostaining of EMT marker - vimentin expression is induced by 
BMP10 (left panel, red) and co-localizes with SMA (green). Vimentin was not 
detectable in both control cultures.  Nuclei are visualized in blue by DAPI. 
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3.7.6. Differentiation of 10T1/2 cells is stimulated by BMP10 addition 
 
 Multipotent mesenchymal 10T1/2 cells are known to differentiate into various 
cell types. MyoD induces fibroblast conversion to muscle cells (Braun et al., 1989), 
whereas their stimulation with TGFβ results in expression of pericyte/vSMC markers 
(Hirshi et al., 1998). Preliminary results indicated that treatment of 10T1/2 with BMP10 
might induce differentiation into a new sub-population of morphologically distinct cells. 
10T1/2 fibroblasts were grown in serum free BMP10 conditioned or control medium 
followed by immunocytochemical analysis as in the case of mBM-MASCs. In BMP10 
enriched medium 10T1/2 cells created cord-like structures, as shown below (Fig. 3.71).  
 
 
 
 
 
 
 
 
 
Fig. 3.71. Phase contrast microphotography of 10T1/2 cells grown in control (A) 
and BMP10 enriched (B) serum free medium for 7 days. The BMP10 but not the 
control serum free medium stimulateed cord-like structure formation. 
 
The first and obvious question was whether the effect of BMP10 on 10T1/2 
differentiation was similar to the TGFβ effect, hence immunodetection of PDGFRβ and 
SM-actin, which serve as pericyte/vSMC markers, was performed.  
Strong induction of PDGFRβ expression was observed in BMP10 treated 
cultures. In cord-like structures SMA co-localized with the PDGF-BB receptor (Fig. 
3.72 middle panel). In a sub-population of small cells, which did not show the this line-
like pattern, PDGFRβ positive cells mostly did not express SM-actin and an overlapping 
signal was found only occasionally. To further investigate the induction of smooth 
muscle markers, the expression of calponin- a late SMCs marker- was examined (Fig. 
3.73).  
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Fig. 3.72. (A) Low power magnification of PDGFRβ (red) and SMA (green) 
immunodetection in 10T1/2 cells treated with BMP10 (left and middle panel), or 
control SF medium (right panel). Nuclei were stained with DAPI (blue). (B) 
Higher magnification of BMP10 treated cells stained as in A. Note the partially 
overlapping signal of PDGFRβ and SMA (arrow) or the lack of their co-
localization (arrowhead) in BMP10 treated cells 
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Fig. 3.73. Immunodetection of calponin (green) in 10T1/2 cells grown in BMP10 
conditioned (left panel) or control (right panel) serum free medium. Arrows 
indicate a monolayer cell negative for calponin. Nuclei are visualized in blue by 
DAPI.  
 
Fig 3.73 shows the results of calponin detection in 10T1/2 cells cultured in 
BMP10 enriched and control medium. Strong calponin expression was found after 
BMP10 treatment in highly organized tube-like structures, but not in other cells. Only a 
minor back-ground signal was noted in control cultures.  
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Addition of BMP10 to stem cell cultures induced expression of endothelial 
markers. Therefore CD31 and Ac-LDL uptake was also examined in 10T1/2 cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.74. A. Low magnification images of PECAM/CD31 (red) and SMA (green) 
immunodetection of 10T1/2 cultured in BMP10 conditioned and control SF 
medium, as well in standard growth medium supplemented with 10% FCS. Nuclei 
are shown in blue. Note three populations of cells in BMP10 treated culture: 
PECAMpos./SMApos. (arrow); PECAMpos./SMAneg. (asterisk) and 
PECAMneg./SMApos. (arrowhead). PECAM and SMA were detected in single cells 
in control cultures at marginal background level.  
 
Two distinct patterns of PECAM/SM-actin expression were found (Fig. 3.74). In 
cord-like structures induced by BMP10, most of the cells expressed both proteins, while 
in areas where theses structures were not yet obvious three phenotypes were noted: 
PECAMpos./SMApos.; PECAMpos./SMAneg. and PECAMneg./SMApos.. It should be 
emphasised that most of cells in this case were PECAMpos./SMAneg.. When cells were 
positive for both antigens, one signal was usually stronger and the other weaker. Ac-
LDL uptake (Fig. 3.75) followed by SM-actin staining confirmed this observation. 
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Red fluorescence indicating endothelial cells were only found in 10T1/2 cells 
grown in serum free BMP10 conditioned medium, but not in the control culture (Fig. 
3.75). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. 75. Identification of endothelial cells on the basis of DiI-Ac-LDL uptake 
(red), followed by SM-actin staining (green) in BMP10 treated (left panel) and 
control cultures (right panel). Nuclei were stained with DAPI (blue).  
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Cells strongly positive for Ac-LDL uptake had only a weak, marginal SMA 
signal and vice versa. Approximately 40% of the cord-like forming cells were AcLDL 
positive, 40% exhibited smooth muscle phenotype and 20% were negative or weakly 
positive for both. Because of the unexpected induction of either smooth muscle or 
endothelial markers by BMP10 addition, their expression was also analyzed at the RNA 
level.   
 
 
 
 
 
 
 
 
 
 
Fig. 3.76. BMP10 induces expression of endothelial markers (POD, CD31), the 
pericyte-specific marker PDGFRβ and the smooth muscles marker calponin in 
10T1/2 cells. Semi-quantitative RT-PCR analysis of BMP10 treated and control 
10T1/2 cells 48 and 96 hours in culture as well as in confluent culture in growth 
medium. The endothelial specific transcription factor- POD is highly expressed 
after 48 hours of BMP10 treatment, whereas cell-surface CD31 is upregulated 
after 4 days. Note the induction of calponin expression by serum deprivation. 
Equal loading of RNA was assured by monitoring expression of the housekeeping 
gene HPRT.   
 
Semi-quantitative RT-PCR analysis confirmed the results of 
immunocytochemistry (Fig. 3.76). Strong induction of the endothelial specific 
transcription factor POD was detectable in 10T1/2 cells already 48 hours after BMP10 
addition and was sustained at the same level 48 hours later. The other cell surface 
endothelial marker- CD31 was weakly expressed after 2 days in conditioned medium 
but its level increased after 96 hours of treatment. Calponin was not detectable at an 
earlier time-point, but on the fourth day of BMP10 treatment its transcription was 
strongly induced. It should be mentioned that serum deprivation also caused an 
expression of calponin albeit at a much lower level. PDGFRβ was also detected in 
treated cells after 48 and 96 hours. 
Vimentin, a mesenchymal marker, is known to be up-regulated during 
endothelial-to-mesenchymal transition (EMT). Vimentin was highly expressed in 
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10T1/2 cells growing in medium containing 10% FCS (Fig. 3.77). Serum deprivation 
resulted in down-regulation of vimentin expression. In fibroblasts grown in serum free 
BMP10 supplemented medium vimentin was also downregulated, but its expression 
level was preserved in a small subpopulaion of cells in cord-like structures. A strong 
signal of vimentin was observed mostly in cells weakly positive or negative for SMA.  
 
 
 
 
 
 
 
 
 
 
      
 
 
 
 
 
 
 
 
 
Fig. 3.77. Downregulation of vimentin expression (red) correlated with SMA 
(green) upregulation in BMP10 treated 10T1/2 cells in cord-like structures. 
Decreased vimentin staining without significant SMA induction was observed in 
control serum free medium in 10T1/2 cells. The right panel represents 10T1/2 
cells grown in standard GM, stained with the same set of markers. Note the strong 
and homogeneous vimentin pattern. Nuclei are visualized in blue by DAPI 
staining.  
 
 
3.7.6.1. Overexpression of BMP10 induces differentiation of 10T1/2 cells 
 
 Since addition of BMP10 to the medium induced differentiation of 10T1/2 cells, 
I investigated whether it is possible to achieve the same effect by direct overexpression 
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of the growth factor. This experiment allowed me to confirm that induction of 
proliferation and differentiation of fibroblasts are direct downstream effects caused by 
BMP10, but not a result of other proteins secreted from 293T cells to the conditioned 
medium. 10T1/2 cells were seeded at equal density and transfected with BMP10-IRES-
GFP plasmid or a pEGFP empty vector as a control. After transfection cells were grown 
in standard growth medium supplemented with 10% FCS to avoid the differentiation in 
response to serum deprivation. It should be emphasized that transfection efficiency was 
comparable for both pEGFP and BMP10-IRES-GFP after 24 hours, when GFP 
expression was clearly visible. Figure 3.78 illustrates the difference in cell morphology 
between control and BMP10 transfected 10T1/2 cells 24 hours after transfection. An 
obvious proliferative effect as well a morphologically distinct shape of BMP10 
transfected cells was noted after 48 hours as shown in Fig. 3.79. Control cells 
expressing GFP remained morphologically indistinguishable from surrounding 
fibroblasts and did not exhibit a high rate of mitosis since only single cells, not clusters 
of green cells were found 48 hours after transfection. Clusters of elongated green cells 
creating network –like structures became visible at the same time point after 
transfection with BMP10-IRES-GFP construct. 
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Fig. 3.78. 10T1/2 cells 24 hours after transfection with BMP10-IRES-GFP and 
control pEGFP vector. GFP positive cells indicating on BMP10 expression 
(BMP10-IRES-GFP transfected) are morphologically distinct from cells 
transfected with the empty vector. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.79. 10T1/2 cells 48 hours after transfection with BMP10-IRES-GFP and 
control pEGFP vector. GFP positive cells indicating BMP10 expression (BMP10-
IRES-GFP transfected) are morphologically distinct from cells transfected with 
the empty vector. Note the increased number of green cells in the 10T1/2 cell line 
transfected with the BMP10 expression construct indicating a pro-mitotic effect of 
BMP10.   
 
The effects of BMP10 overexpression in 10T1/2 cells was more pronounced 72 hours 
after transfection. In contrast to control cultures (data not shown), where only single or 
pairs of GFP positive cells were found, a large number of BMP10 expressing cell 
clusters was visible (Fig. 3.80). In addition to long-shaped cells, a sub-population of 
smaller cells expressing GFP appeared in the culture, as shown in Fig. 3.80. The new 
type of cells was comparable with those induced by BMP10 conditioned medium in 
both 10T1/2 and BM-MASC cell lines. These cells remained connected with elongated 
cells creating “nodes” and formed clusters with each other. The pro-mitotic effect was 
maintained even 72 hours after transfection. 
                                                                                               RESULTS 
 124 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.80. 10T1/2 cells 72 hours after transfection with BMP10-IRES-GFP. Green 
cells expressing BMP10 were highly proliferative. In addition to long-shaped cells, 
a sub-population of smaller BMP10-IRES-GFP expressing cells appeared in the 
culture. 
 
The use of the BMP10-IRES2-GFP expression construct for transfection allows 
to monitor cells, which express BMP10. I asked the question whether in such cells are 
able to create cord/tube-like structures and to take up acetylated low density lipoprotein 
(Ac-LDL), the most reliable and specific method to distinguish endothelial cells. 
As shown below, GFP positive cells expressing BMP10 form three dimensional 
tubes as visualized by phalloidin counterstaining (Fig. 3.81). Cells transfected with the 
control pEGFP vector did not exhibit this feature and were not able to take up Ac-LDL 
(data not shown). In Fig. 3.82 representative images illustrating Ac-LDL uptake by 
BMP10 expressing cells (as estimated by green fluorescence) are shown. All 10T1/2 
cells that express BMP10 were also positive for red fluorescence, indicating the 
presence of LDL in these cells. It should be mentioned that also in some of the cells 
neighbouring GFP positive red fluorescence was noted. 
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Fig. 3.81. Tube-like formation of BMP10-IRES-GFP transfected 10T1/2 cells. 
Panel A- confocal image of cells stained with phalloidin-TRITC (red). Panel B- Z-
position illustrates 3D structure created by transfected cells as illustrated on 
selected confocal sections; C- 3D reconstruction of the confocal images shown in 
A and B. Nuclei were visualized with DAPI (blue). 
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Fig. 3.82. BMP10-IRES-GFP transfected 10T1/2 cells (green) were able to take up 
DiI conjugated acetylated LDL (Ac-LDL) (red). Nuclei were visualized with 
DAPI (blue). 
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Fig. 3.83. 10T1/2 cells transfected with BMP10-IRES-GFP (green) expressed 
calponin (left panel, red) and PDGFRβ (right panel, red). Note that in some of the 
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cells neighbouring transfected cells both markers are detectable. Nuclei were 
visualized with DAPI (blue). 
 
This experiment proved that BMP10 is able to promote differentiation of 
mesenchymal, fibroblastic 10T1/2 cells into endothelial-like cells. As already 
mentioned, the activity of alkaline phosphatase was not detectable in this cell line upon 
BMP10 induction, both by conditioned medium or transfection with BMP10-IRES-GFP 
plasmid. This might indicate a specific and selective induction of differentiation by 
BMP10. 
Since addition of BMP10 to the medium induced expression of smooth muscle 
specific gene expression, for example calponin, I checked whether cells transfected with 
BMP10 express calponin as well. Another question was, if the PDGFRβ receptor is 
detectable in these cells. 
Calponin was detected in transfected, but also in some cells adjacent to BMP10 
expressing cells, as shown in Fig. 3.83. Staining was noted in cord-like, GFP marked 
structures and in the cells that seemed to be recruiting to them. Similar resulst was 
obtained with BMP10 conditioned medium. The expression of the pericyte specific 
gene- PDGFRβ was found to be stimulated by BMP10 (Fig. 3.83). The results of 
BMP10 treatment and transfections of 10T1/2 cells are summarized in Tab. 3.3. 
 
The BMP10effects on 10T1/2 cells 
Cell 
line 
Effects/Markers Control BMP10 
treated 
BMP10 
transfected 
Remarks 
10T1/2   
Proliferation + upregulated upregulated  
Cord-like 
structures 
- induced induced  
Smooth muscle 
cell markers 
+ + + 
PDGFRβ + + + 
10T1/2 cells 
adopt 
pericytes/vSMC 
phenotype in 
SF medium  
Endothelial cell 
markers 
- + + In cells forming 
cord-like 
structures 
 
Vimentin downreguleted + + Expression was 
preserved in 
cord-like 
structures 
Tab. 3.3. Summary of BMP10 influence on 10T1/2 cells. 
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3.7.7. BMP10 induces formation of cord-like structures in primary cultures of 
mouse adult non-cardiomyocytes 
 
3.7.7.1. Characterisation of isolated cells 
 
Since BMP10 was found to be expressed in ventricular cells that do not express 
cardiomyocyte-specific markers, the total population of non-cardiomyocytes was 
isolated from adult mouse heart. These cells were grown in 10% FCS medium and early 
passages (1-3) were used for the experiments. For each experiment, the heterogeneity of 
culture was analyzed by immunocytochemistry on the basis of the following markers: 
fibroblasts (vimentin), myofibroblasts (vimentin and SMA), smooth muscle cells (SMA, 
calponin), pericytes (PDGFRβ) and endothelial cells (PECAM and AcLDL uptake) 
(Fig. 3.84). 
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Fig. 3.84. Characterisation of mANCM isolated from WT mouse heart (A-E) and 
Sca1(Ly6A)-GFP transgenic strain (F). The following antibodies were used to 
estimate the content of different sub-populations of cells in the heterogeneous 
culture: (A)- anti-Vimentin (red)/anti-SMA (green) (fibroblasts, smooth muscle 
cells and myofibroblasts, when co-localize); (B)- anti-CD31 (red- endothelial 
cells); (C)- anti-PDGFRβ (red, pericytes); (D)- anti-Calponin (red, smooth muscle 
cells), and Ac-LDL uptake (E,F- endothelial cells). See text for details. 
 
The average content of fibroblasts, characterised by vimentin but not SMA 
expression, was estimated to be in the range of 90%-95%, depending on the isolation. 
The number of myofibroblasts- cells positive for both, vimentin and SMA, never 
exceeded 3%, and smooth muscle cells judged by the calponin and SMA signal were 
7%-10%. Only a few single cells expressing PDGFRβ were found in the cultures. The 
quantity of endothelial cells as estimated by CD31 immunodetection was at the level of 
30%, whereas 20% of cells were able to take up Ac-LDL. In 50% of Sca1pos cells, 
identified by GFP expression, DiI-Ac-LDL was detected. However, cells that did not 
express the Sca1 antigen did also take up Ac-LDL, as shown in Fig. 3.84F. 
 
 
3.7.7.2. Some mANCM cells express BMP10 in culture 
 
 After isolation of mANCM from the whole heart, cells were grown to reach 
confluence in 10%FCS DMEM medium, trypsinised and plated at two different 
densities: 1x106 and 1x105 per 6 cm plate. The next day the growth medium was 
replaced with serum free BMP10 conditioned or control medium.  
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Fig. 3.85. BMP10 in primary mANCM culture isolated from the Sca1-GFP 
transgenic strain was detected with anti-matBMP10 antibody (red). GFP signal 
was not amplified (green). Arrows indicate the small subpopulation of 
BMP10pos/Sca1neg cells, arrowhead BMP10pos/Sca1pos, asterisk BMP10neg/Sca1pos. 
Nuclei were stained with DAPI (blue).  
 
A proliferative effect of BMP10 was apparent in low-density cell cultures while 
no induction of mitosis by BMP10 was observed in more confluent cultures. Therefore, 
it had to be verified whether BMP10 expression is induced in the high-density cell 
cultures growing in the standard growth medium not supplemented with BMP10. 
BMP10 expression was tested by immunocytochemistry and on the RNA level by RT-
PCR analysis. Since mANCM were isolated from the whole heart, cells expressing 
BMP10 were found in all cultures, independent of cell density (Figs. 3.85 and 3.86). In 
mANCM isolated from Sca1-GFP mouse heart, BMP10pos./Sca1neg. and 
BMP10pos./Sca1pos. were found. Most of the cells BMP10pos./Sca1neg. were smaller than 
those expressing both genes (Fig. 3.85). When cells were plated with lower density, 
only single BMP10pos. cells were found in the culture and BMP10 expression on mRNA 
was also low. In more confluent cultures, the number of cells expressing BMP10 rapidly 
increased, as shown in Fig. 3.86. Induction of BMP10 expression was further confirmed 
by RT-PCR analysis (Fig. 3.86). 
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Fig. 3.86. Low power magnification phase contrast microphotograph of mANCM 
cells 1 day (A) and 7 days (B) in culture and semi-quantitative RT-PCR analysis 
of BMP10 expression level (box). RNA for RT-PCRs was isolated from the 
presented cells (A,B). Confocal images (C,D) of BMP10 immunostaining (green) 
in confluent maNCM. Nuclei were stained with DAPI (blue). 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.87. A highly proliferative sub-population of confluent mANCMs (A) was 
picked and cultured separately in growth medium containing 10%FCS. B- 24 
hours later the cells had fibroblast-like morphology. C- 72 hours in culture, cord-
like structures were noted.  
 
When mANCMs were confluent, either in serum free or FCS supplemented 
medium, highly proliferative cells, which did not form a monolayer appeared in the 
cultures. These cells were BMP10 positive. This might explain the lack of the effect of 
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exogenous BMP10 to confluent cultures as the gene is already efficiently expressed in 
many cells. Clusters of these cells (Fig. 3.87A) were isolated and cultured further in 
growth medium (Fig. 3.87B-C). On day 1, cells exhibited a typical fibroblast-like 
morphology (Fig. 3.87B). Two days later, structures resembling a cord-like pattern were 
visible in the culture (Fig. 3.87C) and although this pattern was conserved later on the 
cord-like structures had an immature apperence. However, when as a result of picking 
cell-cell contacts were disturbed (cells were not confluent), proliferation of this sub-
population of mANCM was significantly diminished, which will be described in detail 
in the next chapter. 
 
 
3.7.7.3. Characterisation of the mANCM subpopulation containing BMP10 
positive cells. 
 
 The tendency to form cord-like structures by a subpopulation of BMP10 positive 
mANCM cells, resembled the effect of BMP10 in all cell lines tested. The structures 
formed by the isolated subpopulation of mANCMs were not “fully developed” and did 
not exhibit the ability to create protrusions allowing long-distance cell-cell contact. 
However, the cells spontaneously were arranged in parallel forming longitudinal chains. 
To characterize the type of cells that create these chains, after isolation clones 
containing BMP10 positive cells, the same set of antibodies as for 10T1/2 and BM-
MASCs was used (Fig. 3.88).  
Aurora B staining showed the disturbed proliferation of the cells growing in 
standard growth medium supplemented in 10% FCS (Fig. 3.88A,B). SM actin was 
detected in contaminating cells, but not in cells building chain-like structures (Fig. 
3.88A,C). Strong vimentin expression indicating a mesenchymal origin was observed. 
PECAM expression was also found (Fig 3.88B), although not so strong as in HUVEC 
cells, that served as positive control and no signal was noted in the negative control 
(data not shown). Only a weak signal for PDGFRβ staining was found in single cells. 
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Fig. 3.88. Characterization of picked subpopulation of mANCMs. Note: (A) 
Impaired proliferation and lack of smooth muscle markers (SMA- green and 
Aurora-B- red). (B) Weak expression of PECAM (red) and single Aurora-B 
positive cells (green). (C) Strong vimentin staining (red) and lack of SMA 
expression (green) indicate the mesenchymal origin. (D) PDGFRβ was found 
only in single cells (red). Nuclei were stained with DAPI (blue). 
 
 
3.7.7.4. Effects of BMP10 on mANCM cells 
 
 BMP10 expression is strongly induced in confluent cultures of maNCM, but 
downregulated after trypsinization when the cell density is lower. To investigate the 
effects of BMP10 on heterogeneous mANCM cells, but avoid induction of endogenous 
BMP10 expression, only low density cultures were used. 1x105 cells were plated on a 6 
cm dish to examine the effects of BMP10. The next day, the growth medium was 
replaced with serum free BMP10 conditioned or control medium and cells were further 
incubated for 96 hours with medium changes every 48 hours. Cells treated with BMP10 
started to create similar structures as observed in the case of mBM-MASCs and 10T1/2 
cells. An identical set of antibodies was used for characterisation of BMP10 induced 
changes. 
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Figure 3.89 illustrates the results of SM actin and Aurora B double staining. In 
BMP10 treated cultures, the highly proliferative cells forming cord-like structures are 
mostly negative for the smooth muscle marker, in contrast to previously described cell 
lines. The overall number of smooth muscle actin positive cells seemed to be reduced. 
Comparable results concerning induction of mitosis were obtained as already 
mentioned. Since cells forming tube-like structures were negative for SM actin it was 
likely that they are endothelial cells. This assumption was confirmed by 
immunostaining, as presented below (Fig. 3.90).  
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Fig. 3.89. BMP10 induced proliferation of SMAneg. cells in the mANCM culture. 
Immunodetection of SM actin (green) and Aurora B (red) in BMP10 treated (left 
panel) and control cultures of mANCM. Nuclei are visualized in blue by DAPI.  
 
Structures induced by BMP10 addition to the medium were strongly positive for 
PECAM. In control serum free and in growth medium cells expressing PECAM were 
forming incomplete line-like structures.  
Since BMP10 forced the expression of PDGFRβ in 10T1/2 and BM-MASC 
cells, the induction of this gene in maNCM was also investigated. In mANCMs cultured 
in standard growth medium only single cells positive for PDGFRβ were found as 
described in chapter 3.7.7.1. Comparable results were obtained when cells were grown 
in serum free control medium. After stimulation with BMP10 most of the cells in cord-
like structures expressed PDGFRβ indicating the acquisition of a pericyte identity (Fig. 
3.91). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.90. BMP10 stimulated PECAM expression in a subpopulation of mANCM. 
CD31 (PECAM) immunodetection in BMP10 treated (left panel) and control 
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(middle-serum free control medium, right panel- growth medium) mANCM. Note 
that CD31pos. cells in BMP10 treated cultures are smaller than in controls and  
formed ring-like structures. Nuclei were counterstained with DAPI (blue).  
 
It is interesting to note, that some cells which express PDGFRβ as a result of 
BMP10 addition did not express SM actin. Often strong PDGFRβ staining was observed 
in cells adjacent to SMApos. cells. Smooth muscle actin was found in bigger, 
morphologically distinct cells outside of the cords and rings. In control cultures co-
localization of SMA and PDGFRβ was visible. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Fig. 3.91. BMP10 induced PDGFRβ expression in cord-like structures. 
Immunodetection of PDGFRβ (red) and SM actin (green) in mANCM cultured in 
serum free BMP10 enriched and control medium as well as in standard growth 
medium. Note that upon BMP10 stimulation the strongest PDGFRβ signal was in 
smaller cells creating ring-like structures and weaker staining was in larger cells in 
cords. Highly organized smooth muscle actin filaments were detected in 
morphologically distinct cells. In tube-like structures SMA showed a disorganized 
pattern. Nuclei are visualized in blue by DAPI staining.   
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The preliminary characterization of mANCM revealed that more than 90% of 
the cells in this heterogeneous culture were positive for vimentin, comparable to the 
changes in vimentin expression observed in 10T1/2 and BM-NCMs upon BMP10 
treatment. The influence of BMP10 addition on vimentin expression in cells of heart 
origin was worth to be examined. Representative images of double vimentin and SMA 
immunodetection in mANCM cultures are shown in Fig. 3.92. 
Vimentin expression was preserved upon BMP10 treatment, although its cellular 
organisation was disrupted. It did not co-localize with smooth muscle actin. Figure 3.92 
clearly illustrates the smaller size of cells forming ring-like structures, in mANCM 
grown in serum free BMP10 enriched medium in comparison to control serum free and 
growth medium. 
The effects of BMP10 treatment on mANCM and bm-MASC cells are displayed 
in Tab. 3.4, whereas Tab. 3.5 summarizes the results observed after BMP10 treatment 
of all cell lines used in this study in comparison to the expression of various BMP 
receptors  
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Fig. 3.92. BMP10 did not influence the expression levels of vimentin (red) but its 
cellular organization in cord-like structures in mANCM. Note that SMA (green) 
filaments were disorganized in ring-like structures as well. Double 
immunodetection of vimentin (red) and SMA (green) in mANCM cultured in 
serum free BMP10 enriched (left panel) and control (middle panel) medium. Right 
panel illustrates the same staining in cells grown in 10% FCS containing medium. 
All images represent the same magnification. Nuclei were stained with DAPI 
(blue).  
 
 
BMP10 effects on mANCM and bm-MASC1 cells 
Cell line Effects/Markers Control BMP10 
treated 
Remarks 
mBM-
MASC1 
 
Proliferation + upregulated  
Cord-like structures - induced  
Smooth muscle cell 
markers + ++ 
SMA expression is 
induced by serum 
deprivation and in 
confluent culture 
PDGFRβ - +  
Endothelial cell 
markers - + 
Co-localization of 
EC and SMC 
markers in BMP10 
treated, but not in 
control culture 
 
Vimentin - +  
mANCM  
Proliferation + upregulated  
Cord-like structures - induced 
In control culture 
not completely 
formed structures 
were observed 
Smooth muscle cell 
markers + +  
PDGFRβ Single 
cells + 
Expressed in cord-
like structures in 
BMP10 treated 
culture 
Endothelial cell 
markers + 
expressed in 
cord-like 
structures 
Expressed in 
morphologically 
distinct cells 
 
Vimentin + + 
BMP10 did not 
affect the expression 
levels of vimentin 
but its cellular 
organisation. 
Tab. 3.4. Summary of BMP10 effects on mANCM and bm-MASC1 cells. 
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Type I Receptors Cell line Effects of BMP10 
Present Absent 
COS1 Lack of induction of ALP activity 
Lack of cord-like structures ALK3 
ALK1 
ALK5 
ALK6 
293T Lack of ALP activity 
Lack of cord-like structures 
ALK3 
ALK5 
ALK6 
ALK1 
C2C12 Induction of ALP activity ALK1 
ALK3 
ALK5 
ALK6 
 
10T1/2 Lack of ALP activity 
Induction of tube-like structures 
formation 
ALK1 
ALK3 
ALK5 
ALK6 
 
mBM-MASC Lack of ALP activity 
Induction of tube-like structures 
formation 
ALK1 
ALK3 
ALK5 
ALK6 
 
mANCM Lack of ALP activity 
Induction of tube-like structures 
formation 
N.D* N.D* 
Tab. 3.5. Summary of BMP10 effects on various cell lines in comparison to expressed 
type I receptors. N.D.- not done because of heterogeneity of culture (*). 
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4. Discussion 
 
4.1. BMP10 expression and localization in healthy murine hearts 
 
 At the beginning of this project only the expression of BMP10 during mouse 
embryonic development was known. Whole mount in situ hybridization and northern 
blot results had also indicated that the expression of BMP10 was restricted to the right 
atrium in adult human tissues (Neuhaus et al., 1999). To investigate more closely the 
expression of BMP10 in adult murine tissues, this study started with the RT-PCR 
analysis of BMP10 expression. The results revealed that BMP10 expression is confined 
to the heart. Within the heart the BMP10 specific PCR product is present only in the 
right atrium confirming previously published expression patterns (Neuhaus et al., 1999). 
By in situ hybridization it was possible to detect BMP10 expression in the majority of 
atrial cells, both interstitial and atrial cardiomyocytes. Transcripts were also found in the 
trabeculated atrial wall of the right atrial appendage and the interatrial septum. 
However, the compact layer of the wall as well as the pericardium do not express 
BMP10. BMP10 transcripts are absent in both ventricular chambers and in the left 
atrium or the left atrial appendage.  
 BMP10 is a cytokine that belongs to the TGFβ family. The leader secretion 
sequence indicates that expression might, but not necessarily has to overlap with the 
localization of BMP10 after secretion. Partially overlapping expression and localization 
domains have been noticed in the case of BMP2 (Sugi et al., 2004). That was the reason 
to generate the antibody specifically recognizing the mature, processed form of BMP10, 
i.e. the active ligand interacting with receptors. After confirmation of the specificity of 
the BMP10 antibody by western blot, immunocyto- and immunohistochemistry, it was 
possible to examine BMP10 protein localization during embryonic development and in 
the adult mouse heart. By in situ hybridization BMP10 during embryogenesis was found 
to be expressed in the heart in the trabeculated, non-compacted myocardium only 
(Neuhaus et al., 1999). Immunodetection of BMP10 at E11.5 revealed that the extent of 
protein localization is significantly broader than the expression domains. Surprisingly, 
accumulation of BMP10 positive cells was found in the walls of the outflow tract. 
Moreover, the mature ligand of BMP10 was found not only in the trabecular layer of the 
developing heart, but also in the compact wall of the ventricles. In ventricular chambers 
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BMP10 localizes in a subpopulation of trabecular cells with a gradual decrease of 
staining intensity in the non-compacted myocardium, where BMP10 transcripts are not 
detectable. Cells that constitute a fine epicardial layer are positive for BMP10 as well. 
Double immunodetection of the myosin heavy chain (MHC), Nkx2.5 and BMP10 
revealed localization of the cytokine in cardiomyocytes, but additionally in interstitial 
cells surrounding muscles.  
Based on the expression and localization profile it seemed likely that BMP10 
might probably act both in an autocrine fashion and in a paracrine way. A 
cardiomyocyte restricted effect of BMP10 action was postulated by Chen (Chen et al., 
2004) but not investigated further since BMP10 deficient embryos die between E9.5 and 
E10.5. Mutant embryos displayed “cardiac dysgenesis with profound hypoplastic 
ventricular walls and absence of trabeculae” (Chen et al., 2004). Based on in situ 
hybridization experiments the authors found that BMP10 expression is restricted to 
muscles cells and postulated that the defective trabeculation and hypoplastic ventricular 
walls in mutants were caused by marked reduction of cardiomyocytes proliferation. It 
was suggested therefore that BMP10 provides a positive growth signal for 
cardiomyocytes. Although the authors recognized abnormal development of the 
endocardial cushion in both outflow tract (OFT) and atrioventricular canal (AVC), and 
found that this phenotype in BMP10 deficient hearts is rescued by BMP10 protein 
supplementation, they could not exclude that this effect was secondary to a severely 
impaired cardiac growth. Since immunodetection with the generated antibody proves 
that BMP10 localizes to the OFT, it is likely that OFT abnormalities in embryos lacking 
BMP10 represent direct effects of this growth factor deficiency. The authors however, 
did not characterize the nature of abnormalities in the OFT (Chen et al., 2004).  
Expression of BMP10 in the neonatal mouse was found to be restricted to the 
right atrium, with transcripts limited by the annulus fibrosus. In contrast to the 
embryonic heart the protein localization predominantly overlapped with in situ 
transcripts detected in infants. However, a vestigial amount of BMP10 protein was 
found in the right ventricle. In the right atrium, two distinct localization patterns of the 
mature ligand were observed. Some cells exhibit cytosolic accumulation of the protein, 
while other cells show BMP10 bound to the membrane.  
In the adult murine hearts BMP10 localizes predominantly to cells of the atrium 
resulting in a homogenous, cell-membrane localization pattern with marginal cytosolic 
staining. Detailed examination shows that additional structures in the heart are able to 
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bind or express BMP10. Immunohistochemistry showed binding of BMP10 by cells of 
the tricuspid valve. Careful in situ transcript detection analysis confirmed the results of 
protein immunodetection, and expression of BMP10 in some cells in the valve was 
found. Moreover, single cells adjacent to the big veins and arteries in the upper atrial 
area of the heart demonstrate BMP10 transcription. The detailed knowledge of BMP10 
expression and localization in the healthy murine heart was required to analyze 
pathological changes of BMP10 expression in different models of cardiomyopathies.  
 
 
4.2. Phenotypic differences and similarities of the mouse models of CMP 
 
One of the primary aims of the present work was the characterization of BMP10 
expression in various models of cardiomyopathies (CMP). In this study both genetic and 
drug induced models resembling dilated and hypertrophic cardiomyopathies were used. 
I took advantage of the accessible and well characterized Desmin knock-out (Milner et 
al., 1996; Thornell et al., 1997, Li et al., 1996) (generous gift from Prof. T. Braun). As 
the second genetic model, 10 months old heterozygous mice deficient in the manganese 
superoxide dismutase gene (MnSOD/SOD2), generated by Dr. T. Loch were used 
(laboratory collection). These models represent examples of desmin related 
cardiomyopathy (Gard et al., 2005; Sanbe et al., 2004; Olivé et al., 2004) and 
mitochondropathy, respectively (Finster, 2004; Russell et al., 2005). Induction of dilated 
cardiomyopathy by doxorubicin administration (Gille et al., 1997; Zhou et al., 2001; 
Childs et al., 2002; Green et al., 2002; Wallace, 2003) was also utilized. Treatment of 
mice with isoproterenol resulting in heart hypertrophy (Boluyt et al., 1995) served as a 
second drug induced model. A detailed pathological description of all models, including 
MRI analysis and characterization of the nature and degree of pathomorphological 
changes were a prerequisite of this study. Parameters for the histopathological analysis 
included the degree of fibrosis and cardiomyocyte hypertrophy, presence or absence of 
myofiber disarray and two types of cell death, namely apoptosis and necrosis. 
Additionally, the levels of ANF, BNP and FHL2 as indicators of heart disorder were 
monitored.  
Desmin deficient mice are the best characterized among the tested models 
(Milner et al., 1996; Milner et al., 1999) and on the basis of published data as well as 
own results exhibit the most severe degree of cardiomyopathy. The desmin protein is an 
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intermediate filament expressed in all types of muscles. The null mutation causes the 
most severe phenotype in cardiac muscles (Milner et al., 1996; Li et al., 1996; Thornell 
1997), which correlates with a higher content of this protein in the myocardium (2%) 
than in skeletal muscles (0.35%) (Price, 1984). Selective microvascular dysfunction was 
also observed in desmin null mice (Loufrani et al., 2001). Desmin mutations resulting in 
dilated cardiomyopathy have been described in humans and the term “desminopathies” 
has been proposed (Li et al, 1999).  
In this study, magnetic resonance analysis of Desmin knock-out mice revealed 
hypertrophy of the heart, confirmed by measurements of myocardial volume. In 
addition impairement of systolic function and chamber dilation was observed, as 
already reported by Milner (Milner, DJ et al., 1999). However, the authors claimed, that 
dilatation of the chambers was accompanied by thinning of the ventricular free walls, 
which is in contrast to our results. An obvious increase in thickness visible in MRI 
images was further confirmed by histological examination. Histological inspection 
revealed advanced calcification, which was visible at a first glance in most of the 
desmin deficient mice, however at different degrees dependent on the genetic 
background. An elevated heart weight to body weight index as compared to WT 
corroborates previously published results (Milner et al., 1999). The histopathological 
analysis confirmed most of the published data (Mavroidis et al., 2002; Milner et al., 
1996). Hearts of mice lacking desmin demonstrate numerous muscle architectural 
defects, with loss of alignment of myofibrils. Fibrous scar tissue develops throughout 
the myocardium and foci of abundantly accumulated collagen VI deposits were found. 
Cardiomyocytes are hypertrophied and the increase in myocyte size among all the tested 
models is the most pronounced in Desmin knock-out mice. Surprisingly, transgenic 
hearts did not contain significant number of apoptotic or necrotic cells as detected by 
TUNEL and Complement9 staining, respectively. Previous publications claimed that 
fibrosis and calcification found in desmin knock-out hearts were the result of high 
incidences of programmed cell death of myocytes (reviewed by Capetanaki, 2002; 
Weisleder et al., 2002) and necrosis (Li et al., 1996). However, this observation was not 
confirmed in the present study. One of the reasons might be that both groups examined 
young animals whereas in the present work older animals (6-8 months) were used, 
because we did not observe striking features of cardiomyopathy in younger knock-out 
mice. This was caused probably by the use of a different genetic background. Moreover, 
the expression level of the marker of cardiac disorders- ANF is significantly upregulated 
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with accumulation in apex, septum and ventricular free wall. ANF is a peptide hormone 
with diuretic, natriuretic and vasorelaxant properties (Rosenzweig et al., 1991; de Bold 
et al., 1996) and its ventricular expression is often correlated with an increase in 
ventricular mass in pathological hearts (Calderone et al., 1995; Matsubara et al., 1990). 
ANF was also shown to be specifically expressed in the regions of hearts with the 
highest degree of tissue pathology (Vikstrom et al., 1998).  
Superoxide dismutase (SOD) catalyzes the dismutation reaction of superoxide 
anion to hydrogen peroxide (Halliwell et al., 1995). Three different SODs are known in 
mammals: cytosolic copper/zinc SOD (Cu/ZnSOD or SOD1), mitochondrial manganese 
SOD (MnSOD or SOD2) and extracellular copper/zinc SOD (EC-SOD or SOD3) (van 
Remmen et al., 2001; reviewed by Bartosz, 2003). Among these three homologues only 
MnSOD exhibits a modulated expression induced by a variety of physiological factors 
suggesting that SOD2 plays a role in other processes than the antioxidant defense 
system (Li et al., 1995; Sato et al., 1995; Nogae et al., 1995).  
Not many data are available concerning cardiomyopathy caused by manganese 
superoxide dismutase deficiency. Two independent groups generated mutant strains 
lacking MnSOD (Li et al., 1995; Lebovitz et al., 1996; Huang et al., 2001). Both 
observed neonatal lethality, although at different time points, dependent on the genetic 
background. In both mutant strains dilated cardiomyopathy was a common finding. 
Neonatal MnSOD homozygous generated in our laboratory by Dr. T. Loch exhibit 
DCM manifested by ventricular cavity enlargement and free wall thinning (data 
provided by Dr. T. Loch, personal communication). Upregulation of ANF expression in 
3 days old neonatal SOD2-/-, but not in heterozygous further confirmed pathological 
changes of the heart.  
Several reports describe the cardiac phenotype in MnSOD deficient homozygous 
mice, but apart for some biochemical reports, not many data are available concerning 
old heterozygous MnSOD mice. An average reduction of enzyme activity in 
heterozygous MnSOD mutants was estimated at the level of 50% (Li et al., 1995), 
whereas the strain generated in our laboratory exhibits only 30% of MnSOD activity 
reduction in the heart (Dr. T. Loch, personal communication). This decrease in the level 
of the enzyme influences the physiological function of the heart as shown in 6 months 
old MnSOD+/- mutants characterized by impaired systolic function and reduced ejection 
fraction (unpublished data, kindly provided by Dr. T. Loch, personal communication). It 
has been assumed that pathological changes will proceed with the age of the animals. 
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During this study a detailed histopathological analysis of 10 months old heterozygous 
MnSOD mice heart was performed. A moderate increase of the degree of fibrosis and 
slight cardiomyocyte hypertrophy was observed in mutants compared to age and strain 
matched controls. A disarrangement of the myocardial architecture, typical for desmin 
knock-outs was not present in MnSOD+/- mice. In heterozygotic MnSOD, only necrotic 
but not apoptotic cells are detected in the myocardium. It has been reported that isolated 
cardiomyocytes from knock-out mice heterozygous for MnSOD are more sensitive to 
apoptosis than heart muscle cells from WT, or untreated MnSOD+/- myocytes (Van 
Remmen et al., 2001). Moreover, another group found induction of the apoptotic 
pathway in vivo, as detected by enhanced staining of the poly(ADP-ribose)polymerase 
(PARP) and activated caspase-3 in heterodeficient SOD2 mice, as soon as 6 to 10 days 
after birth (Strassburger et al., 2005). Both methods are based on detection of cleaved 
forms of PARP (24kDa and 89kDa) and activated caspase-3 (17kDa) and are reliable 
when used in Western Blot (reviewed by Rodriguez et al., 2005). In this study, the 
TUNEL method indicating DNA fragmentation was used for detection of apoptotic cells 
but in contrast to published reports, programmed cell death was not observed in 
MnSOD heterodeficient mice.  
Doxorubicin (adriamycin), an anthracycline, is a potent anti-cancer drug and has 
a wide spectrum of activity (Blum et al., 1974). Doxorubicin has a very high affinity to 
the nucleus (60% of the total intracellular amount of the drug was found in the nucleus) 
and was recognized as a potent DNA modifier inhibiting DNA polymerase and nucleic 
acid synthesis. In addition, anthracyclines are known to stabilize the complex of 
topoisomerase and DNA which leads to protein bound double strand DNA breaks 
(reviewed by DeBeer et al., 2001). In this respect, the primary effect of the adriamycin 
anti-tumor action is the inhibition of proliferation and induction of apoptosis. However, 
the therapeutical potential of doxorubicin is limited by the development of dose-
dependent cardiomyopathy (Unverferth et al., 1982). Both, acute and chronic 
cardiovascular changes have been described in patients undergoing adriamycin 
chemotherapy (reviewed by De Beer et al., 2001). Acute side-effects are usually 
transient and clinically manageable, but chronic effects may develop several weeks or 
even months after repetitive doxorubicin administration in humans. In the 1970s and the 
beginning of the 80s, when doxorubicin was commonly used as a chemotherapeutic 
agent, the mortality rate, due to developed congestive heart failure, has been described 
to vary from 30%-60% (Haq et al., 1985). Signs indicating a cardiotoxic effect include 
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hypotension, tachycardia, cardiac dilation and ventricular failure (Singal et al., 1987; De 
Beer et al., 2001). Several mechanisms leading to adriamycin induced cardiotoxic 
effects have been proposed. These include the free radical hypothesis, Ca2+ overload, 
doxorubicin metabolite- doxorubicinol toxicity, as well direct interactions with the 
contractile system and some other cardiac-restricted targets (Jeyaseelan et al., 1997; 
Lewis et al., 1986; De Beer et al., 2001).  
In the present study, doxorubicin was administrated to 6-8 weeks old ICR mice 
for 14 days. The empirically established dosage (15µg/g of body weight) did not cause 
premature lethality and MRI analysis indicated a moderate degree of heart failure. An 
increase of adriamycin concentration results in a high mortality rate during the drug 
administration period, making further examination impossible. However, even when the 
pathological changes or cardiac dysfunction caused by doxorubicin are not obvious, the 
results revealed significant changes of BMP10 expression in treated hearts. Therefore 
the same drug dosage, time etc, was applied for the experimental groups.  
On the basis of MRI analysis a moderate decrease of ejection fraction in 
comparison to the placebo group was found, and the myocardial volume was slightly, 
but significantly reduced in doxorubicin treated mice. These MRI parameters indicate 
modest chamber dilation. Cardiomyocyte hypertrophy is absent but the “beginning” of 
myofiber disarrangement is clearly visible. Upon doxorubicin administration an 
increase of collagen deposition in the extracellular space resulting in replacement 
fibrosis is evident. Two distinct types of cardiomyocyte death were detected in 
doxorubicine induced cardiomyopathy: necrosis commonly induced by toxic agents and 
apoptosis because doxorubicin exhibits a pro-apoptotic function (De Beer et al., 2001).  
Many studies indicate that dystrophin cleavage is a common pathway to 
advanced heart failure and some link dystrophin loss with cardiomyocyte death 
(Kawada et al., 2005; Kaprielian et al., 2000). Interestingly, cells lacking this membrane 
associated protein are found only in doxorubicin treated mice hearts, but not in other 
models.   
Cardiomyopathies caused by homozygous and heterozygous SOD2 deficiency or 
induced by doxorubicin are considered as mitochondria-related CMPs and the term 
mitochondropathies was proposed by several authors (Finster, 2004; Russell et al., 
2005). Adriamycin was shown to induce activity of MnSOD (Childs et al., 2001) and 
vice versa, MnSOD overexpression modifies early oxidative events of doxorubicin’s 
acute side effects in the heart (Chaiswing et al., 2005). Despite these physiological 
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correlations and independent of the elevated levels of reactive oxygen species which 
lead to heart dysfunction in both models a distinct pathological changes were found in 
both groups. 
Cardiac hypertrophy is observed in various cardiovascular diseases, including 
hypertension, myocardial infarction and cardiomyopathy. In end-stage human heart 
failure elevated levels of plasma catecholamines have been found (Daly et al., 1990) 
and it has been suggested that prolonged β-adrenergic stimulation plays a role not only 
in modulation of cardiac function but also in the development of the hypertrophic 
response (Mueller et al., 1995; Zou et al., 2001). This hypothesis was supported by the 
finding that β-blocker treatment is able to restore cardiac function (Motomura et al., 
1990). Moreover, continuous infusion of a synthetic catecholamine in rats, namely 
isoproterenol (ISO), acting as β-adrenergic receptor agonist, elicits typical hypertrophy 
associated cardiac gene expression (Boluyt et al., 1995; Morisco et al., 2001). For this 
reason, isoproterenol induced hypertrophic cardiomyopathy was included in the study. 
Like doxorubicin, isoproterenol (225µg/g of body weight) was administrated to 6-8 
weeks old ICR mice for 14 days, followed by NMR examination. The applied dosage of 
ISO induced severe heart hypertrophy with impaired systolic function, as clearly visible 
from the end-systolic MRI image at the level of the papillary muscles. This observation, 
together with a significant decrease of ejection fraction, indicates ventricular chamber 
dilation. The elevated myocardial volume, as well the significantly increased heart to 
body weight ratio in comparison to placebo treated controls further confirm the 
diagnosis of cardiac hypertrophy. Histological analysis revealed cardiomyocyte 
enlargement. Modest fibrosis, characterized by collagen accumulation, similar in its 
extent to that observed in doxorubicin induced cardiomyopathy is present as a result of 
isoproterenol administration. Moreover, both types of myocyte death (apoptosis and 
necrosis) were found in the myocardium of this model. However, β-adrenergic 
stimulation does not cause other pathological changes, e.g. myofiber disarray and 
dystrophin disruption. These results are consistent with previously published findings 
(Stanton et al., 1969; Shizukuda et al., 1998). 
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4.3. BMP10 as a novel marker of pathological changes in the heart 
 
In all models tested two types of changes of the localization and expression of 
BMP10 were noted. First, a drastic redistribution of BMP10 correlating with 
quantitative changes of the protein in the right atrium was observed. Second, ventricular 
cells ectopically expressing the BMP10 protein were detected. For example, in Desmin 
knock-outs an ectopic BMP10 expression was found in both right and left ventricle, 
with a higher number of stained cells in the left chamber. In situ immunodetection of 
BMP10 protein further confirmed this observation. Surprisingly, BMP10 positive cells 
mostly localize in the proximity of cardiac vessels and their incorporation in the 
coronary vasculature was also noted. Similar results were obtained in doxorubicin and 
isoproterenol treated hearts as well as in MnSOD heterozygous mice. Moreover, stained 
cells often form clusters, although isolated single cells were also detected in 
doxorubicin treated mice. In cardiomyopathy induced by isopreterenol administration, 
ventricular BMP10 positive cells are not located in tightly packed clusters but still close 
to each other.  
High levels of ectopic BMP10 expression in ventricular myocardium were also 
found in ventricular cardiomyocytes restricted Nkx2.5 knock-out (Pashmforoush et al., 
2004). Inactivation of Nkx2.5 by Cre-recombinase under the control of a myosin light 
chain-2V (MLC2V) promoter, thus preserving transcription factor expression in atrial 
myocytes, leads to marked cardiac enlargement with trabeculae filling the left 
ventricular cavity in both neonatal and adult mutants, due to the persistence of 
trabecular cardiomyocyte proliferation after birth. A similar phenotype was observed in 
human patients with Nkx2.5 mutation. Myocardial overgrowth was also found in 
embryos of transgenic strains overexpressing BMP10 controlled by an ANF promoter 
(Pashmforoush et al., 2004). These data indicate that BMP10 might stimulate 
cardiomyocyte proliferation. However, it indicates two distinct pathways of ectopic 
induction of BMP10 expression, i.e. Nkx2.5 dependent and independent pathways. 
While the former might be restricted to cardiomyocytes and direct negative looping 
BMP10-Nkx2.5 was proposed by the authors (Pashmforoush et al., 2004), there seems 
to be another pathway of BMP10 induction by pathological stimuli which is restricted to 
non-cardiomyocytes. On the other hand the upregulation and ectopic expression of 
BMP10 in Nkx2.5 knock-out mice might also occur by an indirect pathway. The 
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absence of Nkx2.5 might trigger pathological changes that stimulate BMP10 
expression. 
Besides the ectopic ventricular expression of BMP10, deregulation of gene 
expression in the right atrium is observed in all models, as described in chapter 3.5. 
Since these changes are very strong, it is highly probable, that changes in expression of 
atrial BMP10 levels result in overall quantitative deregulation of gene expression in 
pathological murine hearts. These data are summarized in Table 4.1. 
 
 
Summary of BMP10 expression and localization changes 
Qualitative changes  
Ventricles Right Atrium 
Quantitative 
changes 
WT Absent Homogenous 
Membrane location 
- 
Desmin knock-out Clusters of BMP10pos. 
cells 
Membrane location 
Cytosolic accumulation 
Upregulated 
 
SOD heterozygous 
 
Clusters of BMP10pos. 
cells 
Heterogeneous pattern: 
1.Lack of BMP10 
2. Membrane location 
3. Cytosolic accumulation 
 
Downregulated 
Doxorubicin Single BMP10pos. cells Cytosolic accumulation 
Loss of membrane location 
Upregulated 
 
Isoproterenol 
 
Single BMP10pos. cells 
Closely located to each 
other 
Two types of changes: 
1.Homogenous downregulation 
2. Heterogeneous pattern, as in 
SOD+/- 
 
Downregulated 
Nkx2.5 knock-out 
(Pashmforoush et 
al., 2004) 
Expressed in trabeculae 
of adult myocardium 
(in situ hybridization 
data) 
 Upregulated 
Tab. 4.1. Characterization of qualitative and quantitative BMP10 expression 
changes in models of cardiomyopathy of adult mouse. An exact description of the 
observed changes is included in chapter 3.5. 
 
Qualitative and quantitative changes of BMP10 expression in the right atrium 
and ectopic expression of BMP10 in ventricles in models of cardiomyopathies are 
evident. It should also be mentioned that the number of ventricular cells, which 
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ectopically express BMP10 varies significantly between the different models. Desmin 
knock-out displays the most severe pathological phenotype and the number of 
ventricular BMP10 positive cells is the highest among all adult models examined. A 
lower number of cells ectopically expressing BMP10 are present in MnSOD+/-, while 
both drug induced models of cardiomyopathy exhibit the lowest numbers of ventricular 
BMP10pos. cells. Since the number of cells ectopically expressing BMP10 in ventricles 
is low, the general quantitative changes of BMP10 in pathological hearts most probably 
reflect a deregulation of BMP10 in the right atrium. 
 
 
4.4. BMP10 positive cells constitute a subpopulation of cardiac progenitors 
 
Characterization of ventricular cells expressing BMP10 was carried out using a 
double immunolabeling method. Since BMP10 was found in ventricular cells of failing, 
but not of healthy hearts, I became interested in the origin of these cells. It has been 
reported that progenitor cells reside in the heart and that they can be characterized by 
stem cell antigen 1 (Sca1) expression (Oh et al., 2003; Matsuura et al., 2004). 
Moreover, Sca1 positive cells in skeletal muscle were described as small interstitial 
cells adjacent to the basal lamina, typically co-expressing PECAM (CD31) and 
localized in proximity of endothelial cells i.e. Sca1neg./CD31pos. (Oh et al., 2003). In the 
heart Sca1pos. cells were further subdivided into two groups: CD31pos. and CD31neg. the 
latter exhibiting a distinct differentiation potential (Pfister et al., 2005). It was proposed 
that CD31neg. but not CD31pos. cells can differentiate into cardiomyocytes. While 
Sca1pos./CD31neg. express cardiomyocyte specific transcription factors, Sca1pos./CD31pos. 
exhibit both endothelial (based on Tie2 expression) and smooth muscle (as judged by 
SM-actin expression) phenotypes (Pfister et al., 2005). Moreover, circulating Sca1pos. 
cells are also considered by some authors as endothelial progenitor cells (EPCs) and 
were shown to incorporate into vascular sprouts and capillaries in vivo (Takahashi et al., 
1999). Hence, in this study a Sca1-GFP transgenic mouse strain was used and 
cardiomyopathy was induced with doxorubicin and isoproterenol leading to induction of 
ectopic BMP10 expression. Results of characterization of ventricular BMP10 positive 
cells are summarized in table 4.2. 
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Characterization of BMP10 positive cells 
Cell type/ Process Marker Characteristic- cellular 
labeling 
Endothelial Cells PECAM (CD31) BMP10pos./CD31pos. 
BMP10neg./CD31pos. 
BMP10pos./CD31neg. 
Smooth Muscle Cells Smooth Muscle Actin (SMA) BMP10pos./SMApos. 
BMP10neg./SMApos. 
BMP10pos./SMAneg. 
Cardiomyocytes Myosin Heavy Chain (MF20) 
Nkx2.5 
BMP10 pos./MF20 neg. 
BMP10 pos./Nkx2.5 neg. 
Atrium and embryonic heart 
BMP10pos./MF20neg. 
BMP10pos./Nkx2.5pos. 
BMP10pos./MF20neg. 
BMP10pos./Nkx2.5pos. 
Proliferation  Phospho-Histone H3 (pH3) 
 
Aurora B 
BMP10pos./pH3pos. 
BMP10neg./pH3pos. 
BMP10pos./Aurora Bpos. 
BMP10neg./Aurora Bpos. 
Sca1 progenitors Reporter gene expression (GFP) BMP10neg./Sca1pos. 
BMP10pos./Sca1pos. 
BMP10pos./Sca1neg. 
Tab. 4.2. Characterization of cells ectopically expressing BMP10 in ventricles of 
diseased hearts.  
 
The only persistent and common feature of all BMP10pos. cells in ventricular 
chambers was co-expression of proliferation markers (Aurora B and phophorylated 
histone H3) and lack of cardiomyocyte specific gene expression. Ventricular cells 
ectopically expressing BMP10 in failing hearts exhibit both smooth muscle and 
endothelial marker expression. Moreover, co-expression of Sca1 antigen in most of the 
BMP10 positive cells was observed with a correlation of the gradient increase/decrease 
of BMP10/Sca1 signal intensity, respectively. These results might indicate that BMP10 
induced proliferation of Sca1pos./CD31pos. followed by their differentiation. Similar to 
skeletal muscle (Oh et al., 2003), CD31pos., i.e. endothelial  cells incorporated in the 
vessels did not express Sca1 antigen and circulating EPCs which originally expressed 
Sca1 adopted the endothelial phenotype upon incorporation (Takahashi et al., 1999). 
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Thus, from this observation it is evident that cells expressing BMP10 constitute a 
subpopulation of cardiac progenitor cells that contribute to remodeling process in the 
heart. 
 
 
4.5. Pro-mitotic function of BMP10 
 
 Published data clearly indicate that BMP10 stimulates of cardiomyocytes during 
embryogenesis (Chen et al., 2004). In the adult pathological heart a re-expression of 
BMP10 was found in ventricles and seemed to be restricted to muscle cells 
(Pashmforoush et al., 2004). My own results which were obtained using a specific 
antibody against BMP10 clearly exclude that BMP10 is re-expressed in ventricular 
cardiomyocytes in adult hearts. It seems most likely that the poor resolution of the in 
situ hybridization technique used by Pashmforoush led to an incorrect identification of 
BMP10 expressing cells. Furthermore it seems likely that the function of BMP10 can 
differs between adult and embryonic heart as well in case of cardiomyocytes and 
interstitial cells. Recently, overexpression of BMP10 in postnatal myocardium was 
shown to disrupt hypertrophic growth of cardiomyocytes and to induce proliferation of 
non-muscle cells (Chen et al., 2006). Transgenic mice have smaller hearts due to 
smaller cardiomyocyte size, resembling the atrial phenotype, whereas the number of 
myocytes in the heart remains constant. The authors found an increase in ejection 
fraction in mutants (Chen et al., 2006) which supports the hypothesis that inhibition of 
hypertrophic response has a beneficial effect on heart function (Jeong et al., 2006).  
Chen and colleagues used the embryonic heart culture system to prove that 
BMP10 addition can completely rescue the phenotype of hearts isolated from embryos 
with BMP10 null mutation (Chen et al., 2004). BMP10 enriched medium was able to 
restore proliferation in knock-out hearts in vitro. In the present study a BMP10 
conditioned medium was used to investigate the effect of BMP10 on non-muscle cells. 
One could argue that conditioned medium contains also factors secreted by transfected 
cells and the achieved effect results from the action of these growth factors. Hence, to 
monitor the function of BMP10, 10T1/2 cells were directly transfected with a BMP10-
IRES-GFP expression construct.  
The main objective which was addressed using biologically active BMP10 was 
whether ectopic expression of BMP10 in failing heart affected the survival of 
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cardiomyocytes and/or stimulated the proliferation and differentiation of non-
cardiomyocytes in the heart. Basically it is believed that members of the TGFβ/activin 
family exhibit a “destructive” function in pathological hearts (reviewed by Euler-
Taimor et al., 2006). Enhanced expression of these factors is generally related with 
ventricular hypertrophy (Ikeuchi et al., 2004), interstitial fibrosis (Hao et al., 2000; 
Wang et al., 2002) and induction of apoptosis (Francis et al., 2000; Chipuk et al., 2001). 
Even though BMPs belong to the TGFβ superfamily they exert beneficial effects on the 
heart, primarily during heart development (Mozen et al., 2001; Chen et al., 2004). They 
also inhibit apoptosis in adult cardiomyocytes (Izumi et al., 2001). Based on the 
localization of BMP10pos. cells in cardiomyopathic hearts and their phenotype as judged 
by double immunolabeling, the effects of BMP10 was analyzed using various non-
muscle cells such 10T1/2 fibroblasts and adult bone marrow pluripotent mesenchymal 
stem cells (bm-MASCs) (Belema Bedada et al., 2005). Moreover, primary cultures of a 
heterogeneous population of non-cardiomyocytes isolated from adult mouse heart were 
used to study the BMP10 effect on potential target cells.  
10T1/2 cells are known to differentiate into pericytes/vascular smooth muscle 
cells (vSMCs) in response to TGFβ1 (Karen et al., 1998; Darlan et al., 2001; Kale et al., 
2004; Kurzen et al., 2001). In vitro studies using different cell lines of various origins 
and cells isolated from the heart confirmed that the effect of BMP10 is not limited to 
cardiomyocytes. As described in chapter 3.7.3 a strong induction of proliferation was 
observed. Another proof of the pro-mitotic effects of BMP10 was the finding that 
BMP10 expression in mANCM primary cultures correlated with the proliferation of 
certain subpopulation of cells exhibiting great colony forming activity. The ability of 
non-cardiomyocyte cells to give rise to distinct cell populations was described by three 
independent groups. In particular it was demonstrated that Sca1 progenitors of cardiac 
origin which also expressed the CD31 molecule are present in a large number in the 
heart and exhibit great colony forming activity (Oh et al., 2003; Matsuura et al., 2004; 
Pfister et al., 2005). However, the authors ignored the highly proliferative subpopulation 
and concentrated on examination of the differentiation potential of Sca1pos. into 
cardiomyocytes (Oh et al., 2003; Matsuura et al., 2004) or more specifically 
Sca1pos./CD31neg. cells (Pfister et al., 2005). Pro-mitotic function of BMP10 was 
expected and easy to predict as BMP10 during heart development has been also 
implicated in proliferation of cells forming trabeculae (Chen et al., 2004) and BMP10 
overexpression leads to trabecular overgrowth (Pashmforoush et al., 2004). Moreover, 
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ventricular BMP10pos. cells co-express proliferation markers. Cell culture experiments 
showed that BMP10 induces proliferation in all tested cell lines and as mANCMs were 
used, this effect can be also achieved in adult cardiomyopathic hearts further confirming 
observations in heart failure models.  
 
 
4.6. BMP10 is a potent regulator of vasculogenesis/angiogenesis 
 
Besides the increased proliferation rate, addition of BMP10 did also stimulate 
cell differentiation, recruitment and development of three dimensional structures as 
shown below.  
While the proliferative function of BMP10 was expected, the of induction of 
cord/tube-like structure formation by this cardiac restricted cytokine was suprising. 
Even TGFβ1, a known potent factor inducing 10T1/2 fibroblast differentiation to 
pericytes/vSMCs was not able to induce the formation of a 3D structure (Karen et al., 
1998; Kurzen et al., 2004). This effect was achieved only in co-culture systems of 
endothelial cells (ECs) with smooth muscle like 10T1/2 cells using Matrigel™ as a 
frame (Darland et al., 2001). In the present study vessel-like structures expressing both 
endothelial and smooth muscle markers were obtained using BMP10 alone without gel 
support. The same effect was obtained when 10T1/2 cells were directly transfected with 
a BMP10-IRES-GFP expression construct (see chapter 3.7.6.1). BMP10 transfected 
cells exhibit higher rate of proliferation than control, i.e. pEGFP transfected cells. 
BMP10 expressing 10T1/2 cells were also able to recruit each other and neighboring 
cells to form cord-like structures. Furthermore a new subpopulation of small cells (GFP 
positive i.e expressing BMP10) appeared in the culture similar to the conditioned 
medium. 
In MASCs and 10T1/2 cells treated with BMP10 co-localization of SMC and EC 
markers were observed, as described in chapters 3.7.5 and 3.7.6 respectively, for both 
cell lines. In isolated Sca1pos. cells a co-localization of SMC and EC markers was also 
noted (Pfister et al., 2005), similar to the models of CMP where BMP10pos./Sca1pos., 
BMP10pos./CD31pos., BMP10pos./SMApos. cells were found in ventricles. Therefore it is 
likely that cells with this phenotype and differentiation potential reside in the heart and 
might contribute to reverse remodeling processes. This is further supported by the 
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results obtained with mANCM cells that are also able to develop 3D cord-like structures 
in response to BMP10.  
 
      
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.1. Confocal image illustrating the 3-dimensional structure created by 
differentiated 10T1/2 cells as a result of transfection with BMP10 expression 
construct (green). Cells were counterstained with phalloidin-TRITC (red). GFP 
marks transfected cells. Nuclei were visualized with DAPI (blue).   
 
 
4.7. Distinct functions of BMP10- interaction with different receptors 
 
BMP10 exerts it function via interaction with specific receptors. It was not a 
main aim of this study to analyze interactions of BMP10 with specific receptor. 
However it was possible postulate putative BMP10-Receptor interactions based on 
BMP10 expression, localization in combination with published data and the expression 
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profile of the BMPs receptors in different cell lines. Moreover, in the case of proteins 
that are secreted and act via receptors it is not possible to consider the functional 
implication separately from the receptor. It is generally assumed that BMPs can interact 
with three different type I receptors, i.e. ALK2, ALK3, ALK6. ALK-6 is absent in the 
developing heart from midgestation on (Dewulf et al., 1995). In the healthy murine 
heart ALK3 is abundantly expressed in the right atrium with lower expression levels in 
the ventricles and the left atrium, whereas ALK1 is almost absent in regions where 
BMP10 is normally expressed. As ALK6 is not expressed in the adult heart one could 
expect BMP10 to act via the ALK3 receptor. Interaction of BMP10 with this receptor 
was shown by another group (Mazerbourg et al., 2005). The same report indicates the 
possibility of BMP10 binding to ALK6. However, ALK1 was excluded from the study, 
due to the high background activation of the reporter gene. Strong activation of the BRE 
promoter by BMP10 upon binding to ALK1 was ignired by the authors due to the 
background activation (Mazerbourg et al., 2005). Moreover, BMP10 signaling through 
the ALK3 receptor has been proposed to have an anti-hypertrophic action on 
cardiomyocytes, as judged by the expression level of the ALK3 receptor in the heart 
(Chen et al., 2006). My own results show that ALK3 expression in the heart is highest 
in the right atrium, which overlaps with BMP10 expression while the level of ALK1, 
which is very low in the right atrium. Since atrial cardiomyocytes are smaller than 
ventricular cells, the anti-hypertrophic function of BMP10 (Chen et al., 2006) is 
probably achieved by signaling through ALK3. However, even if BMP10 in the right 
atrium or in a transgenic strain (Chen et al., 2006) acts via the ALK3 receptor, it might 
interact with a different receptor in ventricular cells where it is ectopically expressed 
upon pathological stimuli. This possibility is supported by the absence of ALK3 
expression in Sca1pos. heart resident cells (Oh et al., 2003). Additionally, the disruption 
of ALK3 expression in Sca1pos. cells followed by their differentiation revealed an 
unchanged induction of Nkx2.5 expression while induction of other cardiomyocyte 
specific markers, i.e. MEF2C and MHC, were severely impaired (Oh et al., 2003). In 
the proposed negative regulatory loop which employs BMP10-Nkx2.5 (Pashmforoush 
et al., 2004) a cardiac myocyte specific ALK3 deletion had very little effect on 
trabeculation and did not cause an alteration of Nkx2.5 expression (Gaussin et al., 2002; 
Chen et al., 2004). Hence, it is not clear whether BMP10 signaling through the ALK3 
receptor during embryogenic induces myocytes proliferation and differentiation. 
Interestingly, in ALK3 mutant embryos, BMP10 expression in the trabeculae was 
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unchanged, but BMP10 expression was induced in embryonic atria much earlier than in 
wild type (Gaussin et al., 2002), indicating that BMP10 may be downstream of ALK3 in 
atrial myocytes. 
The expression profile of type I receptors in cell lines used in cell culture 
experiments revealed that proliferative and angiogenic effects of BMP10 was observed 
in cells expressing ALK1, ALK3 and ALK5. Cos1 cells have been described as the least 
responsive to BMP10 (Mazerbourg et al., 2005) and express neither ALK1 nor ALK5. 
Overexpression of BMP10 in 293T cells did not cause an effect as in 10T1/2 or 
MASCs. Since the only missing receptor in the 293T cell line is ALK1, it is possible 
that BMP10 binding to ALK1 promotes the angiogenic signaling pathway, however 
further experiments are necessary to support this hypothesis.   
The BMP10 antibody which was generated in the course of the project allowed 
detection of the secreted protein. In mouse embryos, the mature ligand was found in the 
outflow tract in addition to the developing heart chambers. Moreover, BMP10 was 
shown to induce both endothelial and smooth muscle cell phenotypes in vitro followed 
by 3D tube-like structures formation. Cells expressing BMP10 and SMC and/or EC 
markers were also found in various models of cardiomyopathies. TGFβ signaling is 
known to play an important role during vascular remodeling (Oh et al., 2000; Goumans 
et al., 2002) and two type I receptors are implicated in these processes, namely ALK1 
and ALK5. As already mentioned expression levels of ALK1 in right atrium is 
extremely low. So it is unlikely that BMP10 acts via this receptor in the right atrium of 
the healthy heart. However, ALK1 is believed to modulate TGFβ1 signaling during 
angiogenesis (Oh et al., 2000, Seki et al., 2003) and it is specifically expressed in the 
arterial endothelium during embryogenesis with a significant decrease in adult blood 
vessels (Seki et al., 2003). ALK5 was also shown to transmit TGFβ1 signals and its 
expression is restricted to the vascular smooth muscles of vessels (Seki et al., 2006). 
Interestingly, ALK5 expression in the developing heart is confined to trabecular 
muscles, and is not found in the compact wall. Additionally, some mesenchymal cells 
surrounding the aorta expressed ALK5. In the adult heart, expression was found in the 
pulmonary artery valve and some ventricular, but not endothelial cells (Seki et al., 
2006). Surprisingly, null mutation of ALK1 leads to defective differentiation and 
recruitment of smooth muscle cells, while disruption of the ALK5 gene to impaired 
endothelial cells migration and proliferation (Oh et al., 2000; Urness et al., 2000; 
Larsson et al., 2001; Goumans et al., 2003). These data suggest that there is a link 
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between ECs and SMCs dependent on the ALK1/ALK5 pathway. This role was 
assigned to platelet derived growth factor BB (PDGF-BB) released by ECs during the 
resolution phase of angiogenesis. This potent chemoattractant is bound by 
vSMCs/pericytes expressing the PDGFβ receptor (Hellstrom et al., 1999). Additionally, 
PDGF induces TGFβ expression in vSMCs/pericytes (Nishishita et al., 2003). BMP10 
induces expression of EC, vSMC/pericyte markers in vitro, and in vivo BMP10 is 
expressed in Sca1 progenitors which are also known to express these genes (Pfister et 
al., 2005). It is likely that ectopic BMP10 expression induces differentiation of common 
endothelial and smooth muscle progenitors from Sca1pos. resident cells, thus inducing 
angiogenic events in a tissue specific manner. The simultaneous expression of EC, 
vSMC and pericyte markers is already known and was described in vivo (DeRuiter et 
al., 1997). It can be induced in vitro by TGFβ in epicardial explants, in an ALK5 
dependent pathway (Compton et al., 2005). As already mentioned, BMPs are known to 
bind to ALK2, -3 and -6, however, the closest homolog of BMP10, i.e. BMP9 (GDF2) 
has been shown to interact with ALK1 in combination with BMPR II (Brown et al., 
2005). This finding further supports the possible BMP10 action via ALK1 receptor, 
which is known to play a role during angiogenesis. A postulated mechanism is 
presented below (Fig. 4.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.2. Schematic representation of distinct BMP10 functions dependent on the 
interaction with specific receptor. 
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4.8. Functional implications of BMP10 expression in diseased hearts 
 
The purpose of this study was to clarify the possible role of BMP10 in cardiac 
diseases. I investigated, therefore, cardiac tissue from different models of 
cardiomyopathic mice. Data on BMP10 in myocardium is scarce even though BMP10 is 
the only cardiac restricted member of the BMP protein family. Much information can be 
found on the role of BMPs in bone development, pathology and regeneration. In the 
past decade the role of BMPs expressed in heart on the cardiac development was also 
intensively studied. This information, discussed extensively in the Introduction, formed 
the basis of my present work.  
BMPs are known to play an important role during bone repair (Lee et al., 2006). 
The effects include induction of proliferation, migration and differentiation of 
mesenchymal progenitor as well as vascular invasion (Redi, 1997; Okubo et al., 2002; 
Lind et al., 1996; Bostrom et al., 1995). Similar functions were uncovered for BMP10 in 
functional studies which I performed using various cells culture models. The most 
important observation in this context was the induction of morphogenetic events leading 
to the formation of vessel-like, tubular structures.  
The unusual variety of ventricular cells expressing BMP10, the induction of EC, 
vSMC markers and tube formation by BMP10 in vitro allowed to draw the following 
conclusions and to formulate a hypothesis: 
1. As a result of pathological stimuli a new subpopulation of proliferating 
cells appears in the ventricles of the adult heart, which is characterized 
by ectopic BMP10 expression (BMP10pos. cells).  
2. BMP10 is a sensitive marker of heart dysfunction and drastic 
expression changes and redistribution of protein can be found even 
when the pathological phenotype is modest.     
3. A possible function in vasculogenesis or angiogenesis of ventricular 
BMP10pos. cells might be deduced based on their localization and 
characterization. BMP10 can induce proliferation in resident cardiac 
progenitors followed by differentiation into ECs and/or vSMCs. These 
results were further confirmed in vitro using different cell lines.  
4. BMP10 exhibits various functions dependent on the target cells. The 
physiological effect of BMP10 probably differs between the 
embryonic heart and the adult right atrium in the healthy adult heart. 
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Different functions might be assumed for embryonic and atrial 
cardiomyocytes as well as for interstitial cells. It can be hypothesized 
that this effect is achieved by differentially expressed BMP10 
receptors.  
5. The function of BMP10 in the pathological heart is distinct from that 
of the healthy organ. 
6. Ventricular BMP10 positive cells originate from Sca1pos. cells and 
BMP10 signaling can modulate proliferation followed by 
differentiation of Sca1 cardiac progenitors in the failing heart. Cell 
culture experiments together with published data confirm this 
possibility. 
Taken together, these findings allow the conclusion that BMP10 in diseased 
hearts plays a significant role in cardiac remodeling.  
Cardiac remodeling is a determinant of the clinical course of heart disorders. It 
implies that cardiac structure and function slowly deteriorate in response to pathological 
stimuli acting on the heart such as hypertension, pressure or volume overload or genetic 
factors such as in primary or secondary cardiomyopathies. Often, the term “adverse” 
remodeling is used to indicate an aggravation of structure and function until heart 
failure occurs. The most widely used definition of remodeling was given by Cohn in 
2000: 
Cardiac remodeling is defined as gene expression resulting in molecular, cellular 
and interstitial changes and manifested clinically as changes in size, shape and 
function of the heart (Cohn et al., 2000). 
This applies also to the models of cardiomyopathy used in this study. Experimental 
animals similar to human patients show adverse remodeling processes, which involve 
myocytes, the extracellular matrix and the microvasculature. The term reverse 
remodeling definies reversal of the negative effects, i.e. improvement of cardiac 
structure and function. 
It can be hypothesized that BMP10 expression in cardiac ventricles as observed 
in this study might be important for remodeling during the course of the 
cardiomyopathies studied here by allowing a certain adaptation to negative effects of the 
disease. It might be assumed that BMP10 is involved in the remodeling process by 
acting as a protecting factor, i.e. by provoking either, to certain extent, reverse 
remodeling or at least a delay in the occurrence of the heart failure as endpoint of 
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remodeling. Probably the protective effects of BMP10 counteracting adverse 
remodeling processes are twofold: (i) a positive influence on the cardiac 
microvasculature including capillaries and arterioles-arteries based on the results 
presented here, and (ii) BMP10 might have an antihypertrophic effect as shown by 
Chen (Chen et al., 2006). 
The scheme of fig. 4.3 shows the possible action of BMP10 on the cardiac 
microvasculature. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.3. Schematic drawing of the role of BMP10 as a compensatory factor in 
cardiac remodeling.  
 
It is known that proliferation of interstitial cells and activation of endothelial 
cells play a role in cardiac reverse remodeling (Cohn et al., 2000). Induction of the 
proliferation and differentiation by BMP10 of resident cardiac progenitors into 
endothelial and vascular smooth muscle cells - the components of capillaries and 
arteries together with induced migration of these cells might lead to an enhanced cardiac 
vascular development. This may improve the oxygen supply of the hypertrophied and/or 
diseased heart. Therefore, recapitulation of BMP10 expression in pathological ventricles 
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may be a key component of the complex compensatory machinery that is initiated by 
various pathological conditions.  
Even though cardiomyocytes represent the major proportion of the protein mass 
of the heart (approximately 75%) they constitute only a minor part of the cell number 
(around 25%) in the heart (reviewed by Shapiro et al., 1996). Although there is 
sometimes the tendency to consider only the response of myocytes in the development 
of cardiomyopathy, the integration of other cell types should not be ignored. Non-
cardiomyocytes such as vascular smooth muscle, vascular and endocardial endothelial 
cells, fibroblasts and components of the nervous system play an important role in the 
development of the pathological as well as physiological responses.  
In the current work I proved that BMP10 is a cardiac specific factor able to 
induce proliferation and differentiation of mesenchymal progenitors to endothelial and 
vascular smooth muscle cells followed by tube-like structure assembly. Therefore it is 
highly probable that ectopic expression of BMP10 in pathological hearts has a 
beneficial pro-angiogenic function. 
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5. Summary 
 
PURPOSE:  
BMP10 is a cardiac specific member of the TGFβ superfamily and the 
expression of this cytokine is limited to the right atrium of the healthy heart. In the work 
presented here, I attempted to unveil the function of BMP10 in the pathological adult 
heart.  
 
MATERIAL AND METHODS:  
The expression and localization of BMP10 was studied in embryonic, neonatal and 
adult mouse hearts. Two genetic (heterozygous MnSOD and Desmin knock-out strains) 
and two drug induced (doxorubicin and isoproterenol) murine models of 
cardiomyopathies were used to investigate the changes of BMP10 expression and 
localization. MRI analysis was used to determine alterations of cardiac function and 
histopathological examination to identify changes of myocytes and the interstitium was 
carried out in the hearts of all models tested. The TUNEL method (apoptosis) and 
Complement9 staining (necrosis) were used for determination of cell death. Quantitative 
changes of BMP10 in the pathological murine hearts were monitored on the RNA level 
by semi-quantitative and real-time RT-PCR as well on the protein level by western blot. 
The levels of ANF, BNP and FHL2 as indicator of heart disorder were examined. 
Redistribution of BMP10 mRNA expression in diseased hearts was shown by in situ 
hybridization. By overexpression of the His-tagged mature region of the BMP10 in 
E.coli and its purification it was possible to generate an antibody specifically 
recognizing the mature secreted domain of the BMP10. Therefore, BMP10 localization 
in the healthy and cardiomyopathic murine hearts was investigated. The generation of 
expression construct producing functional BMP10 protein allowed to conduct in vitro 
experiments. Cell culture experiments using medium enriched in active BMP10 protein 
allowed evaluation of the BMP10 action on the primary culture of isolated non-
cardiomyocytes as well as multipotent mesenchymal 10T1/2 fibroblasts and the bone 
marrow derived stem cell line bm-MASCs. Immunocytochemistry and RT-PCR 
analysis of treated cells wereused to analyze the effects of BMP10 in vitro. 
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RESULTS: 
1. During embryonic heart development BMP10 expression was found in the 
trabeculated myocardial layer, and BMP10 protein was observed additionally in the 
outflow tract, the compacted heart wall and the epicardial layer.  
2. BMP10 in the healthy adult heart is expressed in the right atrium and after secretion 
binds to the membrane of both atrial cardiomyocytes and interstitial cells. Moreover, 
expression and binding of this protein was observed in the tricuspid valve and cells 
adjacent to the arteries in the upper atrial area of the heart.  
3. The murine models used in this study represent the dilated and hypertrophic type of 
cardiomyopathy and exhibit different degrees of cardiac dysfunction characterized 
by changes in myocardial volume and reduced ejection fraction. Interstitial and 
replacement fibrosis, cardiomyocyte hypertrophy, myofiber disarray and cell death 
in respect to necrosis and apoptosis were detected but the degree of structural 
changes was different in all models. The number of apoptotic or necrotic cells was 
very low. 
4. In diseased hearts two types of qualitative BMP10 distribution changes were found. 
The subcellular localization of BMP10 in cells of the right atrium was changed. In 
addition, BMP10 was re-expressed in ventricular cells.  
5. In Desmin knock-out and in doxorubicin induced dilated cardiomyopathy 
upregulation of the BMP10 expression was found, while quantification of BMP10 in 
MnSOD heterozygous and isoproterenol treated mouse heart revealed its 
downregulation. These variations in BMP10 quantity were monitored at the RNA 
and protein level. The number of BMP10 positive cells in the ventricles of 
pathological hearts is low, and therefore quantitative changes represent most 
probably the deregulation of BMP10 expression in the right atrium. 
6. Ventricular cells ectopically expressing BMP10 in pathological hearts are Sca1pos. 
and show signs of proliferation. Characterization of the ventricular BMP10pos. cells 
revealed that they constitute a heterogeneous population of cells often expressing 
endothelial and smooth muscle cell markers, but never cardiomyocyte specific 
genes. BMP10 is expressed, however, by embryonic and atrial cardiomyocytes.  
7. BMP10 effects are dependent on the differentially expressed receptors in various 
cell lines. The effect of BMP10 in C2C12 cells is limited to the induction of 
osteoblast differentiation. In contrast, BMP10 induced multipotent mesenchymal 
10T1/2 embryonic fibroblasts, adult bone marrow mesenchymal stem cells and in 
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non-cardiomyocytes isolated from the adult mouse heart to express smooth muscle, 
endothelial and pericyte markers. Moreover, cells expressing these markers are able 
to form 3D tube-like structures indicating a possible role of BMP10 in angiogenesis.  
 
CONCLUSION: 
On the basis of these results it can be concluded that BMP10 acts in an autocrine 
and paracrine fashion. As expression and localization of BMP10 changes dramatically 
even when the pathological changes are still moderate, BMP10 may play an important 
role in the disease process of dilated and hypertrophic cardiomyopathy. In 
cardiomyopathic hearts ventricular BMP10pos. cells seem to originate from cardiac Sca1 
progenitors and it might be concluded that BMP10 induces their proliferation and 
differentiation. In addition, cell culture experiments show that BMP10 induced 
differentiation of mesenchymal cells to endothelial, smooth muscle cells and pericytes 
leading to the assembly of tube-like structures. BMP10 may play a protective role in the 
cardiomyopathies studied here by stimulating the development of the cardiac 
microvasculature including capillaries, arterioles and small arteries. This process might 
result in an inhibition or at least a delay of adverse remodeling of the heart, which is 
part of an important adaptive process to cardiac diseases. Further studies including the 
inactivation of BMP10 in the adult heart are necessary to investigate the BMP10 
function in vivo. 
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6. Zusammenfassung 
 
ZIEL DER STUDIEN: 
BMP10 ist ein herzspezifisches Mitglied der TGFβ-Superfamilie. Die 
Expression dieses Zytokins ist auf das rechte Atrium des gesunden Herzens begrenzt. In 
der vorliegenden Arbeit bemühte ich mich, die Funktion von BMP10 im pathologischen 
adulten Herzen aufzudecken.  
 
MATERIAL & METHODEN: 
Die Expression und Lokalisation von BMP10 wurde im embryonalen, 
neonatalen und adulten Mausherzen untersucht. Zwei genetisch ( heterozgote MnSOD 
und Desmin knock-out Stämme) und zwei Drogen induzierte (Doxorubizin und 
Isoproterenol) murine Kardiomyopathiemodelle wurden genutzt, um Veränderungen der 
BMP10 Expression und Lokalisation zu prüfen. An den Herzen aller getesteten Modelle 
wurden MRI-Analysen durchgeführt, um kardiale Funktionsänderungen zu bestimmen, 
und histopathologische Betrachtungen unternommen, um Veränderungen der Myozyten 
und des Interstitiums aufzudecken. Die TUNEL Methode (Apoptose) und die 
Complement9-Färbung (Nekrose) dienten der Feststellung von Zelltod. In den 
pathologischen Mäuseherzen wurden die quantitative Veränderungen von BMP10 auf 
RNS-Ebene durch semi-quantitative und „real-time“ RT-PCR kontrolliert, indessen auf 
Proteinebene durch die Methode des Western Blots. Die ANF-, BNP- und FHL2-Level 
als Indikatoren für Herzstörungen wurden ebenfalls analysiert. Die Neuverteilung der 
BMP10 mRNS-Expression in geschädigten Herzen wurde durch in situ 
Hybridisierungen gezeigt. Die Lokalisation des BMP10 Proteins in gesunden und 
pathologischen Herzen wurde mit einem Antikörper untersucht, der spezifisch die 
aktive Domäne von BMP10 erkennt. Für die Generierung des Antikörperes wurde zuvor 
das reife, mit einem His-Schwanz versehene Protein in E. coli überexprimiert und 
aufgereinigt. Die Herstellung eines Expressionskonstrukts, das ein funktionsfähiges 
BMP10 Protein produziert, ermöglichte die Durchführung von in vitro Experimenten. 
Zellkulturexperimente mit aktivem BMP10 Protein angereichertem Medium, 
ermöglichte die Aufklärung der BMP10-Aktivität im Primärkulturen von nicht-
Kardiomyozyten, in multipotenten mesenchymalen 10T1/2 Fibroblasten und einer 
Knochenmark abstammenden Stammzelllinie bm-MASC (engl.: „bone marrow derived 
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mesenchymal adult stem cells“). Immunozytochemische und RT-PCR Analysen an den 
behandelten Zellen dienten der Aufklärung der BMP10-Effekte in vitro.  
 
ERGEBNISSE: 
1. Während der embryonalen kardialen Entwicklung konnte die Bmp10 Expression im 
trabekulierten Myokard detektiert werden. Das BMP10 Protein wurde außerdem im 
Ausflusstrakt, der kompaktierten Herzwand und im Epikard nachgewiesen. 
2. Bmp10 wird im gesunden adulten Herzen im rechten Atrium exprimiert. Nach der 
Sekretion bindet das Protein an die Membranen beider atrialen Kardiomyozyten und 
die interstitialen Zellen. Des Weiteren wurden die Expression und die Bindung des 
Proteins in den Trikuspidalklappen und den benachbarten Zellen der Arterien in der 
oberen atrialen Region des Herzen beobachtet. 
3. Die murinen Modelle, die in dieser Studie verwendet wurden, repräsentieren die 
dilative und die hypertrophe Form der Kardiomyopathie. Sie weisen verschiedene 
Grade der kardialen Dysfunktion auf, die charkaterisiert sind durch Veränderungen 
im myokardialen Volumen und eine reduzierte Ejektionsfraktion. Interstitiale und 
reparative Fibrose, kardiomyozytäre Hyperthrophie, Fehlanordnung der 
Herzmuskelfasern und Zelltod in Bezug auf Apoptose und Nekrose konnte in allen 
Modellen festgestellt werden. Jedoch der Grad der jeweiligen strukturellen 
Veränderung war different. Die Anzahl der apoptotischen und nekrotischen Zellen 
war sehr gering. 
4. In den geschädigten Herzen konnten zwei Typen einer qualitativen Veränderung der 
BMP10 Verteilung gefunden werden. Zum einen war die subzelluläre Lokalisation 
von BMP10 im rechten Atrium verändert, und zum anderen wurde BMP10 in 
ventrikulären Zellen re-exprimiert. 
5. In der Desmin-defizitären Maus und in Doxorubizin-induzierten dilativen 
Kardiomyopathien konnte eine Hochregulation der BMP10 Expression gefunden 
werden, während die Quantifizierung von BMP10 in MnSOD heterozygoten und 
Isoproterenol behandelten Mäusenherzen eine Runterregulation aufdeckte. Diese 
Variationen der BMP10 Quantität wurden auf RNS- und Proteinebene kontrolliert. 
Die Anzahl der BMP10 positiven Zellen in den Ventrikeln der pathologischen 
Herzen ist gering. Folglich repräsentieren die quantitativen Veränderungen 
höchstwahrscheinlich die Deregulierung der BMP10 Expression im rechten Atrium. 
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6. Ventrikuläre Zellen, die ektopisch BMP10 im pathologischen Herz exprimieren, sind 
Sca1pos und weisen Anzeichen der Proliferation auf. Die Charakterisierung dieser 
BMP10pos Zellen enthüllte, dass sie eine heterogene Population von Zellen darstellen, 
die oftmals endotheliale Marker und solcher glatter Muskulatur exprimieren, aber 
niemals Kardiomyozyten-spezifische Gene. Dennoch wird BMP10 von embryonalen  
und atrialen Kardiomyozyten exprimiert.  
7. Die BMP10-Effekte sind abhängig von differentiell exprimierten Rezeptoren in den 
verschiedenen Zelllinien. Die Effekte von BMP10 auf C2C12 Zellen sind limitiert 
auf die Induktion der Osteoblastendifferenzierung. Im Gegensatz dazu induziert 
BMP10 in multipotenten mesenchymalen 10T1/2 Fibroblasten, adulten 
Knochenmark abstammenden mesenchymalen Stammzellen und in nicht-
Kardiomyozyten, die aus dem adulten Mausherzen isoliert wurden, endotheliale, 
perikardiale und für glatte Muskulatur typische Marker. Darüber hinaus sind die 
Zellen, die diese Marker exprimieren, in der Lage, dreideimensionale röhrenartige 
Strukturen zu bilden. Dies weist auf eine mögliche Rolle von BMP10 während der 
Angiogenese hin. 
 
SCHLUSSFOLGERUNGEN: 
 Basierend auf den dargestellten Ergebnissen kann geschlussfolgert werden, dass 
BMP10 auf eine autokrine und parakrine Art und Weise wirkt. Da die BMP10 
Expression und Lokalisation sich dramatisch verändern, auch wenn die pathologischen 
Veränderungen noch moderat sind, ist es möglich, dass BMP10 eine wichtige Rolle im 
Krankheitsverlauf der dilativen und hypertrophen Kardiomyopathien spielt. In 
kardiomyopathischen Herzen scheinen die ventrikulären BMP10pos Zellen aus kardialen 
Sca1 Vorläufern hervorzugehen. Es könnte gefolgert werden, dass BMP10 ihre 
Proliferation und Differenzierung induziert. Des Weitern haben Zellkulturexperimente 
gezeigt, dass BMP10 die Differenzierung von mesenchymalen Zellen zu endothelialen 
Zellen, Zellen der glatten Muskulatur und Perizyten induziert, was schließlich zur 
Bildung von röhrenähnlichen Strukturen führt. In den untersuchten Kardiomyopathien 
spielt BMP10 eine protektive Rolle, indem es die Entwicklung der kardialen 
Mikrovaskulatur inklusive der Kapillaren, Arteriolen und kleinen Atrierien stimuliert. 
Dieser Prozess resultiert möglicherweise in einer Inhibition oder zumindest einer 
Verzögerung der nachteiligen Umgestaltung des Herzens, welche Teil des wichtigen 
adaptiven Prozess an Herzerkrankungen ist. Weitere Studien, inklusive der 
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Inaktivierung von BMP10 im adulten Herzen sind notwendig, um die BMP10 Funktion 
in vivo zu untersuchen. 
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7. ABBREVIATIONS 
 
3D   three-dimensional 
A    Adenine 
ActR   activin receptor 
ALK   activin receptor-like kinases 
ALP   Alkaline phosphatase 
ANF   Atrial Natiuretic Factor 
Ao   aorta 
AVC   Atrioventricular Canal 
AVCD   Atrioventricular canal defects 
BAMBI  BMP and activin membrane bound inhibitor 
BLAST  Basic Local Alignment Search Tool 
BMP   Bone Morphogenetic Protein 
BMP10  Bone Morphogenetic Protein 10 
BMPR   BMP receptor 
BNP   Brain Natiuretic protein 
bp   base pairs 
BRAM1  BMP receptor associated molecule 1 
BrdU    Bromo-deoxy-Uridine  
BSA   Bovine Serum Albumine 
C   Cytosine 
cDNA    DNA complementary to mRNA 
CMP   cardiomyopathy 
Co-Smads  Common-partner Smads 
DOX   doxorubicin 
E   Embryonic day 
EC   Endothelial cells  
ECG   Electrocardiogram 
EF   Ejection fraction 
EMT   Endothelial to mesenchymal transition 
EPI   Epicardial layer 
ERK   Extra-cellular signal regulated kinase 
                                                                                    ABBREVIATIONS 
 172 
ES   embryonic cells  
EST   expressed sequence tag 
EtOH   ethanol 
FCS   Fetal Calf Serum 
FHL   Four and half LIM protein 
FKBP12  FK506-binding protein 12 
FOV   Field of view 
FRT   Flp recombinase recognition site 
g   gram 
G   Guanine 
GDF   growth/differentiation factor 
GDNF   glial cell line-derived neurotrophic factor 
GFP   Green Fluorescence Protein 
GM   Growth medium 
H   hour 
IAS   Interatrial septum 
IRES   internal ribosome entry site 
I-Smads  Inhibitory Smads 
ISO   Isoproterenol 
kbp   kilo base pairs 
kDa    kilo Daltons 
KO   Knock-out 
LA   Left atrium 
LAA   Left atrium appendage 
LV   Left ventricle 
M   mol 
mANCM  mouse adult non-cardiomyocytes 
MAPK  Mitogen activated protein kinase 
matBMP10  mature region of the Bone Morphogenetic Protein 10 
mBM-MASC1 mouse bone marrow mesenchymal adult stem cell line 1 
MeOH   Methanol 
mg   milligram 
MHC   Myosin heavy chain 
min.   minute 
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ml   milliliter 
mM   mili Mol 
MRI   Magnetic Resonance Imaging 
mRNA  messenger RNA 
neg.   negative 
ng   nanogram 
nm   nanometer 
NMR   Nuclear magnetic resonance 
o.n.   over night 
OFT   Outflow tract 
P   Phosphorylation site 
PBS   Phosphate Buffered Saline 
PBT   PBS+Tween20 
PCR   Polymerase Chain Reaction 
PDGFRß  platelet-derived growth factor receptor ß 
PFA   Paraformaldehyde 
PGK   phosphoglycerol kinase 
pmol   piko mol 
pos.   positive 
RA   Right atrium 
RAA   Right atrium appendage 
RNA   ribonucleic acid 
R-Smads  Receptor-regulated Smads 
RT   Repetition time 
RT-PCR  Reverse Transcriptase Polymerase Chain Reaction 
RV   Right ventricle 
Sca1   stem cell antigen 1 
SDS-PAGE  SDS polyacrylamide gel electrophoresis 
SF   Serum Free medium 
SMA   Smooth muscle actin 
SOD   superoxide dismutase 
T   Tesla 
TE   echo time 
TGFß   Transforming Growth Factor ß 
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TR   Trabeculae 
TUNEL  Terminal dUTP deoxynucleotidyl transferase nick end-labeling 
DCM   dilated cardiomyopathy 
U   unit 
v/v   volume/volume 
vSMC   vascular smooth muscle cell 
wt   wild type 
µg   microgram 
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8. Appendix 
 
8.1. Curriculum Vitae  
 
DATE OF BIRTH: 13 August 1977 
STATUS:           married  
NATIONALITY:    Polish 
 
EDUCATION: 
 
1996 -2001  Student of Agricultural University of Poznań, Faculty of 
Biotechnology (G.P.A: 4.6/5.0), Engineer and Master of Science 
Diploma made at the Institute of Bioorganic Chemistry Polish 
Laboratory of tRNA, Team of Protein Biosynthesis. Master Thesis 
Diploma defended on June 2001 (5.0/5.0). Rector’s prize for 
achievements during studies. 
 
RESEARCH EXPERIENCE: 
 
1999-2000 volunteer work in Protein Biosynthesis Laboratory in Institute of 
Bioorganic Chemistry Polish Academy of Sciences  
2000-2001 Engineer and Master of Science Diploma at Institute of 
Bioorganic Chemistry Polish Academy of Sciences. Thesis:  
 “Investigating of conformational changes of eukariotic ribosome 
using antisense oligonucleotides hybridisation method” 
11.2001-4.2005 Marie Curie fellow, Probiodrug, Halle, Germany 
1.05.2002- 01.2005  Ph.D. student at the Marthin-Luther University Halle-Wittenberg, 
Germany; Institute for Physiological Chemistry, involved in two 
projects belonging to one grant: “Functional Genomics of the 
ageing heart: Affected genes and their mode of action” 
02.2005 – 06.2005  PhD student at the Martin Luther University Halle -Wittenberg, 
Medicine Faculty, Institute of Physiological Chemistry; Max- 
Planck Institute of Heart and Lung Research –Bad Nauheim. 
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07.2005 -   to present, PhD student at the University Klinik  
Giessen – Marburg, Max-Planck Institute of Heart and Lung 
Research –Bad Nauheim. 
 
CONFERENCES AND COURSES 
 
1. Polish American Conference Physico-Chemical Methods in Biotechnology and 
Material Science; 5-7 June 2000, Poznan, Poland 
2. International Conference " Molecular Architecture of Evolution: Primary and 
Secondary Determinants" Poznan, Poland, (2000)  
3. Theoretical Course “RNA Structure and Function” International Centre for Genetic 
Engineering and Biotechnology; 9-12 April 2001, Trieste, Italy  
 
PUBLICATIONS: 
 
Piotrowska, I., Dudzinska, B., Twardowski, T., (2002) Structure and function of 
prokaryotic ribosome (in Polish). Advances in Biochemistry 48(1), 2-19  
 
8.2. Publications and scientific activity in congresses during PhD studies 
 
8.2.1. Publications 
Presented results have not been published. 
 
8.3.2. Presentation 
 
Results have not been presented during scientific congresses.  
 
8.3.4. Courses 
 
RNAi Myores Workshop, Villie-Morgon, 2006 
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